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1.1 Natural products 
Chemical substances derived from plants, animals and microorganisms which usually 
have biological activities are defined as natural products. Natural products and their 
derivatives had played an important role of being a source of active ingredients for 
therapeutic drugs.1 
 
In the ancient time, people had started to use local flora and fauna to treat various 
diseases. Some traditional healing systems, such as traditional Chinese medicine, 
Ayurveda, as well as western medicine, were developed at that time.2 As a result, an 
increasing number of crude preparations were discovered to have medicinal effects.  
 
The chemical investigation of plants has started already a long time ago in medicinal 
research. The analgesic morphine (1) was first isolated in 1804 by Friedrich Sertürner, as 
the active principle in opium poppy known in ancient Egypt. In 1831, the German 
pharmacist Heinrich Mein first prepared crystallized atropine (2) from Atropa belladonna 
(Solanaceae).3 In 1952, antihypertensive reserpine (3) was isolated from Rauwolfia 
serpentine, an Indian snakeroot used for the treatment of fever and snakebites, which 
significantly attracted scientists’ attentions on natural products.4 The isolation of 
anticancer drugs vinblastine (4) and vincristine (5), was independently reported from a 
Madagascar periwinkle, Vinca rosea, by Noble and Svoboda in 1958 and 1960.5 In 1969, 
the well-known anticancer drug, taxol (6), was initially isolated from the Western Pacific 
Yew Taxus brevifolia, and it was reported to be beneficial for treatment of ovarian and 
breast cancer. In 1972, a research group led by Tu Youyou discovered artemisinin (7) from 
the leaves of Artemisia annua, which is effective in treating malaria.6,7 
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Nowadays, scientists investigate the natural products for chemotherapeutic use from 
different natural sources: plant kingdom, microbial and marine world, animal sources, as 
well as venoms and toxins. A large variety of chemical constituents has been isolated 
from nature. Together with synthetically modified natural products, natural products 
have been developed to be suitable for the treatment of almost all human diseases.8 
According to a recent review analyzing the source of new drugs from 1981 to 2010, it is 
said that more than 50% of currently marketed drugs are actually natural products or 
derived from natural products.9 
 
Despite the great success of natural products in drug discovery, classical natural 
product-based drug research has been gradually replaced by molecular target-based 
drug discovery. This decreased emphasis can be attributed to two major factors: the 
introduction of the approach of high-throughput screening (HTS) and the development 
of combinatorial chemistry.9 The HTS process based on molecular targets can quickly test 
the bioactivity of numerous compound samples. However, most natural product 
programs could not meet this increased demand, not to mention crude natural product 
extracts are always complex mixtures with serious impurity influence. Combinatorial 
chemistry was also developed to offer more “drug-like” chemical compounds to provide 
the perfect hit in HTS efforts. 
 
Although the approach involving the combination of HTS and combinatorial chemistry 
will no doubt create more opportunities for drug discovery, it is surprising that this 
approach delivered only one antitumor drug Nexavar (8) approved by FDA in 2005 for 
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renal carcinoma and in 2007 for hepatocellular carcinoma.10  
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Clearly, drug discovery still faces a number of challenges. Nevertheless, a combination of 
modern natural product development and improved combinatorial chemistry linked with 
HTS will undoubtedly supply more unique and highly promising lead compounds for the 
drug discovery process.11 
 
The typical process of discovering natural products as lead compounds, is 
bioassay-guided purification. A general scheme for the isolation of bioactive natural 
products and their development towards a drug candidate is shown in Figure 1.1.1 
 
 
 
 
                                             extraction 
 
 
 
Processing biotesting experiments 
 
                                              
Fractionate (liquid-liquid and 
chromatographic partition,  
HPLC and LC-MS analysis, etc.) 
 
                                              
                                             Structure elucidation 
                                             (UV, IR, NMR, MS, etc.) 
 
 
                                             Evaluation of 'natural SAR', synthesis of 
derivatives, scale-up purification 
 
 
 
Figure 1.1 Chemical process for natural product drug discovery 
 
 
Raw material 
Crude extracts 
Bioactive concentrate 
Bioactive pure compounds 
Potential lead 
Development drug candidate 
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1.2 Genus Gynura and overview of compounds isolated from Gynura Cass. 
1.2.1 Description of the genus Gynura 
Gynura species, belonging to the tribe Senecioneae in the family Asteraceae, are always 
succulent herbs, rarely shrubs (Figure 1.2). Their leaves grow alternately, in dentate or 
pinnate divided shape. They have typical discoid capitula, solitary or few to numerous 
corymbose in yellow or purple color. Involucres are campanulate or cylindric, with 9-13 
uniseriate phyllaries and scarious margins. Receptacle is flat, areolate or shortly fimbriate. 
Anthers are entire or subauriculate at base. Style branches are slender and puberulent. 
Achenes are cylindric with ribs.12 
 
 
Figure 1.2 Representative Gynura species: G. japonica (1-4), G. pseudochina (5-8) 
 
The genus Gynura comprises approximately 40 species mainly distributed in Asia, Africa 
and Australia, of which 10 species were recorded in the south of China. They are 
systematic classified as below:12 
 
 Gynura barbareifolia Gagnepain  
 Gynura bicolor (Roxburgh ex Willdenow) Candolle  
 Gynura cusimbua (D. Don) S. Moore  
 Gynura divaricata (Linnaeus) Candolle  
 Gynura elliptica Y. Yabe & Hayata  
 Gynura formosana Kitamura  
 Gynura japonica (Thunberg) Juel  
 Gynura nepalensis Candolle  
 Gynura procumbens (Loureiro) Merrill  
 Gynura pseudochina (Linnaeus) Candolle  
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1.2.2 Phytochemical investigation of plant species from the genus Gynura 
Previous chemical investigations on Gynura Cass. demonstrated the presence of 
pyrrolizidine alkaloids, steroids, flavonoids, triterpenoids, chromone derivatives, 
cerebrosides and phenolics.13-44 Besides, aliphatic compound derivatives, organic acids 
and other compounds were reported as well. All the compounds and their origin are 
listed in Table 1.1 and their chemical structures are shown as below. 
 
Table 1.1 Overview of natural products isolated from Gynura Cass. 
Compound name Plant origin Reference 
1. Pyrrolizidine alkaloids   
1.1  Retronecine type   
senecionine (9) G. segetum 
G. sarmentosa 
G. elliptica 
13-17 
18 
19 
gynuramine (10) G. scandens 20 
acetylgynuramine (11) G. scandens 20,21 
integerrimine (12) G. divaricata 22 
usaramine (13) G. divaricata 22 
jacobine (14) G. crepidioides 23 
jacoline (15) G. crepidioides 23 
seneciphylline (16) G. segetum 16 
seneciphyllinine (17) G. segetum 16 
spartioidine (18) G. segetum 16 
1.2  Otonecine type   
otosenine (19) G. sarmentosa 17 
senkirkine (20) G. sarmentosa 
G. elliptica 
17 
19 
2. Steroids   
3-epi-diosgenin 3-O-β-D-glucopyranoside (21) G. japonica 24 
3-epi-ruscogenin (22) G. japonica 24 
3-epi-sceptrumgenin 3-O-β-D-glucopyranoside (23) G. japonica 24 
3-epi-neoruscogenin (24) G. japonica 24 
β-sitosterol 3-O-β-D-glucopyranoside (25) G. procumbens 
G. formosana 
G. japonica 
G. divaricata 
25 
26 
27 
28 
stigmasterol 3-O-β-D-glucopyranoside (26) G. procumbens 
G. formosana 
G. divaricata 
G. japonica 
25 
26 
28 
27 
β-sitosterol (27) G. procumbens 25 
 G. formosana 26 
 G. divaricata 28,29 
 G. bicolor 30 
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 G. japonica 27 
stigmasterol (28) G. procumbens 
G. formosana 
G. divaricata 
G. japonica 
25 
26 
28,29 
27 
β-sitosterone (29) G. japonica 27 
stigmasterone (30) G. japonica 27 
(22E,24S)-7-hydroperoxystigmasta-5,22-dien-3-ol (31) G. japonica 27 
(24R)-7-hydroperoxystigmasta-5,22-dien-3-ol (32) G. japonica 27 
(22E,24S)-stigmasta-1,4,22-trien-3-one (33) G. japonica 27 
(22E,24S)-stigmasta-1,4-dien-3-one (34) G. japonica 27 
3. Flavonoids   
quercetin (35) G. divaricata 
G. bicolor 
29,31 
32 
quercetin 3-O--D-glucopyranoside (isoquercitin, 36) G. divaricata 
G. bicolor 
29 
32 
quercetin 3-O--L-rhamnopyranoside (37) G. bicolor 32 
quercetin 3-O-rutinoside (rutin, 38) G. procumbens 
G. formosana 
G. divaricata 
G. bicolor 
G. pseudochina 
33,34 
35,36 
31,29 
30,32 
37 
quercetin 
3-O--L-rhamnopyranosyl-(16)--D-galactopyranoside 
(39) 
G. procumbens 33,34 
kaempferol (40) G. divaricata 
G. bicolor 
31 
30,32 
kaempferol 3-O-β-D-glucopyranoside (astragalin, 41) G. divaricata 
G. procumbens 
G. bicolor 
31 
33,34 
30 
kaempferol 3-O-rutinoside (42) G. procumbens 
G. formosana 
G. divaricata 
G. bicolor 
33,34 
35,36 
29 
30 
kaempferol 
3-O--L-rhamnopyranosyl-(16)--D-galactopyranoside 
(43) 
G. formosana 36 
kaempferol 3-O-robinobioside (44) G. formosana 35 
kaempferol 3,7-di-O--D-glucopyranoside (45) G. divaricata 31 
kaempferol 3-O-rutinoside-7-O--D-glucopyranoside (46) G. divaricata 31 
homoplantaginin (47) G. bicolor 30 
anthocyanin (48) G. bicolor 18 
 G. aurantiaca cv. 18 
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4. Triterpenoids   
-amyrin (49) G. formosana 
G. bicolor 
38 
30 
β-amyrin (50) G. formosana 
G. bicolor 
38 
30 
β-amyrin 3-O-β-D-glucopyranoside (51) G. bicolor 30 
3-epi-friedelanol (52) G. formosana 26 
 G. divaricata 29 
 G. bicolor 30 
3-O-acetyl-epi-friedelanol (53) G. formosana 
G. divaricata 
26 
29 
friedelin (54) G. formosana 
G. divaricata 
26 
28 
isobauerenone (55) G. formosana 26 
isobauerenol (56) G. formosana 26 
glutinol (57) G. formosana 26 
-tocospirone (58) G. japonica 27 
5. Chromone derivatives   
6-acetyl-2-hydroxymethyl-2-methylchroman-4-one (59) G. formosana 
G. japonica 
38,39 
27 
6-acetyl-2,2-dimethylchroman-4-one (60) G. elliptica 
G. japonica 
19 
27 
6-hydroxy-2,2-dimethylchroman-4-one (61) G. elliptica 19 
gynunone (62) G. elliptica 19 
gynunol (63) G. elliptica 19 
gynuraone (64) G. japonica 27 
6. Cerebrosides   
gynuramides 1-4 (65-68) G. japonica 40 
1-O--D-glucopyranosyl-(2S,3S,4R,10E)-2-[(2R)-2-hydro-
xyltricosanoylamino]-10-octadecene-1,3,4-triol (69) 
G.divaricata 41 
1-O--D-glucopyranosyl-(2S,3S,4R,10Z)-2-[(2R)-2-hydro-
xyltricosanoylamino]-10-octadecene-1,3,4-triol (70) 
G.divaricata 42 
1-O--D-glucopyranosyl-(2S,3S,4R,10E)-2-[(2R)-2-hydro-
xyldocosanoylamino]-10-octadecene-1,3,4-triol (71) 
G.divaricata 43 
7. Phenolics   
3,5-di-caffeoylquinic acid (72) G. pseudochina 
G.divaricata 
37 
31 
4,5-di-caffeoylquinic acid (73) G. pseudochina 37 
5-caffeoylquinic acid (chlorogenic acid, 74) G. pseudochina 37 
oleuropein (75) G. aurantiaca 44 
caffeic acid (76) G. formosana 35,36 
syringaldehyde (77) G. elliptica 19 
benzoic acid (78) G. japonica 27 
4-hydroxybenzoic acid (79) G. bicolor 30 
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vanillin (80) G. elliptica 
G. japonica 
19 
27 
8. Terpenylcoumarin   
gynurone (81) G. crepidioides 45 
9. Aliphatic compound derivatives   
1-tridecene-3,5,7,9,11-pentayne (82) G. crepidioides 45 
n-eicosane (83) G. divaricata 28 
methyl palmitate (84) G. formosana 46 
methyl linoleate (85) G. formosana 46 
methyl oleate (86) G. formosana 46 
octadecan-1-ol (87) G. bicolor 30 
docosan-1-ol (88) G. formosana 46 
tetracosan-1-ol (89) G. divaricata 28 
octacosan-1-ol (90) G. divaricata 28 
dotriacontan-1-ol (91) G. formosana 26 
2,3-dihydroxypropyl palmitate (92) G. formosana 46 
3(20)-phytene-1,2-diol (93) G. formosana 46 
10. Organic acids   
succinic acid (94) G. segetum 15 
palmitic acid (95) G. divaricata 
G. japonica 
28 
27 
hexacosanoic acid (96) G. japonica 27 
octacosanoic acid (97) G. divaricata 28 
11. Pyrimidines   
thymine (98) G. segetum 15 
uracil (99) G. formosana 38 
12. Purine   
adenine (100) G. segetum 15 
adenosine (101) G. divaricata 29 
uridine (102) G. divaricata 29 
13. Others   
pheophorbide a (103) G. formosana 46 
pheophorbide b (104) G. formosana 46 
caryophyllene oxide (105)  G. japonica 27 
2,6-dimethoxy-1,4-benzoquinone (106) G. japonica 27 
D-mannitol (107) G. segetum 15 
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Pyrrolizidines 
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Steroids 
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O
Chapter 1 
11 
HO
H
H
H
OOH        HO
H
H
H
OOH  
31                                       32 
 
O
H
H
H
 
33: Δ22 
34 
 
Flavonoids 
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Triterpenoids 
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Chromone derivatives 
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Phenolics 
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1.3 Natural Flavonoids as Potential Herbal Medication for the Treatment of Diabetes 
Mellitus and Its Complications 
Diabetes mellitus, followed by its various complications, is becoming a serious threat to 
human health in the world. The development of antidiabetic medication from natural 
products, especially those originated from plants with a traceable folk-usage history in 
treating diabetes, is receiving more attention. Many studies highlighted not only the 
benefits of natural flavonoids with hypoglycemic effects, but also their importance in the 
management of diabetic complications. This part describes selected natural flavonoids 
(active natural components) that have been validated for their hypoglycemic properties, 
together with their mechanisms of action. Also their activities in the treatment of 
diabetes complications demonstrated via laboratory diabetic animal models, in vitro and 
in clinical trials using human subjects, are discussed. Published papers from 2000 to date 
on flavonoids and diabetes were covered through accessing databases of Web of Science 
and PubMed. The major potential benefits of natural flavonoids discussed here clearly 
suggest that these substances are lead compounds with sufficient structural diversity of 
great importance in the antidiabetic drug developing process. 
 
1.3.1 Introduction 
Diabetes mellitus is a metabolic disorder disease with hyperglycemia (high blood glucose) 
as its most typical character. This hyperglycemia results in three classical symptoms of 
diabetes: polyuria, polydipsia and polyphagia. The World Health Organization divides 
diabetes mellitus into three main types: Type 1, Type 2 and gestational diabetes. Type 1 
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diabetes (formerly known as Insulin-Dependent Diabetes Mellitus) results from an insulin 
production problem, which requires lifelong administration of insulin. Type 2 diabetes 
(formerly called Non-Insulin-Dependent Diabetes Mellitus) is caused by the body’s defect 
in insulin response, called insulin resistance. Type 2 diabetes comprises 90% of people 
with diabetes around the world, mainly due to obesity and physical inactivity. 
Gestational diabetes is hyperglycemia with onset or first recognition during pregnancy.47 
 
Data from the International Diabetic Federation (IDF) demonstrates that the number of 
people with diabetes in 2011 has reached 366 million, representing 5.23% of the world’s 
population.48 With 90 million adults with this disease, China has become the country 
with the largest population of diabetics in the world. According to the IDF, diabetes and 
its complications have a significant economic impact on medical expenditure, which 
already accounts for 5-18% of the total healthcare budget in many countries. 
 
With a centuries-old history till now, humans use natural substances, mostly by means of 
a plant extract or a crude medical recipe, to cure diseases. Many of them serve as leads 
of important drugs that have become mainstays in modern therapy.49 For example, 
metformin, belonging to a biguanide class of antidiabetic drugs, is originally from Galega 
officinalis, a plant used in folk medicine.50 Acarbose, the most widely used α-glucosidase 
inhibitor for the treatment of Type 2 diabetes, resulted from a screening performed by 
Bayer AG of natural products isolated from Actinomycetes species for inhibition of 
digestive enzymes.51 Natural products are an abundant source for antidiabetic drug 
discovery despite the lack of content determination, quality and safety control. By 
following an integrated approach and using correct procedures, antidiabetic agents from 
medicinal plants especially used in folk medicine for diabetes treatment may provide an 
alternative to the classical drugs used (insulin and oral hypoglycemic agents), with few 
side effects and low cost for the maintenance of treatment.52 
 
Flavonoids are a class of plant secondary metabolites with the backbone of flavone 
(2-phenylchromen-4-one). Important subgroups are flavanols, flavonols, flavones, 
isoflavones, flavanones, flavanonols, chalcones and anthocyanins, which are defined by 
the functional groups attached to the basic flavonoid structure (Table 1.2). They have a 
broad range of biological activities and numerous studies have been carried out on their 
potential role in the treatment of diabetes and its complications. This overview gathers 
information on the in vitro and in vivo bioassay of plants containing flavonoids used in 
the treatment of conditions consistent with diabetes symptomatology. It summarizes the 
progress in natural flavonoid research, emphasized on the treatment of diabetes and its 
complications. Because of the multifactorial pathogenicity of diabetes, information on 
the mechanism of action of natural flavonoids in the treatment of diabetes is presented 
at the beginning. 
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Table 1.2 Flavonoid subgroups and their structures 
Group Structure Group Structure 
flavanol O
OH  
flavonol 
O
O
OH
 
flavone 
O
O  
isoflavone 
O
O  
flavanone 
O
O  
flavanonol 
O
O
OH
 
chalcone 
O  
anthocyanin O
 
 
1.3.2 Mechanisms of action of natural flavonoids for the treatment of diabetes 
mellitus 
Currently, insulin injection and oral administration of antidiabetic drugs are the mainstay 
of available therapy for the treatment of diabetes mellitus. Antidiabetic drugs in the 
western market can be classified as sensitizers, secretagogues, insulin analogues, 
α-glucosidase inhibitors, amylin analogues and others, which are used as monotherapy 
or in combination by the patients whose disease is more serious for a better glycemic 
regulation.53 Unfortunately, most of them have prominent side effects and, moreover, 
lack the ability to prevent the development of diabetic complications. Worldwide, 
pharmacologists are devoted to the search for alternative therapeutic approaches for 
this metabolic disease.54 
 
Up to now, more and more plants used as ethnopharmacological antidiabetic remedies 
are being confirmed, and their responsible chemical profiles for the hypoglycemic effect 
are being studied. Moreover, the mechanism of action of these substances is being 
elucidated in a meticulous way. The main mechanisms of action of natural flavonoids 
can be described as below, and information of the corresponding flavonoids is listed in 
Table 1.3. 
 
1.3.2.1 Action on islet β-cells and release of insulin from β-cells 
When blood sugar concentration rises, β-cells of the endocrine pancreas release insulin, 
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the hormone that controls the level of glucose, into the blood stream.55 Decreased 
viability and dysfunction of pancreatic β-cells leads to the development of diabetes as 
critical metabolic disorder. 
 
Many flavonoids were proposed as potential antidiabetic agents because they exert 
multiple actions on islet β-cells. In this respect, the functions of flavonoids can be divided 
into (i) protection against β-cell damage,56,57,58 (ii) increased proliferation of islet β-cells59 
and (iii) preservation of insulin signaling by increased insulin secretion.60-63 
 
1.3.2.2 Enhancement of glucose utilization in tissues and organs 
Diabetes is a disease with disorders in glucose metabolism, which means the deficiency 
of glucose utilization, inducing an increased glucose output. Glucose utilization involves 
the cellular glucose transport, which is mediated by the family of facilitative glucose 
transporters (GLUTs) as solute carriers. This process occurs through a signaling pathway 
involving the insulin receptor tyrosine kinase.64 In diabetes, this complex system of 
insulin-stimulated whole-body glucose utilization is impaired, probably because of 
defective GLUT-4 translocation and aberrant insulin signal transduction.65 
 
It has been proven that several naturally occurring flavonoids affect this transduction and 
enhance the utilization of glucose, by their action on glucose transport66-69 and 
insulin-receptor signaling.70-72 
 
1.3.2.3 Reduction of breakdown of glycogen 
In the course of consumption, glucose is phosphorylated to glucose-6-phosphate by 
glucokinase, followed by glycogen synthesis, glycolysis or triglyceride synthesis.73 Insulin 
inhibits gluconeogenesis and glycogenolysis by its effect on regulating the transcription 
of genes encoding hepatic and muscular enzymes, such as phosphoenolpyruvate 
carboxykinase and glucose-6-phosphatase (G-6-Pase).74 
 
Flavonoids have been found to increase the glucokinase level, thus promoting glycogen 
synthesis,56,75 to reduce G-6-Pase and phosphoenolpyruvate carboxykinase gene 
expression, thus inhibiting gluconeogenesis or glycogenolysis,76-79 or both.80-83 
 
1.3.2.4 Inhibition of α-glucosidase to reduce intestinal glucose absorption 
Carbohydrates are hydrolyzed to their corresponding monosaccharides by enzymes 
present in the brush border of small intestine before absorption. Among these enzymes, 
α-glucosidase is the most important enzyme in carbohydrate digestion. Acarbose, a 
popular antidiabetes drug, working as α-glucosidase inhibitor, can significantly decrease 
the Type 2 diabetics’ fasting and postprandial blood glucose, glycosylated hemoglobin 
and improve insulin sensitivity effectively.84,85 
 
Many flavonoids can be used as α-glucosidase inhibitors,86-92 and they can prevent the 
digestion of carbohydrates and delay the glucose absorption. Hence, α-glucosidase 
inhibitors reduce the impact of carbohydrates on blood sugar. Besides, sucrase, maltase 
General introduction 
20 
and α-amylase inhibitors86,93,94 also show hypoglycemic potential in the treatment of 
diabetes mellitus. 
 
1.3.2.5 Antioxidant free radical scavenging activity 
The cytotoxic action of alloxan and streptozotocin (STZ), which are mostly used to build 
up diabetes mellitus in experimental animals, is mediated by reactive oxygen species 
(ROS).95 Diabetics and experimental animal models exhibit high oxidative stress, and it 
has been suggested to be one factor on the development of diabetes related 
complications. 
 
Flavonoids are well-known for their function as natural antioxidant agents by scavenging 
reactive oxygen species, by virtue of the number and arrangement of their phenolic 
hydroxyl groups attached to aromatic ring structures.96 The protective effects of 
flavonoids in diabetes as antioxidants are often ascribed to their capacity to scavenge 
free radicals in vitro,97-100 to activate antioxidant enzymes,101 and to increase 
non-enzymic antioxidants.102 
 
1.3.2.6 Inhibition of AGE formation and AGE-mediated damage 
Advanced glycation end-products (AGEs) are the result of a chain of chemical reactions 
initiated by a glycation reaction (Maillard reaction). An abnormally elevated blood 
glucose level in diabetes mellitus causes the formation of AGEs in vivo, which is 
implicated in the development of chronic diabetic complications.103 
 
Suppression of the formation of Maillard reaction products by dietary phenolic 
compounds has also been shown in food model systems. Structure-activity studies of 
flavan-3-ols on the formation of Maillard reaction products in a glucose/glycine model 
system showed that the main mechanism by which these flavanols reduced product 
formation was the trapping of reactive carbonyl compounds, formed from sugar 
fragmentation.104 
 
Moreover, many studies have demonstrated that free radicals such as hydrogen peroxide, 
superoxide anion radicals and singlet oxygen, participate in the formation of AGEs. Those 
substances with outstanding antioxidant activity or/and free radical scavenging 
properties inhibit the formation of AGEs.105 Flavonoids possess additional properties 
relevant to prevent diabetic complications with their potent antioxidant abilities, by 
providing a protective effect against hyperglycemia-mediated protein damage.106 
 
There are increasing reports on natural products with combined antiglycation, 
antioxidant properties and reduced toxicity.107 As such, a number of plant-derived 
flavonoids105,108 and a purified micronized flavonoid fraction109 have been reported to 
inhibit glycation. 
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Table 1.3 Mechanisms of action of natural flavonoids for the treatment of diabetes mellitus 
Flavonoid Category Structure Mechanism 
Literature 
reference 
Quercetin (35) flavonols 
O
OH O
OH
OH
OH
HO
 
35 
promotion of glycogen synthesis; 
protection of β-cells against 
damage; 
inhibition of α-glucosidase 
[56]; 
[56-58]; 
[89] 
Myricetin (108) flavonols 
O
OH O
OH
OH
HO
OH
OH
 
108 
activation of glucose transport; 
stimulation of glucose uptake; 
promotion of glycogen synthesis; 
inhibition of sucrase, maltase and 
α-amylase 
[67]; 
[71]; 
[75]; 
[94] 
 
Kaempferol (40) flavonols 
O
OH O
OH
OH
HO
 
40 
inhibition of sucrase, maltase and 
α-amylase 
[94] 
Apigenin (109) flavones 
O
OOH
OH
HO
 
109 
scavenging of free radicals [100] 
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Luteolin (110) 
flavones 
 
O
OOH
OH
HO
OH
 
110 
inhibition of both α-glucosidase 
and α-amylase 
[86] 
Eupatilin (111) flavones 
OOH
OMe
HO
MeO
O
OMe
 
111 
enhancement of pancreatic β-cell 
function to increase insulin 
[62] 
Genistein (112) isoflavones 
O
OH O
HO
OH  
112 
proliferation of islet β-cells; 
stimulation of insulin secretion in 
pancreatic β-cells; 
inhibition of 
glucose-6-phosphatase; 
reduction of breakdown of 
glycogen 
[59]; 
[61]; 
 
[79]; 
[82] 
Daidzein (113) isoflavones 
O
HO O
OH  
113 
stimulation of glucose uptake; 
reduction of breakdown of 
glycogen 
[67]; 
[72] 
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7-O-Methylaromadendrin (114) flavanonols 
OMeO
OH O
OH
OH
 
114 
stimulation of glucose uptake [72] 
Isoquercitin (36) 
flavonol 
glycosides 
O
OOH
OH
OH
OO OH
OH
OH
HO
HO
 
36 
inhibition of α-glucosidase; 
inhibition of advanced glycation 
endproduct formation 
[88, 89]; 
[105] 
 
Hyperin (115) 
flavonol 
glycosides 
O
OH O
OH
HO
OH
O O
HO
OH
OH
OH
 
115 
inhibition of advanced glycation 
endproduct formation 
[105], [108] 
Kaempferol 3-O-rutinoside (42) 
flavonol 
glycosides 
OOH
OH O
OH
O
OH
OH
O
HO
O
O
OHHO
HO
  
42 
inhibition of α-glucosidase [92] 
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Rutin (38) 
flavonol 
glycosides 
O
OOH
OH
OH
O
O
HO
OH
O
OH
O
HO
OH
HO
HO
 
38 
inhibition of α-glucosidase; 
reduction of breakdown of 
glycogen; 
activation of signaling in 
pancreatic β-cells; 
scavenging of free radicals; 
activation of antioxidant enzymes; 
increase non-enzymic antioxidants 
[89], [105]; 
[83]; 
 
[63]; 
[100]; 
[101]; 
[102] 
Isorhamnetine 3-O-rutinoside (116) 
flavonol 
glycosides 
O
OOH
OH
HO
OMe
O
O
HO
OH
O
OH
O
HO
OH
HO
  
116 
inhibition of α-glucosidase [88] 
Kaempferol 3-neohesperidoside (117) 
flavonol 
glycosides 
O
OH O
OH
HO
O
O
OH
HO
HO
O O
HO
OH
OH
  
117 
stimulation of glucose uptake [70] 
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Isorhamnetin 3,7-di-O-β-D-glucopyranoside 
(118) 
flavonol 
glycosides 
O
OOH
OH
O
O
OH
HO
HO
O
O
HO
OH
OH
HO
OH
OMe
118 
scavenging of free radicals [98] 
Kaempferitrin (119) 
flavonol 
glycosides 
O
OH
O
OOH
O
O
O
OH
HO
HO
OH
OH
OH  
119 
scavenging of free radicals; 
stimulation of glucose uptake 
[99]; 
[68] 
Quercetin 3-O-α-(2"-galloyl)-rhamnoside 
(120) 
kaempferol 3-O-α-(2"-galloyl)-rhamnoside 
(121) 
flavonol 
glycosides 
O
OOH
OH
HO
R
O
O
HO
HO
O
O
OH
OH
OH
  
120: R = OH 
121: R = H 
inhibition of 
glucose-6-phosphatase 
[77] 
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Kaempferol 3-O-α-L-rhamnopyranoside 
(3"E,4"E)-di-p-coumaric acid ester (121), 
 kaempferol 3-O-α-L-rhamnopyranoside 
(3"E, 4"Z)-di-p-coumaric acid ester (122) 
flavonol 
glycosides 
O
OOH
OH
HO
O
O
OH
R2O
R1O OH
O
O OH
EC=
ZC=
 
121: R1 = R2 = EC 
122: R1 = EC, R2 = ZC 
inhibition of α-glucosidase [87] 
Corchoruside A (123), 
corchoruside B (124) 
flavonol 
glycosides 
O
OH O
OH
O
O
RO
OH
OH
OH
O
O
MeO
OH
O
HO
HO
HO
HO
O
caffeoyl:
 
123: R = caffeoyl 
 124: R = H 
inhibition of α-glucosidase [90] 
Quercetin 3-O-(6-O-caffeoyl)-β-galactoside 
(125), 
kaempferol 3-O-(6-O-caffeoyl)-β-galactoside 
(126), 
kaempferol 3-O-6-O-caffeoyl)-β-glucoside 
(127) 
flavonol 
glycosides 
OH
OH
O
OHO
OH O
OH
R1
O
OO
HO
OH
R2
R3
 
125: R1 = R2 = OH, R3 = H 
126: R1 = R3 = H, R2 = OH 
127: R1 = R2 = H, R3 = OH 
inhibition of maltase [93] 
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Hesperidin (128) 
flavanone 
glycosides 
O
OH O
OCH3
OH
O
O
O
OH
HO
HO
O
OH
HO
HO
 
128 
inhibition of 
glucose-6-phosphatase; 
reduction of breakdown of 
glycogen 
[78]; 
 
[81] 
Naringin (129) 
flavanone 
glycosides 
O
OH O
OH
O
O
HO
HO
O
O
OH
OH
HO
OH
 
129 
inhibition of 
glucose-6-phosphatase; 
reduction of breakdown of 
glycogen 
[78]; 
 
[81] 
Vitexin (130) 
flavone 
C-glycosides 
O
OOH
OH
HO
O
HO
HO
OH
OH
 
130 
inhibition of α-glucosidase [88] 
Swertisin (131) 
flavone 
C-glycosides 
O
OOH
OH
MeO
O
OH
HO
HO
OH
 
131 
inhibition of α-glucosidase [88] 
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Apigenin 6-C-glucosyl-7-O-glucoside (132) 
flavones 
C-glycoside 
O
OOH
OH
O
OH
HO
HO
OH
O
OH
HO
HO
OH
O
 
132 
inhibition of α-glucosidase [91] 
Cyanidin 3-O-glucoside (133) anthocyanins 
O
OH
OH
HO
O
OH
O
HO
OH
OH
HO
 
133 
inhibition of advanced glycation 
endproduct formation 
[108] 
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1.3.3 Natural flavonoids with antidiabetic activities reported from in vivo studies 
Besides the studies on the mechanisms of action of flavonoids against diabetes, 
attention was also given to their activities in the treatment of experimental diabetic 
animals. New studies on natural flavonoid compounds with diverse skeletons and 
antidiabetic potential reported since 2000 to date are presented here, with the 
parameters tested (Table 1.4). 
 
Treatments with quercetin (35) were reported to significantly and dose-dependently 
decrease the plasma glucose, cholesterol and triglyceride (TG) level and to normalize the 
glucose tolerance curves of STZ-induced diabetic rats.56 In a similar diabetic model, 
quercetin (35) administration resulted in a decrease in serum glucose and an increase in 
serum insulin levels. A preservation of islet cells was observed as well. In addition, by 
reducing plasma malondialdehyde (MDA), a marker of lipid peroxidation, the quercetin 
(35) treatment could reduce STZ-induced oxidative stress.57,58 
 
In a study on treatment with rutin (38), the glycoside of quercetin (35), parameters such 
as plasma glucose and glycosylated hemoglobin (HbA1c) were found to be significantly 
reduced, together with an increase of insulin, C-peptide, hemoglobin and protein levels 
in STZ-induced diabetic Wistar rats. Treatment of diabetic rats with rutin (38) also 
resulted in a prevention of oxidative stress, since a decrease of thiobarbituric acid 
reactive substances (TBARS) and lipid hydroperoxides and an increase of non-enzymatic 
antioxidants were detected.102 
 
Kaempferitrin (119), which was isolated from the butanol fraction of Bauhinia forficata 
Link (Fabaceae) leaves, was found to decrease serum glucose levels significantly both in 
normal and alloxan-induced diabetic rats. The effect was maintained throughout the 
period studied. However, kaempferitrin (119) failed to change the glucose tolerance 
curve during the time course.99 
 
Water decoctions of the plant Cecropia obtusifolia Bertol. (Cecropiaceae), also called 
“Guarumbo” in Mexico, are traditionally used for the treatment of Type 2 diabetes. 
Bioassay-guided isolation of the active components from this plant, led to the 
identification of isoorientin (134), a natural flavonoid. Further pharmacological tests 
showed that isoorientin (134) exhibited a significant hypoglycemic effect comparable to 
that of glibenclamide, an antidiabetic drug stimulating insulin release in STZ-induced 
diabetic rats.110 
 
The flavone eupatilin (111), isolated from Artemisia princeps Pampan. (Asteraceae), was 
used to study the dose-response effects on blood glucose regulation and pancreatic 
β-cell function in C57BL/KsJ-db/db diabetic mice, a model for diabetic dyslipidemia. It 
was demonstrated that the supplementation of eupatilin (111) significantly lowered the 
fasting blood glucose concentration, glycated hemoglobin and plasma glucagon levels, 
while it simultaneously increased the hepatic glycogen content, plasma insulin and 
adiponectin levels.62 
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Genistein (112) and daidzein (113), the major isoflavones of soybean (Glycine max) 
(Fabaceae), were found to lower blood glucose, increase the insulin/glucagon ratio and 
the C-peptide level and to preserve β-cells of the pancreas in the non-obese diabetic 
mice, a model of the onset of Type 1 diabetes. Improved plasma TG and free fatty acid 
concentrations were also observed with the supplements of genistein (112) and daidzein 
(113). These results suggest the beneficial effect of genistein (112) and daidzein (113) on 
diabetes.111 
 
Another study showed that the supplement of genistein (112) increased the plasma 
insulin level and glucokinase level while decreased the HbA1c and 
glucose-6-phosphatase level of the STZ-induced diabetic rats. An increase of hepatic 
superoxide dismutase, catalase and glutathione peroxidase activities were also observed 
in the groups treated with genistein (112). The results again suggested genistein’s 
beneficial potential for hyperglycemia and related diabetic complications.79 
 
In an investigation of a natural flavonoid, apigenin 6-C-(2"-O-α-L-rhamnopyranosyl)- 
β-L-fucopyranoside (135), which was isolated from Averrhoa carambola L. (Oxalidaceae) 
leaves, an acute lowering effect on blood glucose was observed in hyperglycemic rats. 
The compound could also significantly stimulate the 14C-glucose uptake and the 
glucose-induced insulin secretion112. Apigenin 6-C-β-L-fucopyranoside (136), another 
natural flavonoid with the same aglycone (109) from this plant, showed a similar effect in 
hyperglycemic normal rats.113 
 
Naringenin (137), which is a citrus-derived (Rutaceae) flavanone, displayed both 
lipid-lowering and insulin-like properties. In low-density lipoprotein (LDL) receptor-null 
mice fed with a western diet, a model of diet-induced insulin resistance, the addition of 
naringenin (137) could decrease plasma lipids, liver TG and cholesterol, normalize blood 
glucose, plasma insulin, and glucose tolerance. These effects prove naringenin’s potential 
on metabolic syndrome.114 
 
Naringin (129), a naringenin (137) glycoside, and hesperidin (128), also citrus-derived 
bioflavanones, both significantly decreased blood glucose, elevated hepatic glucokinase 
activity and glycogen concentration in C57BL/KsJ-db/db mice. Two 
bioflavonoid-supplemented groups of mice also demonstrated significantly increased 
plasma insulin, C-peptide, and leptin levels. The results suggest that hesperidin and 
naringin help to prevent the progression of hyperglycemia.81 
 
Besides, hesperidin (128) also proved to have a preventive action against diabetic 
embryopathies. With a decrease on maternal glycemia, hesperidin (128) treatment 
increased the number of implantations, foetuses and the foetal weights. A decrease of 
maternal body weight in pregnant diabetic mice was observed as well. In addition, the 
malformations and resorption rates were reduced.115 
 
Chapter 1 
31 
Phloridzin (138), a dihydrochalcone, is naturally occurring in apples, species Malus 
domestica (Rosaceae). Diets containing phloridzin (138) showed antihyperglycemia 
activities, however, unlike quercetin (35), it failed to improve hypoinsulinemia and tissue 
lipid peroxidation in STZ-induced diabetic mice. In a gene expression responses test, 
dietary phloridzin (138) indicated to reverse the abnormal overexpression of 
sodium/glucose cotransporter 1, cytochrome P450 2B10, and epoxide hydrolase 1 in the 
small intestine, as well as that of glucose transporter 2 in the kidney of STZ-induced 
diabetic mice.116 
 
Two chalcones, 4-hydroxyderricin (139) and xanthoangelol (140) were isolated from the 
ethanol extract of Angelica keiskei (Apiaceae), a Japanese herb named “Ashitaba”. Two 
weeks feeding of basal diets containing 4-hydroxyderricin (139) and xanthoangelol (140) 
both decreased blood glucose levels of KK-Ay mice, an animal model of metabolic 
syndrome. In a glucose uptake assay, 4-hydroxyderricin (139) showed stronger activity, 
compared with xanthoangelol (140).117 
 
Green tea, the leaves of Camellia sinensis (Theaceae), is a significant source of a type of 
flavonoids called catechins. The green tea catechins include (-)-epigallocatechin gallate 
(EGCG, 141), (-)-epigallocatechin, (-)-epicatechin gallate, and (-)-epicatechin (142). An 
injection of EGCG (141) produced a significant decrease in serum glucose levels, food 
intake and body weight in Sprague Dawley rats, as well as in lean and obese Zucker 
rats.118 Additionally, (-)-epicatechin (142), the active compound in the extract of 
Pterocarpus marsupium Roxb bark, which is traditionally used in Indian folk medicine to 
treat diabetes, also showed significant hypoglycemic effects.119 
 
Anthocyanins, with their aglycone derivatives, called anthocyanidins, belong to the 
flavonoids. Of these groups, pelargonidin (143), which is abundantly present in common 
bean (Phaseolus vulgaris L.) (Fabaceae), together with pelargonodin 3-O-rhamnoside and 
pelargonidin 3-galactoside, displayed significant hypoglycemic effects in diabetic rats. 
Moreover, pelargonidin (143) treatment was found to decrease blood glucose, normalize 
glucose tolerance and improve serum insulin levels in STZ-induced diabetic rats. A 
decrease of serum superoxide dismutase and catalase levels, with an increase of 
malondialdehyde level, was observed in the experiment as well.120 
 
Silybinin (144) is the major flavonolignan from the extracts of milk thistle seed, Silybum 
marianum (Asteraceae). In patients with Type 2 diabetes mellitus and associated chronic 
liver disease, a better glucose and lipid metabolism was observed after the treatment 
with a silybinin β-cyclodextrin complex agent. The same trend towards normalization 
was achieved in mean daily blood glucose, HbA1c and insulin levels. Moreover, insulin 
sensitivity, which was estimated by MDA, an index of oxidative stress, was improved 
after the use of silybinin (144) in Type 2 diabetes patients.121 
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Table 1.4 Natural flavonoids with antidiabetic activities reported from in vivo studies 
Flavonoid Category Struture Dosage Marker/parameter tested/evaluated 
Literature 
reference 
Quercetin (35) flavonols 
O
OH O
OH
OH
OH
HO
 
35 
10, 15 
mg/kg 
decreased the plasma glucose, cholesterol and TG, 
normalized the glucose tolerance; 
decreased serum glucose, MDA and NO, elevated 
serum insulin and antioxidant enzyme activities; 
decreased serum glucose and MDA, restored vascular 
function, increased antioxidant capacity 
[56]; 
 
[57]; 
 
 
[58] 
Rutin (38) 
flavonol 
glycosides 
O
OOH
OH
OH
O
O
HO
OH
O
OH
O
HO
OH
HO
HO
 
38 
25, 50, 
100 
mg/kg 
decreased fasting plasma glucose, HbA1c, insulin, 
C-peptide, hemoglobin, protein levels, TBARS and lipid 
hydroperoxides, increased non-enzymatic antioxidants 
[102] 
Kaempferitrin (119) 
flavonol 
glycosides 
O
OH
O
OOH
O
O
O
OH
HO
HO
OH
OH
OH  
119 
50, 
100, 
200 
mg/kg 
decreased blood glucose [99] 
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Isoorientin (134) 
flavonol 
glycosides 
O
O
OH
OH
O
OH
HO
HO
HO
OH
O OH
OH
 
134 
3 
mg/kg 
decreased plasma glucose [110] 
Eupatilin (111) flavones 
OOH
OMe
HO
MeO
O
OMe
 
111 
50, 200 
mg/kg 
lowered fasting blood glucose, 
HbA1c and plasma glucagon, increased glycogen 
content, plasma insulin and adiponectin 
[62] 
Genistein (112) isoflavones 
O
OH O
HO
OH 
112 
200 
mg/kg 
 
600 
mg/kg 
decreased blood glucose level, 
increased the insulin/glucagon ratio and the C-peptide, 
improved plasma TG and free fatty acid; 
increased the plasma insulin and glucokinase, 
decreased HbA1c and glucose-6-phosphatase 
[111]; 
 
 
[79] 
 
Daidzein (113) isoflavones 
O
HO O
OH 
113 
200 
mg/kg 
decreased blood glucose level, 
increased the insulin/glucagon ratio and the C-peptide, 
improved plasma TG and free fatty acid 
[111] 
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Apigenin 6-C-(2"-O- 
α-L-rhamnopyranosyl)- 
β-L-fucopyranoside 
(135) 
flavone 
C-glycosides 
O
OOH
OH
HO
O
OHO
HO
O
HO
HO OH
 
135 
50 
mg/kg 
lowered blood glucose level, 
stimulated glucose-induced insulin secretion 
[112] 
Apigenin 6-C-β-L- 
fucopyranoside (136) 
flavone 
C-glycosides 
O
OOH
OH
HO
O
OH
OH
HO
 
136 
50 
mg/kg 
lowered blood glucose level, 
stimulated glucose-induced insulin secretion, 
regulated glycogen synthesis 
[113] 
Naringenin (137) flavanones 
O
OH O
OH
HO
 
137 
3% 
w/w 
decreased plasma lipids, liver TG and cholesterol, 
normalized blood glucose, plasma insulin and glucose 
tolerance 
[114] 
Hesperidin (128) 
flavanone 
glycosides 
O
OH O
OCH3
OH
O
O
O
OH
HO
HO
O
OH
HO
HO
 
128 
200 
mg/kg 
 
20 
mg/kg 
 
reduced blood glucose, elevated hepatic glucokinase 
activity and glycogen concentration, 
increased plasma insulin, C-peptide and leptin levels; 
decreased maternal body weight, glycaemia, 
malformations and resorption rates, 
enhanced implantations, foetuses and foetal weights 
[81]; 
 
 
[115] 
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Naringin (129) 
flavanone 
glycosides 
O
OH O
OH
O
O
HO
HO
O
O
OH
OH
HO
OH
 
129 
200 
mg/kg 
reduced blood glucose, elevated hepatic glucokinase 
activity and glycogen concentration, 
increased plasma insulin, C-peptide and leptin levels 
[81] 
Phloridzin (138) chalcones 
OH
O
OH
OH
O
O
OH
HO
HO
HO
OH
 
138 
0.5 % 
diet 
improved hyperglycemia, 
reversed the abnormal overexpression 
[116] 
4-Hydroxyderricin 
(139) 
chalcones 
OOH
OH
MeO
 
139 
0.15 % 
diet 
reduced blood glucose [117] 
Xanthoangelol (140) chalcones 
OOH
OH
HO
 
140 
0.15 % 
diet 
reduced blood glucose [117] 
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()-Epigallocate- 
chingallate (141) 
catechins 
O
OH
OH
OH
HO
O
O
OH
OH
OH
OH  
141 
82 
mg/kg 
decreased glucose serum [118] 
()-Epicatechin (142) catechins 
O
OH
OH
HO
OH
OH
 
142 
15, 30 
mg/kg 
decreased glucose serum [119] 
Pelargonidin (143) anthocyanins 
O
OH
OH
HO
OH
 
143 
3 
mg/kg 
decreased blood glucose levels, 
improved serum insulin and glucose tolerance, 
increased superoxide dismutase and catalase, 
lowered MDA and fructosamine 
[120] 
Silybinin (144) flavonolignan 
O
O
O
OH
OMe
OH
OH O
OH
HO
 
144 
135 
mg/day 
decreased fasting blood glucose [121] 
Abbreviations: TG, triglyceride; MDA, malondialdehyde; NO, nitric oxide; HbA1c, glycated haemoglobin; TBARS, thiobarbituric acid reactive substances 
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1.3.4 Studies on flavonoids used for the treatment of diabetic complications 
Diabetes is a chronic, life-long disease which needs careful management. It can lead to 
various complications such as cardiovascular disease, kidney failure, nerve damage and 
blindness. The beneficial effects of flavonoids are numerous, involved in battling many 
types of diabetic complications. Their specific bioactivities on different diabetic 
complications, with the parameters tested, are stated in Table 1.4. 
 
1.3.4.1 Treatment of diabetes-related cardiovascular disease 
Diabetes has become a major risk factor for cardiovascular disease (CVD), and in turn, 
the CVD is the main cause of death in people with diabetes.122 More and more 
epidemiological studies have suggested an inverse association between the dietary 
intake of flavonoids and the risk for vascular disease, which attracted scientists’ interest 
on flavonoids.123 
 
Pycnogenol, a flavonoid-rich (catechin, epicatechin, taxifolin, and procyanidins) extract 
from the bark of the French maritime pine (Pinus maritima) (Pinaceae), was reported to 
show beneficial effects on the cardiovascular system. Pycnogenol treatment in Type 2 
diabetes individuals achieved blood pressure control, decreased serum endothelin-1, an 
endothelial-derived vasoconstrictor peptide associated with modulating the vascular 
tone. Additionally, pycnogenol mediated a significant improvement in serum LDL 
cholesterol, a predictor of cardiovascular disease in individuals with diabetes. The results 
suggested that pycnogenol has beneficial effects in Type 2 diabetes-related 
cardiovascular disease.124 
 
For those drugs with poor solubility, cyclodextrins can be used in pharmaceutical 
preparations to increase the bioavailability. In a study of the effects on left ventricle 
dysfunction in STZ-induced diabetic rats, β-cyclodextrin complexes of quercetin (35) and 
rutin (38) significantly decreased serum TG and cholesterol levels. In the 
histopathological studies, the degree of myocardial necrosis was less in rutin-treated 
animals, with decreased myocardial fructose levels. This investigation demonstrates that 
quercetin (35) and rutin (38) have a cardioprotective activity.125 
 
In another study, the treatment with phytoestrogenic isoflavones genistein (112) and 
daidzein (113) effectively improved glucose toxicity-induced cardiac mechanical 
malfunction in ventricular myocytes.126 Both results suggest that the flavonoids-related 
preparations have a therapeutic role against diabetes-associated cardiac defects. 
 
1.3.4.2 Treatment of diabetic nephropathy 
Diabetic nephropathy is one of the most serious complications in diabetes mellitus, and 
it could cause end-stage renal failure among patients undergoing chronic hemodialysis 
therapy127. Together with a good hypoglycemic activity, flavonoids could be used to 
prevent the development and progression of nephropathy. 
 
The flavonoid mixture silymarin, was tested for its effect on oxidative stress and renal 
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tissue morphology in alloxan-induced diabetic rats. Tissue damage caused by alloxan was 
prevented by silymarin treatment and the activity and gene expression of the three 
antioxidant enzymes (SOD, glutathione peroxidase and catalase) were restored after the 
treatment with silymarin. These results suggest that silymarin can be useful in the 
treatment of diabetic nephropathy.128 
 
Supplementation of green tea catechin, recovered the destroyed balance between 
prostacyclin and thromboxane A2, an index of kidney function, in the kidney microsomes 
of STZ-induced diabetic rats. Catechin also adjusted the kidney thiobarbituric acid 
reactive substance (TBARS) content, an index of lipid peroxidation, to the normal 
level.129,130 Besides, treatment with tea catechin significantly reduced albuminuria in 
diabetic rats. Moreover, it helped to normalize the glomerular hypertrophy and 
interstitial fibrosis.131 These results suggest that tea catechin can contribute to the 
prevention of diabetic kidney failure. 
 
In a study of EGCG (141), a type of catechins abundant in green tea, treated rats with 
subtotal nephrectomy and STZ injection showed decreased hyperglycemia, suppressed 
proteinuria and lipid peroxidation. In a renal damage pathological test, reduced renal 
advanced glycation endproduct accumulation and related protein expression in the 
kidney cortex were observed. These results proved EGCG’s beneficial effect on abnormal 
glucose metabolism-associated renal damage.132 
 
Another study showed that breviscapine (145), a flavonoid isolated from the Chinese 
herb Erigeron breviscapus, significantly alleviated albuminuria, glomerular hypertrophy 
and tubulointerstitial injury in STZ-induced diabetic rats, which involves a renoprotective 
effect through suppression of renal macrophage recruitment.133 
 
O
OH O
OH
O
OH
O
OH
O
HO
HO
HO
 
Breviscapine 145 
 
1.3.4.3 Treatment of oxidative stress-associated diabetic complications 
Diabetes is closely associated with oxidative stress, by which it produces excessive free 
radicals to contribute to the development of diabetes, and further to accelerate diabetic 
complications.134 Natural flavonoids are helpful in many oxidative stress problem related 
diabetic complications such as diabetic neuropathic pain, renal and liver damage. 
 
Several laboratory studies showed that quercetin (35) may be beneficial in diabetic 
neuropathy. Quercetin-treated STZ-induced diabetic and nondiabetic mice both 
exhibited a marked increase in tail-flick latencies.135 Additionally, chronic treatment with 
quercetin (35) significantly produced an improvement of cold allodynia and thermal 
hyperalgesia in STZ-induced diabetic rats.136 In a study of the evaluation of the flavonoid 
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baicalein (146) on diabetic peripheral neuropathy, this compound was shown to reverse 
nerve conduction deficit and small sensory nerve fiber dysfunction.137 
 
O
OH O
HO
HO
 
Baicalein 146 
 
Another report showed that quercetin (35) treatment significantly decreased oxidative 
stress with markers such as superoxide dismutase, catalase, serum creatinine and blood 
urea nitrogen levels increased in STZ-injected rats. Moreover, renal dysfunction evidence 
such as proteinuria, polyuria, creatinine and urea clearance were improved.138 The 
treatment with rutin (38) adjusted the antioxidant status of diabetic rats by decreasing 
lipid peroxidative products and by increasing enzymatic (SOD, catalase, glutathione 
peroxidase and glutathione reductase) and nonenzymatic antioxidants (reduced 
glutathione, vitamin C and E).101 The findings suggest that the protective role of 
flavonoids on diabetic organs damage, probably is materialized through their 
antioxidative action. 
 
1.3.4.4 Treatment of diabetes-related hyperlipidemia 
Diabetes mellitus is a metabolic syndrome, with hyperglycemia and hyperlipidemia often 
seen together in this disease. Flavonoids are found to have not only antidiabetic activity 
but also a hypolipidemia effect. 
 
Rutin (38) was found to have a beneficial effect on lipids, lipoproteins, lipid-metabolizing 
enzymes and glycoproteins.139 Apigenin (109) was demonstrated to alleviate 
hyperlipidemia and atherosclerosis in diabetes, by increasing phosphorylation of 
hepatocellular adenosine monophosphate-activated protein kinase (AMPK), which plays 
an important role in the pathogenesis of hyperlipidemia in diabetes.140 
 
1.3.4.5 Treatment of diabetic complications associated with advanced glycation 
end-products 
Advanced glycation end-products (AGEs) are a diverse class of biomolecules resulting 
from non-enzymatic glycation of amino acids, peptides, proteins or amines with reducing 
sugars, such as glucose and fructose, or its autooxidation products. They are specifically 
the result of the Maillard reaction.103 The AGEs play an important role in the 
development of diabetic complications, such as neuropathy, retinopathy and 
nephropathy.107 Flavonoids have the proven ability to inhibit the formation of AGEs. 
 
In a study of the protective potential against protein damage of four flavonoids, 
isoquercitin (36) and hyperin (115) exerted a stronger inhibitory activity against the 
formation of AGEs in vitro. The activities were more potent than that of aminoguanidine, 
a known glycation inhibitor.105 In another study, isoquercitin (36) with two other flavonol 
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glycosides, quercetin 3-O-α-L-arabinopyranosyl-(1→2)-β-D-glucopyranoside (147) and 
astragalin (41), isolated from the leaves of Eucommia ulmoides Oliv. (Eucommiaceae), 
were demonstrated as glycation inhibitors as well.141 
 
O
OH O
OH
HO
OH
O
OH
HO
HO
O
O
OH
OH
OH
O
 
Quercetin 3-O-α-L-arabinopyranosyl-(1→2)-β-D-glucopyranoside 147 
 
1.3.4.6 Treatment of other diabetic complications 
Poorly controlled diabetics can cause an accelerated development of the following 
complications. 
 
Diabetic retinopathy (damage to the retina) is also a type of complication from diabetes 
mellitus, which induces blindness at the end. Treatment with genistein (112) significantly 
inhibited retinal vascular leakage in STZ-induced diabetic rats. A decrease of retinal 
albumin, phosphotyrosine levels and proliferating cell nuclear antigen were observed as 
well.142 
 
Diabetes also causes depression, along with the inefficient plasma glucose control and 
increased risk of diabetic complications. Quercetin (35) showed a potential in therapy for 
depression associated with diabetes. It markedly reduced the immobility period in 
STZ-induced diabetic mice, compared with that of fluoxetine and imipramine, the 
classical antidepressants.143 
 
Osteopenia (lowered bone mineral density) is also a diabetic complication. Myricetin 
(108) displayed protective effects on 2-deoxy-D-ribose-induced cytotoxicity in 
osteoblastic MC3T3-E1 cells and osteoblast dysfunction.144 A similar activity was found 
after treatment with kaempferol (40).145 These results suggest that both myricetin (108) 
and kaempferol (40) are beneficial in diabetes-related bone diseases. 
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Table 1.4 Effects of flavonoids in the treatment of diabetic complications 
Flavonoid Diabetic complication Marker/parameter tested/evaluated 
Literature 
reference 
(–)-Epigallocatechin-3-O-gallate (141) diabetic nephropathy 
reduction of kidney weight, TC, TBARS, serum urea nitrogen, serum 
creatinine, creatinine clearance and urinary protein excretion 
[132] 
Apigenin (109) hyperlipidemia 
increase of AMPK and ACC phosphorylation, 
prevention of high-glucose-induced lipid accumulation 
[140] 
Breviscapine (145) diabetic nephropathy 
reduction of kidney weight, urinary albumin excretion rate, 
tubulointerstitial injury, MDA, 
increase of SOD, CAT and GSH-PX 
[133] 
Catechins diabetic nephropathy 
improvement of prostacyclin / thromboxane A2 ratio, 
decrease of TBARS; 
reduction of urinary albumin excretion rate, 
normalization of interstitial fibrosis area 
[129, 130]; 
 
[131] 
 
Daidzein (113) cardiovascular disease reduction of mechanical malfunction in ventricular myocytes [126] 
Genistein (112) 
cardiovascular disease 
diabetic retinopathy 
reduction of mechanical malfunction in ventricular myocytes; 
decrease of retinal vascular permeability, retinal albumin, 
phosphotyrosine and proliferating cell nuclear antigen 
[126]; 
[142] 
 
Isoquercitin (36), 
hyperin (115) 
AGE formation inhibition of glycation [105] 
Myricetin (108), 
kaempferol (40) 
osteopenia 
increase of cell survival, ALP activity, collagen, osteocalcin, 
osteoprotegerin and calcium deposition; 
decrease of MDA, protein carbonyl and 
advanced oxidation protein products 
[144]; 
 
[145] 
 
Pycnogenol 
cardiovascular disease 
kidney failure 
decrease of endothelin-1, LDL-cholesterol and urinary albumin [124] 
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Quercetin (35) 
cardiovascular disease 
diabetic nephropathy 
 
 
diabetic neuropathy 
 
 
AGE formation 
depression 
decrease of body mass, TG, cholesterol, myocardial fructose; 
decrease of proteinuria, polyuria, serum creatinine, blood urea 
nitrogen and MDA, 
increase of creatinine and urea clearance, SOD, CAT, GSH-PX; 
increase of tail withdrawal latency; 
attenuation of cold allodynia, hyperalgesia, increase of tail 
immersion and hot-plate pain threshold; 
inhibition of glycation; 
reduction in immobility period 
[125]; 
[138]; 
 
 
[135]; 
[136]; 
 
[108]; 
[143] 
Quercetin 3-O-α-L-arabinopyranosyl- 
(1→2)-β-D-glucopyranoside (147), 
astragalin (41), 
isoquercitin (36) 
AGE formation inhibition of glycation [141] 
Rutin (38) 
Hyperlipidemia 
 
 
 
oxidative stress-related diseases 
decrease of cholesterol, TG, free fatty acids, phospholipids, 
LDL-cholesterol, very LDL-cholesterol, HMG-CoA reductase, 
glycoproteins, TBARS and HP 
increase of LPL, LCAT, HDL-cholesterol; 
increase of GSH, Vitamin C, Vitamin E, SOD, CAT and GSH-PX 
[139] 
 
 
 
[101] 
Silymarin diabetic nephropathy restoration of SOD, GSH, CAT [128] 
Abbreviations: TC, total cholesterol; TBARS, thiobarbituric acid reactive substances; AMPK, AMP- activated protein kinase; ACC, acetyl-CoA carboxylase; 
MDA, malondialdehyde; SOD, superoxide dismutase; CAT, catalase; GSH-PX, glutathione peroxidase; ALP, alkaline phosphatase; LDL, low-density lipoprotein; 
TG, triglyceride; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A; LPL, lipoprotein lipase; LCAT, lecithin-cholesterol acyltransferase; HDL, high-density 
lipoprotein; HP, hydroperoxides; GSH, glutathione 
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1.3.5 Conclusion and further perspectives 
As the incidence of diabetic patients around the world continues to rise and due to the 
complexity and diversity of the disease etiology, together with its multiple complications, 
medicinal researchers have increasing responsibilities to seek for effective drugs for the 
treatment of diabetes mellitus. Natural products and their derivatives have been among 
the most productive source of bioactive molecules in drug discovery.146 The contribution 
of natural products to the development of antidiabetic agents is clearly evident, as we 
discussed at the beginning. Flavonoids are a large group of natural products, and 
according to the literature, more than 10,000 different flavonoids from widespread 
plant sources have been reported with each year, hundreds of newly identified 
flavonoids being recorded.147 
 
Flavonoids exhibit multiple biological activities, such as antiviral, antiinflammatory, 
antiproliferative and anticancer activity, attracting the interest of scientists. Their well 
noted ability to reduce free radical formation and to scavenge free radicals highlights 
the antioxidant activity of flavonoids.148 Recent investigations have demonstrated that 
flavonoids are also very promising antidiabetic agents. The major potential benefits of 
natural flavonoids discussed in this overview clearly demonstrate that these substances 
represent remarkable lead compounds with a diversity of molecular structure and 
biological activity, in relation to the antidiabetic drug discovery process. Although 
considerable scientific progress has been made in unraveling the effect of flavonoids on 
diabetes, diabetic complications and their mechanism of action, especially over the past 
10 years, the pharmacokinetic factors including the absorption, metabolism and 
toxicological aspects of flavonoids, together with the missing steps in the 
flavonoid-signaling network based on the complex mechanism of insulin action shall 
have to be concerned.149 
 
On the other hand, a large number of plant extracts have gained gratifying results in 
experimental animal models and clinical studies for the treatment of diabetes mellitus. 
Unlike a single chemical entity aimed at a specific single target, multi-flavonoid-rich 
plant extracts managed to alleviate the disorder of diabetes mellitus, probably through 
an integrated effect upon multi-target sites. Flavonoids are very common in several 
comestible fruits and vegetables as parts of our daily food consumption.150 There is no 
doubt that plant extracts should be viewed as a potential complementary treatment for 
diabetes. 
 
Diabetes mellitus is a chronic disease which is difficult to cure. Without the control of 
blood glucose it fastly develops diabetic complications. The evidences from published 
literature demonstrate that some flavonoids, such as quercetin (35) and rutin (38), show 
multifunctional health benefits in diabetes and its complications due to their acting on 
many targets with high affinity. Nowadays, more antidiabetic research studies are 
focused on its pathogenesis, and the studies of the action of active ingredients are 
relatively small. Flavonoids, as an important class of natural products with high 
pharmacological activities, provide new insights into the potential role of lead 
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compounds in diabetes treatment. The knowledge offered from this overview should 
help to provide leads to the ultimate goal of developing new more efficient therapeutic 
drugs for the treatment of diabetes mellitus and its complications, in spite of the fact 
that more clinical and experimental studies are obviously needed. 
 
1.4 Purpose and the goal of the present research 
Diabetes mellitus, as a worldwide chronic disease, is still rapidly increasing. Diabetes and 
its complications have caused serious burden on world’s economy. Most notably, more 
than 80% of diabetes deaths occur in low and middle-income countries.  
 
The traditional Chinese medicine, which uses natural medicines originating mainly from 
herbs by distinctive traditional medical theory, has demonstrated valuable practice and 
shows a bright future in the therapy of diabetes and its complications. Many 
prescriptions including Simple Recipes and Compound Recipes have been applied in the 
therapy of diabetes with a varying medical emphasis on different symptoms of the 
disease.52 Compared to the classical drugs (insulin and oral hypoglycemic agents) for the 
treatment of diabetes, some folk secret recipes showed outstanding curative effects with 
fewer side effects and lower cost for the maintenance of treatment of this lifelong 
disease. In this respect, the rich Chinese traditional medicines covering large numbers of 
medicinal plants offer a great potential for such discoveries. It is important to elucidate 
the active principles and to understand the mechanism of action of the natural 
medicines from traditional Chinese medicinal plants used in the treatment of diabetes.  
 
The genus Gynura Cass. (Asteraceae family) displays a broad range of uses in traditional 
Chinese medicine. As local secret recipes, G. bicolor and G. divaricata have been used to 
treat diabetes in Jiangsu, Zhejiang and Sichuan province in south China and showed 
excellent effects. Certain patients can successfully control their blood glucose levels in a 
normal status by eating the leaves of these two species or by drinking them as a tea.151 
In China, G. divaricata is mostly a wild species, while G. bicolor is cultivated as a 
vegetable in some regions. These two plants have been introduced and cultivated in the 
Nanjing Botanical Garden (Mem. Sun Yat-Sen) since 2000 by the Jiangsu Provincial Key 
LAB For Plant EX SITU Conservation. 
 
However, literature reports on these plants are limited and little is known about the 
antidiabetic chemical constituents from the plants. Our research group in China 
performed pharmacological tests to prove the hypoglycemic effect of these two plants. 
These tests showed that both ethyl acetate and butanol extracts of G. bicolor showed a 
significant effect on lowering the blood glucose level in normal and alloxan-diabetic mice, 
while the ethyl acetate and butanol extracts of G. divaricata were effective on lowering 
the blood glucose level in alloxan-diabetic mice in a low dosage. These results indicate 
that G. bicolor and G. divaricata are promising plants for the development of natural 
products for the treatment of diabetes mellitus. Therefore, it is very important to 
perform further research on the isolation of the active chemical constituents and on 
their mechanism of action.151 
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Based on the above consideration, the present research was undertaken to investigate 
the chemical ingredients of unstudied G. bicolor and G. divaricata, and to study their 
hypoglycemic bioactivity by evaluation of the pharmacological effects in in vitro models. 
Combined with the chemical study and biotesting of the hypoglycemic compounds of 
these two plants, the final goal of these research activities is to obtain some lead 
medicinal compounds for the treatment of diabetes mellitus, although this may, of 
course, not be realized within the scope of this thesis.  
 
Furthermore, essential oils are volatile secondary metabolites produced by aromatic 
plants and play an important role in the protection and life cycle of plants.152 Due to 
their interesting biological effects, they play an important role in traditional 
pharmacopoeia. Therefore, for the first time, the volatiles from fresh leaves of G. bicolor 
and Gynura divaricata are studied using a SPME method coupled with GC-MS.  
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2.1 Introduction 
Gynura bicolor (Roxb. & Willd.) DC is a herb, about 50-100 cm high; the stems are 
glabrous, rather woody at the base; leaves are obovate or oblanceolate; blade adaxially 
green while abaxially becoming purplish when dry (Figure 2.1). Capitula are numerous, 
peduncles about 3-4 cm; involucres campanulate; florets are orange to reddish; corolla 
distinctly exceeding involucres, 13-15 mm; tube 10-12 mm; lobes are ovate-triangular. 
Anthers are rounded at the base, or slightly acute. Style branch tips subulate, papillose. 
Achenes are brownish, cylindric, glabrous, 10-15-ribbed. Pappus white, silky, easily 
deciduous. The flower time is May to October.12 
 
 
Figure 2.1. Gynura bicolor (Roxb. & Willd.) DC 
 
Gynura bicolor, which has been cultivated as a popular vegetable, is not only known to 
be nutritive but is also used for the treatment of diabetes in the south of China. Our 
previous pharmacological tests proved that the ethyl acetate and n-butanol extracts of 
the aerial parts of the plant had significant effects on lowering blood glucose level in 
normal and alloxan diabetic mice.151 However, there are few reported phytochemical 
investigations of this species. To our knowledge, only two studies investigated the 
volatiles153,154 and one research reported on some anthocyanins155 from this plant. 
Therefore, this further research was conducted on the isolation and identification of the 
active chemical constituents from G. bicolor. The bioassay study of the isolated 
compounds on potential hypoglycemic activity, en route towards the development of 
natural products for the treatment of diabetes mellitus, was planned as well. 
 
2.2 Experimental 
2.2.1 Plant materials 
The aerial parts of G. bicolor for chemical constituent investigation were collected in 
June 2010 in Nanjing Botanical Garden Mem. Sun Yat-sen, in the south of the Zijin 
Mountain, Nanjing, China. The plant was identified by Professor Guo Rong-lin at the 
Institute of Botany, Jiangsu Province and Chinese Academy of Sciences. A voucher 
specimen (No. 510310-1) was deposited in the herbarium, Institute of Botany, Jiangsu 
Province and Chinese Academy of Sciences. 
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2.2.2 Instrumentation 
Silica gel 60 (0.015-0.040 mm for column chromatography; Merck) was used as normal 
phase, whereas LiChroprep RP-18 (40-63 m particle size; Merck) was used as reversed 
phase column material. MCI gel CHP20P (75-150m, 400-600 Å mean pore size; 
Mitsubishi Chemical Corp.) and Sephadex LH-20 (GE healthcare) were used for column 
chromatography as well. TLC analyses were carried out on silica gel plates (KG60-F254, 
Merck). The melting point was measured with an X-6 micro-melting point apparatus 
(Beijing Tech). 1H and 13C NMR spectra were obtained on a JEOL 300 spectrometer. The 
HPLC instrument consisted of an Agilent (Waldbronn, Germany) model 1100 liquid 
chromatograph with diode array detector. The HPLC-MS consisted of Agilent LC/MSD 
1100 series, and the prep-LC consisted of Agilent 1100 serious equipped with VWD 
detector and automatic fraction collector. Automatic flash chromatography was 
performed by The Reveleris Flash System from GRACE, United States. 
 
2.2.3 Extraction and Purification 
2.2.3.1 Extraction 
Dry aerial parts of G. bicolor (2.9 kg) were cut into small pieces and extracted with 80% 
aqueous ethanol at 70 ˚C twice to afford 295 g of crude extract after evaporation in 
vacuo of the solvent. The crude extract was dissolved in ethanol, coated on silica and 
dried, then successively extracted exhaustively with n-hexane, CH2Cl2, EtOAc and MeOH. 
The solvent was removed and the sample was dried before starting the next extraction 
with a new solvent. Extraction was executed with stirring at 40 ˚C of water-bath heating. 
The extracts were filtered and concentrated by evaporation under reduced pressure with 
a rotavapor at 40 ˚C to afford a dark green n-hexane residue (0.8 g, 0.03% yield), a dark 
CH2Cl2 residue (3.4 g, 0.12% yield), a dark EtOAc residue (7.7 g, 0.27% yield), and a dark 
brown MeOH residue (121.3 g, 4.18% yield). 
 
2.2.3.2 Study of the dichloromethane extract of the aerial parts of G. bicolor 
The CH2Cl2 extracted fraction (3.4 g) was adsorbed on 8.0 g of silica gel and further 
fractionated by column chromatography over silica gel, eluted with CH2Cl2 containing 
increasing concentrations of MeOH (Table 2.1). The fractions were collected in 50 mL 
tubes and after monitoring by TLC, a total of 6 different combined fractions (Fr. B1-6) 
were obtained (Table 2.2). 
 
Table 2.1 Programme for fractionation of the CH2Cl2 extract of G. bicolor by column chromatography 
Mobile phase 
Gradient elution 
Solvent volume (mL) 
Start End 
CH2Cl2 100 100 1000 
CH2Cl2/MeOH 100:2 100:2 1020 
CH2Cl2/MeOH 100:4 100:4 1040 
CH2Cl2/MeOH 100:10 100:10 1430 
CH2Cl2/MeOH 100:25 100:25 500 
CH2Cl2/MeOH 100:100 100:100 400 
MeOH (clean up) 100 100 300 
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Table 2.2 Column chromatography fractionation of the CH2Cl2 extract of G. bicolor 
Fraction Weight (mg) 
Fr. B1 1050 
Fr. B2 600 
Fr. B3 655 
Fr. B4 280 
Fr. B5 214 
Fr. B6 302 
 
2.2.3.2.1 Isolation of 5-(hydroxymethyl)furfural 148 
Fr. B1 (1050 mg) was adsorbed on a reverse phase LiChroprep RP-18 (1500 mg) and 
rechromatographed over a reverse phase column. After eluting by a gradient of water 
and methanol (50-100%) (Table 2.3) and monitoring by normal phase TLC, four combined 
fractions (Fr. B1-1~4) were obtained (Table 2.4). 
 
Table 2.3 Programme for separation of fraction Fr. B1 of G. bicolor by column chromatography 
Mobile phase 
Gradient elution 
Solvent volume (mL) 
Start End 
MeOH/H2O 50:50 50:50 300 
MeOH/H2O 70:30 70:30 300 
MeOH/H2O 85:15 85:15 300 
MeOH (clean up) 100 100 300 
 
Table 2.4 Column chromatography fractionation of Fr. B1 of G. bicolor 
Fraction Weight (mg) 
Fr. B1-1 176 
Fr. B1-2 105 
Fr. B1-3 144 
Fr. B1-4 133 
 
Fr. B1-2 (105 mg) was submitted to further purification with an automatic flash 
chromatography system on a normal phase column eluted by a gradient of CH2Cl2 and 
methanol (0-8%). The automatic flash chromatography conditions were (Table 2.5 and 
2.6):  
 
Table 2.5 Automatic flash chromatography conditions of Fr. B1-2 of G. bicolor 
Run conditions 
Cartridge: Reveleris 12 g Silica 
Solvent A: CH2Cl2 
Solvent B: Methanol  
Flow rate: 30 mL/min 
Detector: ELSD 
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Table 2.6 Automatic flash chromatography gradient method of Fr. B1-2 of G. bicolor 
Gradient Method 
Step Time (min.) %B 
1 0 0 
2 15 8 
 
The eluates from 8.3-10.6 min were combined, concentrated by evaporation under 
reduced pressure with a rotavapor and finally dried on high vacuum to afford a pure 
compound (148, 7.3 mg) as a colorless oil. 
 
By comparison of its 1H, 13C NMR and ESI-MS spectral data with those reported,156 the 
compound 148 was identified as 5-(hydroxymethyl)furfural. 
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5-(Hydroxymethyl)furfural 148: colorless oil; ESI-MS m/z: 127 [M+H]+; 1H NMR δ ppm 
(DMSO-d6, 300 MHz): 4.49 (2H, s, CH2OH), 6.59 (1H, d, J = 3.3 Hz, H-4), 7.48 (1H, d, J = 3.3 
Hz, H-3), 9.53 (1H, s, CHO); 13C NMR δ ppm (DMSO-d6, 75 MHz): 178.6 (CHO), 162.8 (C-5), 
152.3 (C-2), 125.0 (C-4), 110.3 (C-3), 56.5 (CH2OH). 
 
2.2.3.2.2 Isolation of benzoic acid 78 and 4-hydroxybenzaldehyde 149 
Fr. B1-1 (176 mg) was subjected to column chromatography over MCI gel eluted by a 
gradient of water and methanol (20-100%) for further separation (Table 2.7).  
 
Table 2.7 Programme for separation of fraction Fr. B1-1 of G. bicolor by column chromatography 
over MCI gel 
Mobile phase Gradient elution Solvent volume (mL) 
MeOH/H2O 20:80 150 
MeOH/H2O 40:60 200 
MeOH/H2O 60:40 200 
MeOH/H2O 80:20 150 
MeOH (clean up) 100 100 
 
Fractions MeOH/H2O 40:60 and 60:40 (102 mg) were mixed together and re-separated 
with silica gel column chromatography using a gradient of CH2Cl2 and MeOH as eluent 
(Table 2.8). Based on their identity (monitoring by TLC under UV 254 and 365 nm), 
fractions which had similar chromatographic behaviour were combined for subsequent 
purification.  
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Table 2.8 Programme for separation of the fraction 40:60-60:40 of G. bicolor 
Mobile phase Gradient elution Solvent volume (mL) 
CH2Cl2 100 200 
CH2Cl2/MeOH 100:1 600 
CH2Cl2/MeOH 100:2 400 
CH2Cl2/MeOH 100:10 300 
 
The CH2Cl2/MeOH 100:1-100:2 eluent was collected and two major bands with Rf value 
from 0.5-0.6 were observed on TLC plate (eluent: CH2Cl2/MeOH (10:1)) under UV 
detector. After solvent evaporation, a grey mixture was obtained. The mixture (28 mg) 
was dissolved in 1 mL HPLC grade methanol, then rechromatographed with an isocratic 
reversed phase preparative-HPLC elution with H2O/MeOH (35:65) for further purification. 
Prep-HPLC conditions were: C18 column with guard catridge, 21.2 mm ID  150 mm (5 
m); flow rate 6 mL/min; detection UV 254 nm; room temperature; injection volume 150 
L per time; running time 18 mins per injection; automatic fraction collector mode 
peak-based. 
 
The eluates from 12.6-13.7 and 13.9-15.3 min were collected respectively, concentrated 
by evaporation under reduced pressure with a rotavapor and finally dried on high 
vacuum to afford two pure compounds 78 (5.4 mg) and 149 (6.7 mg) as white powder. 
 
Analysis of their spectral data, together with comparison with data available in the 
literatures,157,158 allowed to elucidate the structures of the compound 78 and 149 and to 
identify them as benzoic acid and 4-hydroxybenzaldehyde, respectively. 
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Benzoic acid 78: white powder; m.p. 118-119 C; ESI-MS m/z: 121 [M-H]-; 1H NMR δ ppm 
(CDCl3, 300 MHz): 7.46-7.52 (2H, m, Harom), 7.60-7.65 (1H, m, Harom), 8.12 (2H, d, J = 7.2 
Hz, Harom); 
13C NMR δ ppm (CDCl3, 75 MHz): 171.7 (COOH), 133.9 (C-4), 130.3 (C-2 and 
C-6), 129.3 (C-1), 128.6 (C-3 and C-5). 
 
4-Hydroxybenzaldehyde 149: white powder; m.p. 108-109 C; ESI-MS m/z: 121 [M-H]-; 
1H NMR δ ppm (MeOH-d4, 300 MHz): 6.89 (2H, d, J = 8.5 Hz, H-3 and H-5), 7.76 (2H, d, J = 
8.5 Hz, H-2 and H-6), 9.74 (1H, s, CHO); 13C NMR δ ppm (CDCl3, 75 MHz): 190.9 (CHO), 
161.4 (C-4), 132.5 (C-2 and C-6), 130.1 (C-1), 116.0 (C-3 and C-5). 
 
2.2.3.2.3 Isolation of vanillic acid 80 
Fr. B1-3 (144 mg) was subjected to column chromatography on MCI gel eluted by a 
Study of the chemical constituents of the aerial parts of Gynura bicolor 
52 
gradient of water and methanol (20-100%) for further separation (Table 2.9).  
 
Table 2.9 Programme for separation of fraction Fr. B1-3 of G. bicolor by column chromatography 
over MCI gel 
Mobile phase Gradient elution Solvent volume (mL) 
MeOH/H2O 20:80 150 
MeOH/H2O 40:60 200 
MeOH/H2O 60:40 200 
MeOH/H2O 80:20 150 
MeOH (clean up) 100 100 
 
After monitoring by TLC with UV detection (254 and 365 nm), the 40% (methanol in 
water) eluent was collected for subsquent purification. Solvent removal by evaporation 
under reduced pressure yielded a grey mixture. The mixture (32 mg) was additionally 
purified by column chromatography on silica gel using CH2Cl2/MeOH (20:1) as eluent to 
afford a pure product (compound 80, 3.1 mg). 
 
By comparison of its 1H, 13C NMR and ESI-MS spectral data with those reported,159 the 
compound 80 was identified as vanillic acid. 
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Vanillic acid 80: white powder; m.p. 210-211 C; ESI-MS m/z: 167 [M-H]-; 1H NMR δ ppm 
(MeOH-d4, 300 MHz): 3.90 (3H, s, OCH3), 6.84 (1H, d, J = 8.3 Hz, H-5), 7.55 (1H, d, J = 1.8 
Hz, H-2), 7.56 (1H, dd, J = 8.3, 1.8 Hz, H-6); 13C NMR δ ppm (MeOH-d4, 75 MHz): 170.0 
(COOH), 152.7 (C-4), 148.7 (C-3), 125.3 (C-6), 123.0 (C-1), 115.8 (C-2), 113.8 (C-5), 56.4 
(OCH3). 
 
2.2.3.2.4 Isolation of ficusic acid 150 
Fr. B2 (600 mg) was fractionated with an automatic flash chromatography system on a 
reversed-phase column (C-18, 12 g) eluted by a gradient of water and methanol 
(50-100%) to get four fractions (Fr. B2-1~4). The automatic flash chromatography 
conditions were (Table 2.10 and 2.11):  
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Table 2.10 Automatic flash chromatography conditions of Fr. B2 of G. bicolor 
Run conditions 
Cartridge: Reveleris 12 g C18 
Solvent A: Water 
Solvent B: Methanol  
Flow rate: 30 mL/min 
UV1 wavelength: 220 nm 
UV2 wavelength: 280 nm 
ELSD carrier Isopropanol 
Injection type: Dry sample 
 
Table 2.11 Automatic flash chromatography gradient method of Fr. B2 of G. bicolor 
Gradient Method 
Step Time (min.) %B 
1 0 50 
2 20 60 
3 20 80 
4 20 100 
5 2 100 
 
The combined fractions were concentrated by evaporation under reduced pressure with 
a rotavapor and after monitoring by TLC with UV detection, four combined fractions (Fr. 
B2-1~4) were obtained (Table 2.12). 
 
Table 2.12 Column chromatography fractionation of Fr. B2 of G. bicolor 
Fraction Weight (mg) 
Fr. B2-1 248 
Fr. B2-2 175 
Fr. B2-3 64 
Fr. B2-4 83 
 
Fr. B2-1 (248 mg) was further subjected to column chromatography over MCI gel eluted 
by a gradient of water and methanol (20-100%) (Table 2.13). The 60% (methanol in water) 
eluent (56 mg) was collected for subsequent purification. Upon further silica gel column 
chromatography (CH2Cl2/MeOH, 100:1 to 10:1) (Table 2.14) and prep-HPLC (H2O/CH3CN, 
75:25), a pure compound 150 (2.2 mg) was obtained. The prep-HPLC conditions were: 
C18 column with guard cartridge, 21.2 mm ID  150 mm (5 m); flow rate 6 mL/min; 
detection UV 220 nm; room temperature; injection volume 200 L per time; running 
time 15 mins per injection; automatic fraction collector mode peak-based. 
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Table 2.13 Programme for separation of fraction Fr. B2-1 of G. bicolor by column chromatography 
over MCI gel 
Mobile phase Gradient elution Solvent volume (mL) 
MeOH/H2O 20:80 200 
MeOH/H2O 40:60 200 
MeOH/H2O 60:40 200 
MeOH/H2O 80:20 200 
MeOH (clean up) 100 100 
 
Table 2.14 Column chromatography fractionation of the fraction MeOH/H2O 60:40 of G. bicolor 
Mobile phase Gradient elution Solvent volume (mL) 
CH2Cl2/MeOH 100:1 400 
CH2Cl2/MeOH 100:2 400 
CH2Cl2/MeOH 100:10 200 
 
Analysis of its spectral data, together with comparison with data available in the 
literature,160 allowed to elucidate the structure of the compound 150 and to identify it as 
ficusic acid. 
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Ficusic acid 150: white powder; ESI-MS m/z: 197 [M+H]+; 1H NMR δ ppm (CDCl3, 300 
MHz): 1.27 (3H, s, H-11), 1.31 (3H, s, H-12), 1.34 (1H, t, J = 12.1 Hz, H-5b), 1.51 (1H, t, J = 
11.7 Hz, H-3b), 1.59 (3H, s, H-8), 2.04 (1H, ddd, J = 12.1, 4.0, 2.2 Hz, H-5a), 2.54 (1H, ddd, 
J = 11.7, 3.9, 2.2 Hz, H-3a), 4.06-4.19 (1H, m, H-4), 5.71 (1H, s, H-9). 13C NMR δ ppm 
(CDCl3, 75 MHz): 181.5 (C-10), 172.0 (C-2), 113.1 (C-9), 86.9 (C-1), 64.9 (C-4), 49.7 (C-3), 
47.9 (C-5), 35.2 (C-6), 30.0 (C-8), 25.6 (C-12), 25.1 (C-11). 
 
2.2.3.2.5 Isolation of dehydrovomifoliol 151 and loliolide 152 
Fr. B2-2 (175 mg) was further subjected to column chromatography over MCI gel eluted 
by a gradient of water and methanol (20-100%) (Table 2.15). The 40-60% (methanol in 
water) eluent (93 mg) was combined for subsquent purification. Upon further silica gel 
column chromatography (petroleum ether/EtOAc, 10:1 to 1:1) (Table 2.16) and 
prep-HPLC (H2O/CH3CN, 75:25), two pure compounds 151 (Rt: 12.0-12.8 min., 0.5 mg) 
and 152 (Rt: 15.3-17.1 min., 4.0 mg) were obtained. The prep-HPLC conditions were: C18 
column with guard cartridge, 21.2 mm ID  150 mm (5 m); flow rate 6 mL/min; 
detection UV 220 nm; room temperature; injection volume 150 L per time; running 
time 20 mins per injection; automatic fraction collector mode peak-based. 
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Table 2.15 Programme for separation of fraction Fr. B2-2 of G. bicolor by column chromatography 
over MCI gel 
Mobile phase Gradient elution Solvent volume (mL) 
MeOH/H2O 20:80 150 
MeOH/H2O 40:60 150 
MeOH/H2O 60:40 150 
MeOH/H2O 80:20 150 
MeOH (clean up) 100 100 
 
Table 2.16 Column chromatography fractionation of the fractions MeOH/H2O 40:60 and 60:40 of G. bicolor 
Mobile phase Gradient elution Solvent volume (mL) 
Petroleum ether/EtOAc 10:1 330 
Petroleum ether/EtOAc 8:1 360 
Petroleum ether/EtOAc 4:1 500 
Petroleum ether/EtOAc 2:1 300 
Petroleum ether/EtOAc 1:1 200 
 
Analysis of their spectral data, together with comparison with data available in the 
literatures,161,162 allowed to elucidate the structure of compound 151 and 152 as 
dehydrovomifoliol and loliolide, respectively. 
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Dehydrovomifoliol 151: colorless gum; ESI-MS m/z: 223 [M+H]+; 1H NMR δ ppm (CDCl3, 
300 MHz): 1.03 (3H, s, H-12), 1.11 (3H, s, H-11), 1.89 (3H, s, H-13), 2.31 (3H, s, H-10), 
2.34 (1H, d, J = 17.1 Hz, H-2a), 2.51 (1H, d, J = 17.1 Hz, H-2b), 5.96 (1H, s, H-4), 6.47 (1H, 
d, J = 16.0 Hz, H-8), 6.84 (1H, d, J = 16.0 Hz, H-7). 13C NMR δ ppm (CDCl3, 75 MHz): 197.4 
(C-3), 197.0 (C-9), 160.3 (C-5), 145.0 (C-7), 130.4 (C-8), 127.9 (C-4), 79.4 (C-6), 49.6 (C-2), 
41.5 (C-1), 28.5 (C-10), 24.4 (C-11), 23.0 (C-12), 18.8 (C-13). 
 
Loliolide 152: colorless needles; m.p. 148-149 C; ESI-MS m/z: 197 [M+H]+; 1H NMR δ 
ppm (CDCl3, 300 MHz): 1.27 (3H, s, H-9), 1.47 (3H, s, H-10), 1.53 (1H, dd, J = 14.3, 3.9 Hz, 
H-2a), 1.78 (1H, dd, J = 14.3, 3.9 Hz, H-4a), 1.79 (3H, s, H-11), 1.98 (1H, dt, J = 14.3, 2.8 Hz, 
H-2b), 2.47 (1H, dt, J = 14.3, 2.8 Hz, H-4b), 4.30-4.37 (1H, m, H-3), 5.70 (1H, s, H-7). 13C 
NMR δ ppm (CDCl3, 75 MHz): 182.5 (C-6), 172.0 (C-8), 113.0 (C-7), 86.8 (C-1), 66.9 (C-3), 
47.4 (C-2), 45.7 (C-4), 36.0 (C-5), 30.7 (C-9), 27.1 (C-11), 26.6 (C-10). 
 
Noteworthy, the 1H and 13C NMR spectral data of compound 152, which were in 
correspondence with loliolide,162 were also nearly identical with those of a compound, 
Study of the chemical constituents of the aerial parts of Gynura bicolor 
56 
named pubinernoid A, which was isolated from Schisandra pubescens var. pubinervis.163 
The structural proposal for pubinernoid A, with the same molecular formula as loliolide, 
was (4S*,6R*)-4-hydroxy-4,8,8-trimethyl-9-oxabicyclo[4.2.1]non-1-en-3-one, with an 
atypical value of 183.2 ppm for the chemical shift of the keto group. However, upon 
comparing GC-MS spectral data with data available in the WILEY6N database, compound 
152 was identified as loliolide. 
 
The GC-MS conditions were: HP-5MS (crosslinked 5% PH ME siloxane) capillary column 
(30 m  0.25 mm i.d., 0.25 m film thickness) and the gas carrier was helium, at 1 
mL/min rate. The injector and MS-transfer line temperatures were maintained at 220 
and 290 °C, respectively. Oven temperature was held at 40 °C for 3 min, raised to 180 °C 
at 2 °C/min and then to 250 °C at 10 °C/min (5 min hold). Electron impact mass spectra 
recorded at 40–500 mass range. An electron ionization system was used with ionization 
energy of 70 eV. 
 
Loliolide 152: EIMS, m/z: 196(M+, 10), 178(76), 163(43), 151(25), 140(44), 135(48), 
111(100), 107(46), 95(31), 79(23), 67(22), 57(20), 43(54). 
 
2.2.3.2.6 Isolation of vomifoliol 153 and boscialin 154 
Fr. B3 (655 mg) was fractionated with an automatic flash chromatography system on a 
reversed-phase column (C-18, 12 g) eluted by a gradient of water and methanol 
(50-100%) to get four fractions (Fr. B3-1~4). The automatic flash chromatography 
conditions were (Table 2.17 and 2.18):  
 
Table 2.17 Automatic flash chromatography conditions of Fr. B3 of G. bicolor 
Run conditions 
Cartridge: Reveleris 12 g C18 
Solvent A: Water 
Solvent B: Methanol  
Flow rate: 30 mL/min 
UV1 wavelength: 220 nm 
UV2 wavelength: 280 nm 
ELSD carrier Isopropanol 
Injection type: Dry sample 
 
Table 2.18 Automatic flash chromatography gradient method of Fr. B3 of G. bicolor 
Gradient Method 
Step Time (min.) %B 
1 0 50 
2 10 50 
3 20 70 
4 20 90 
5 10 100 
6 5 100 
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The collected fractions were concentrated by evaporation under reduced pressure with a 
rotavapor and after monitoring by TLC with UV detection, three combined fractions (Fr. 
B3-1~3) were obtained (Table 2.19). 
 
Table 2.19 Column chromatography fractionation of Fr. B3 of G. bicolor 
Fraction Weight (mg) 
Fr. B3-1 194 
Fr. B3-2 305 
Fr. B3-3 112 
 
Fr. B3-2 (305 mg) was further subjected to column chromatography over MCI gel eluted 
by a gradient of water and methanol (20-100%) (Table 2.20). The 60% (methanol in water) 
eluent (92 mg) was collected for subsquent purification. A prep-HPLC method was 
developed over a reversed phase preparative column to yield two pure compounds 153 
(Rt: 11.0-12.3 min, 1.2 mg) and 154 (Rt: 12.3-12.5 min, 0.8 mg). The prep-HPLC 
conditions were: C18 column with guard cartridge, 21.2 mm ID  150 mm (5 m); 
H2O/CH3CN (72:28) isocratic, flow rate 6 mL/min; detection UV 230 nm; room 
temperature; injection volume 200 L per time; running time 22.5 mins per injection; 
automatic fraction collector mode peak-based. 
 
Table 2.20 Programme for separation of fraction Fr. B3-2 of G. bicolor by column chromatography 
over MCI gel 
Mobile phase Gradient elution Solvent volume (mL) 
MeOH/H2O 20:80 200 
MeOH/H2O 40:60 200 
MeOH/H2O 60:40 300 
MeOH/H2O 80:20 200 
MeOH (clean up) 100 100 
 
Analysis of their spectral data, together with comparison with data available in the 
literatures,164,165 allowed to elucidate the structure of compound 153 and 154 as 
vomifoliol and boscialin, respectively. 
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Vomifoliol 153: colorless gum; ESI-MS m/z: 283 [M+OAc]-; 1H NMR δ ppm (CDCl3, 300 
MHz): 1.01 (3H, s, H-11), 1.09 (3H, s, H-12), 1.31 (3H, d, J = 6.6 Hz, H-10), 1.90 (3H, d, J = 
1.1 Hz, H-13), 2.25 (1H, d, J = 17.1 Hz, H-3a), 2.46 (1H, d, J = 17.1 Hz, H-3b), 4.37-4.47 (1H, 
m, H-9), 5.81 (1H, m, H-7), 5.85 (1H, m, H-8), 5.91 (1H, m, H-5). 13C NMR δ ppm (CDCl3, 
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75 MHz): 198.1 (C-4), 162.8 (C-6), 135.8 (C-8), 129.0 (C-7), 127.0 (C-5), 79.1 (C-1), 68.1 
(C-9), 49.8 (C-3), 41.2 (C-2), 24.1 (C-11), 23.9 (C-10), 23.0 (C-12), 19.0 (C-13). 
 
Boscialin 154: colorless gum; ESI-MS m/z: 285 [M+OAc]-; 1H NMR δ ppm (CDCl3, 300 
MHz): 0.81 (3H, d, J = 6.6 Hz, H-13), 0.88 (3H, s, H-11), 1.04 (3H, s, H-12), 1.33 (1H, m, 
H-5a), 1.50-1.71 (2H, m, H-3), 1.81-1.89 (1H, m, H-5b), 2.04 (1H, m, H-6), 2.29 (3H, s, 
H-10), 3.84-3.96 (1H, m, H-4), 6.37 (1H, d, J = 16.0 Hz, H-8), 6.76 (1H, d, J = 16.0 Hz, H-7). 
13C NMR δ ppm (CDCl3, 75 MHz): 197.9 (C-9), 150.7 (C-7), 130.4 (C-8), 77.1 (C-1), 66.5 
(C-4), 45.1 (C-3), 40.0 (C-2), 39.0 (C-5), 34.0 (C-6), 28.3 (C-10), 25.2 (C-11), 24.7 (C-12), 
16.0 (C-13). 
 
2.2.3.3 Study of the ethyl acetate extract of the aerial parts of G. bicolor 
The EtOAc extracted fraction (7.7 g) was adsorbed on 15 g of C18 silica and further 
fractionated by reversed phase column chromatography over C18 silica, eluted with 
water containing increasing concentrations of MeOH (Table 2.21). The fractions were 
collected in 100 mL tubes, after monitoring by TLC, a total of 5 different combined 
fractions (Fr. C1-5) were obtained (Table 2.22). 
 
Table 2.21 Programme for fractionation of the EtOAc extract of G. bicolor by column 
chromatography 
Mobile phase Gradient elution Solvent volume (mL) 
MeOH/H2O 20:80 500 
MeOH/H2O 40:60 1200 
MeOH/H2O 60:40 1200 
MeOH/H2O 80:20 1000 
MeOH (clean up) 100 500 
 
Table 2.22 Column chromatography fractionation of the EtOAc extract of G. bicolor 
Fraction Weight (g) 
Fr. C1 1.3 
Fr. C2 0.7 
Fr. C3 2.1 
Fr. C4 2.9 
Fr. C5 0.5 
 
2.2.3.3.1 Isolation of 4-hydroxybenzoic acid 79 
Fr. C2 (724 mg) was submitted to fractionation with an automatic flash chromatography 
system on a reversed-phase column (C-18, 40 g) eluted by a gradient of water and 
methanol (20-100%). The automatic flash chromatography conditions were (Table 2.23 
and 2.24):  
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Table 2.23 Automatic flash chromatography conditions of Fr. C2 of G. bicolor 
Run conditions 
Cartridge: Reveleris 40 g C18 
Solvent A: Water 
Solvent B: Methanol  
Flow rate: 25 mL/min 
UV1 wavelength: 254 nm 
UV2 wavelength: 280 nm 
ELSD carrier Isopropanol 
Injection type: Dry sample 
 
Table 2.24 Automatic flash chromatography gradient method of Fr. C2 of G. bicolor 
Gradient Method 
Step Time (min.) %B 
1 0 20 
2 120 100 
 
Following monitoring by TLC under UV, four different fractions (Fr. C2-1~4) were 
obtained (Table 2.25), after concentration by evaporation under reduced pressure with a 
rotavapor. 
 
Table 2.25 Column chromatography fractionation of Fr. C2 of G. bicolor 
Fraction Weight (mg) 
Fr. C2-1 72 
Fr. C2-2 510 
Fr. C2-3 54 
Fr. C2-4 30 
 
Fr. C2-2 (510 mg) was further subjected to column chromatography over silica gel eluted 
by a solvent gradient system consisting of CHCl3-MeOH-H2O (Table 2.26) to yield 5 
fractions (Fr. C2-2-1~5, Table 2.27). 
 
Table 2.26 Programme for fractionation of Fr. C2-2 of G. bicolor by column chromatography 
Mobile phase Gradient elution Solvent volume (mL) 
CHCl3/MeOH 100:1 300 
CHCl3/MeOH 20:1 400 
CHCl3/MeOH 10:1 700 
CHCl3/MeOH 6:1 700 
CHCl3/MeOH/H2O 8:2:0.3 700 
CHCl3/MeOH/H2O 7:3:0.5 700 
CHCl3/MeOH/H2O 6:4:1 700 
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Table 2.27 Column chromatography fractionation of Fr. C2-2 of G. bicolor 
Fraction Weight (mg) 
Fr. C2-2-1 -- 
Fr. C2-2-2 190 
Fr. C2-2-3 -- 
Fr. C2-2-4 113 
Fr. C2-2-5 -- 
 
Based on TLC, Fr. C2-2-4 (113 mg) was rechromatographed on a reversed-phase column 
with an automatic flash chromatography system eluted with an isocratic solvent system 
MeOH/H2O (50:50). The collected fractions (56 mg), using a peak-based mode, were 
finally purified with silica gel column chromatography eluted by CHCl3/MeOH (9:1) to 
yield a pure product (compound 79, 13.6 mg). 
 
Analysis of its spectral data, together with comparison with data available in the 
literature,159 allowed to elucidate the structure of compound 79 as 4-hydroxybenzoic acid. 
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4-Hydroxybenzoic acid 79: white powder; m.p. 209-210 C; ESI-MS m/z: 137 [M-H]-; 1H 
NMR δ ppm (DMSO-d6, 300 MHz): 7.77 (2H, dd, J = 8.8, 3.9 Hz, H-2 and H-6), 6.80 (2H, dd, 
J = 8.8, 3.9 Hz, H-3 and H-5); 13C NMR δ ppm (MeOH-d4, 75 MHz): 167.7 (COOH), 162.1 
(C-4), 132.1 (C-2 and C-6), 122.0 (C-1), 115.7 (C-3 and C-5). 
 
2.2.3.3.2 Isolation of roseoside 155 and benzyl β-D-glucopyranoside 156 
Fr. C2-2-2 (190 mg) was further subjected to column chromatography over silica gel 
eluted by a gradient of CHCl3 and methanol (100:1-6:1) (Table 2.28). Six fractions (Table 
2.29) were obtained and two of them were selected for subsquent purification.  
 
Table 2.28 Programme for separation of Fr. C2-2-2 of G. bicolor 
Mobile phase Gradient elution Solvent volume (mL) 
CHCl3/MeOH 100:1 500 
CHCl3/MeOH 100:2 500 
CHCl3/MeOH 100:5 500 
CHCl3/MeOH 100:10 500 
CHCl3/MeOH 6:1 300 
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Table 2.29 Column chromatography fractionation of Fr. C2-2-2 of G. bicolor 
Fraction Weight (mg) 
Fr. C2-2-2-1 15 
Fr. C2-2-2-2 13 
Fr. C2-2-2-3 12 
Fr. C2-2-2-4 20 
Fr. C2-2-2-5 26 
Fr. C2-2-2-6 35 
 
Fr. C2-2-2-3 (12 mg) was finally purified by HPLC on a RP18 column to afford a product 
(compound 155, 2.2 mg). The analytical HPLC conditions were the following: column, 
inertsil ODS-SP, 5 m 4.6  250 mm, Shimadzu; elution, isocratic mode with MeOH/H2O 
(36:64); flow rate, 0.8 mL/min; detection, UV 254 nm; eluted time, 10.1 min; running 
time, 15 min. The preparative-HPLC conditions were: C18 column with guard cartridge, 
21.2 mm ID  150 mm (5 m); elution, isocratic mode with MeOH/H2O (36:64); flow rate, 
6 mL/min; detection, UV 254 nm; room temperature; injection volume, 150 L per time; 
running time, 18 mins per injection; automatic fraction collector mode peak-based. The 
sample was dissolved in 1 mL MeOH and filtered with 0.45 m filter prior to injection. 
The eluates from 15.3-16.2 min were mixed and dried under high vacuum to afford 
compound 155. 
 
Analysis of the spectral data, together with comparison with data available in the 
literature,166 allowed to elucidate the structure of compound 155 as (6S,9S)-roseoside. 
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(6S,9S)-Roseoside 155: white powder; m.p. 98-99 C; ESI-MS m/z: 445 [M+OAc]-; 1H 
NMR δ ppm (MeOH-d4, 300 MHz): 0.93 (3H, s, H-11), 0.95 (3H, s, H-12), 1.20 (3H, d, J = 
6.1 Hz, H-10), 1.86 (3H, d, J = 1.1 Hz, H-13), 2.08 (1H, d, J = 17.1 Hz, H-2a), 2.53 (1H, d, J = 
17.1 Hz, H-2b), 3.02-3.26 (4H, m, H-2’, 3’, 4’ and 5’), 3.54 (1H, dd, J = 12.1, 6.1 Hz, H-6’a), 
3.77 (1H, dd, J = 12.1, 2.2 Hz, H-6’b), 4.18 (1H, d, J = 7.7 Hz, H-1’), 4.41-4.49 (1H, m, H-9), 
5.64 (1H, dd, J = 16, 7.2 Hz, H-8), 5.79 (1H, s, H-4), 5.90 (1H, d, J = 16 Hz, H-7); 13C NMR δ 
ppm (MeOH-d4, 75 MHz): 201.3 (C-3), 167.1 (C-5), 133.8 (C-7), 133.7 (C-8), 127.1 (C-4), 
101.2 (C-1’), 80.0 (C-6), 78.4 (C-3’), 78.2 (C-5’), 74.9 (C-2’), 74.6 (C-9), 71.7 (C-4’), 62.8 
(C-6’), 50.8 (C-2), 42.4 (C-1), 24.7 (C-12), 23.5 (C-11), 22.2 (C-10), 19.6 (C-13). 
 
Fr. C2-2-2-4 (20 mg) was finally purified by HPLC on a RP18 column to afford a pure 
product (compound 12, 1.1 mg). The analytical HPLC conditions were the following: 
column, inertsil ODS-SP, 5m 4.6  250mm, Shimadzu; elution, isocratic mode with 
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MeOH/H2O (36:64); flow rate, 0.8 mL/min; detection, UV 254 nm; eluted time, 9.6 min; 
running time, 13 min. The preparative-HPLC conditions were: C18 column with guard 
cartridge, 21.2 mm ID  150 mm (5 m); elution, isocratic mode with MeOH/H2O (36:64); 
flow rate, 6 mL/min; detection, UV 254 nm; room temperature; injection volume, 150 L 
per time; running time, 18 mins per injection; automatic fraction collector mode 
peak-based. The sample was dissolved in 1 mL MeOH and filtered with 0.45 m filter 
prior to injection. The eluates from 14.5-15.0 min were mixed and dried under high 
vacuum to afford compound 156. 
 
Analysis of the spectral data, together with comparison with data available in 
literatures,167,168 allowed to elucidate the structure of compound 156 as benzyl 
β-D-glucopyranoside. 
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Benzyl β-D-glucopyranoside 156: white powder; m.p. 114-115 C; ESI-MS m/z: 329 
[M+OAc]-; 1H NMR δ ppm (MeOH-d4, 300 MHz): 3.25-3.35 (4H, m, H-2’, 3’, 4', 5’), 3.69 
(1H, dd, J = 11.8, 5.5 Hz, H-6’a), 3.90 (1H, dd, J = 11.8, 1.9 Hz, H-6'b), 4.35 (1H, d, J = 7.7 
Hz, H-1'), 4.66 (1H, d, J = 11.6 Hz, H-7a), 4.94 (1H, d, J = 11.6 Hz, H-7b), 7.24-7.44 (5H, m, 
H-2, 3, 4, 5, 6); 13C NMR δ ppm (MeOH-d4, 75 MHz): 139.1 (C-1), 129.3 (C-3 and C-5), 
129.2 (C-2 and C-6), 128.7 (C-4), 103.3 (C-1’), 78.1 (C-3’ and C-5’), 75.1 (C-2’), 71.7 (C-4’ 
and C-7), 62.8 (C-6’). 
 
2.2.3.3.3 Isolation of protocatechuic acid 157 
Fr. C3 (2.1 g) was split into four equal parts and each part was submitted to fractionation 
with an automatic flash chromatography system on a reversed-phase column (C-18, 40 g) 
eluted by a gradient of water and methanol (20-100%). The automatic flash 
chromatography conditions were (Table 2.30 and 2.31):  
 
Table 2.30 Automatic flash chromatography conditions of Fr. C3 of G. bicolor 
Run conditions 
Cartridge: Reveleris 40 g C18 
Solvent A: Water 
Solvent B: Methanol  
Flow rate: 25 mL/min 
UV1 wavelength: 254 nm 
UV2 wavelength: 280 nm 
ELSD carrier Isopropanol 
Injection type: Dry sample 
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Table 2.31 Automatic flash chromatography gradient method of Fr. C3 of G. bicolor 
Gradient Method 
Step Time (min.) %B 
1 0 20 
2 120 100 
 
Following monitoring by TLC under UV, four different fractions (Fr. C3-1~4) were 
obtained (Table 2.32), after concentration by evaporation under reduced pressure with a 
rotavapor. 
 
Table 2.32 Column chromatography fractionation of Fr. C3 of G. bicolor 
Fraction Weight (mg) 
Fr. C3-1 70 
Fr. C3-2 1200 
Fr. C3-3 318 
Fr. C3-4 421 
 
Fr. C3-1 (70 mg) was further subjected to column chromatography over Sephadex LH-20 
gel eluted by an isocratic solvent system consisting of MeOH/H2O (90:10) to yield three 
fractions (Fr. C3-1-1~3, Table 2.33). 
 
Table 2.33 Column chromatography fractionation of Fr. C3-1 of G. bicolor 
Fraction Weight (mg) 
Fr. C3-1-1 -- 
Fr. C3-1-2 46 
Fr. C3-1-3 -- 
 
Fr. C3-1-2 (46 mg) was submitted to chromatography over silica gel eluted by an isocratic 
solvent system CHCl3/MeOH (8:1) to afford a pure product (compound 157, 12.5 mg). 
 
Analysis of its spectral data, together with comparison with data available in the 
literature,159 allowed to elucidate the structure of compound 157 as protocatechuic acid. 
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Protocatechuic acid 157: white powder; m.p. 194-195 C; ESI-MS m/z: 153 [M-H]-; 1H 
NMR δ ppm (MeOH-d4, 300 MHz): 7.34 (1H, s, H-2), 7.32 (1H, dd, J = 7.0, 1.7 Hz, H-6), 
6.69 (1H, d, J = 7.0 Hz, H-5); 13C NMR δ ppm (MeOH-d4, 75 MHz): 168.9 (COOH), 150.2 
(C-4), 144.8 (C-3), 122.6 (C-6), 121.8 (C-1), 116.4 (C-2), 114.4 (C-5). 
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2.2.3.3.4 Isolation of kaempferol 40 
Fr. C3-2 (1200 mg) was further subjected to column chromatography over silica gel 
eluted by a solvent gradient system consisting of CHCl3-MeOH-H2O (Table 2.34) to yield 
five fractions (Fr. C3-2-1~5, Table 2.35). 
 
Table 2.34 Programme for fractionation of Fr. C3-2 of G. bicolor by column chromatography 
Mobile phase Gradient elution Solvent volume (mL) 
CHCl3/MeOH 100:1 600 
CHCl3/MeOH 20:1 1000 
CHCl3/MeOH 10:1 2000 
CHCl3/MeOH 4:1 1500 
CHCl3/MeOH/H2O 8:2:0.3 1000 
CHCl3/MeOH/H2O 7:3:0.5 800 
CHCl3/MeOH/H2O 6:4:1 500 
 
Table 2.35 Column chromatography fractionation of Fr. C3-2 of G. bicolor 
Fraction Weight (mg) 
Fr. C3-2-1 65 
Fr. C3-2-2 70 
Fr. C3-2-3 200 
Fr. C3-2-4 40 
Fr. C3-2-5 130 
 
Fr. C3-2-2 (70 mg) was submitted to chromatography over silica gel eluted by as isocratic 
solvent system CHCl3/MeOH (10:1). The similar fractions were combined and additionally 
purified by column chromatography over Sephadex LH-20 gel eluted by MeOH/H2O 
(80:20) to afford a pure yellowish product (compound 40, 6.3 mg). 
 
Analysis of its spectral data, together with comparison with data available in the 
literature,169 allowed to elucidate the structure of compound 40 as kaempferol. 
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Kaempferol 40: yellow powder; m.p. 267-268 C; ESI-MS m/z: 287 [M+H]+; 1H NMR δ 
ppm (DMSO-d6, 300 MHz): 12.48 (1H, s, 5-OH), 10.80 (1H, brs, 4’-OH), 10.12 (1H, brs, 
7-OH), 9.42 (1H, brs, 3-OH), 8.04 (2H, d, J = 9.1 Hz, H-2’ and H-6’), 6.92 (2H, d, J = 9.1 Hz, 
H-3’ and H-5’), 6.43 (1H, d, J = 2.2 Hz, H-8), 6.18 (1H, d, J = 2.2 Hz, H-6); 13C NMR δ ppm 
(DMSO-d6, 75 MHz): 176.4 (C-4), 164.5 (C-7), 161.3 (C-9), 159.8 (C-4’), 156.7 (C-5), 147.3 
(C-2), 136.2 (C-3), 130.1 (C-2’ and C-6’), 122.2 (C-1’), 116.0 (C-3’ and C-5’), 103.5 (C-10), 
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98.8 (C-6), 94.0 (C-8). 
 
2.2.3.3.5 Isolation of 2-phenylethyl -D-glucopyranoside 158 
Fr. C3-2-3 (200 mg) was further subjected to column chromatography over silica gel 
eluted by a gradient of CHCl3 and methanol (20:1-4:1) (Table 2.36) to afford four 
fractions (Table 2.37).  
 
Table 2.36 Programme for separation of Fr. C3-2-3 of G. bicolor 
Mobile phase Gradient elution Solvent volume (mL) 
CHCl3/MeOH 20:1 500 
CHCl3/MeOH 10:1 800 
CHCl3/MeOH 8:1 1500 
CHCl3/MeOH 6:1 1000 
CHCl3/MeOH 4:1 500 
 
Table 2.37 Column chromatography fractionation of Fr. C3-2-3 of G. bicolor 
Fraction Weight (mg) 
Fr. C3-2-3-1 18 
Fr. C3-2-3-2 27 
Fr. C3-2-3-3 25 
Fr. C3-2-3-4 24 
 
Fr. C3-2-3-3 (25 mg) was finally purified by HPLC on a RP18 column to afford a pure 
product (compound 158, 1.1 mg). The analytical HPLC conditions were the following: 
column, inertsil ODS-SP, 5 m 4.6  250 mm, Shimadzu; elution, isocratic mode with 
MeOH/H2O (35:65); flow rate, 0.8 mL/min; detection, UV 254 nm; eluted time, 12.3 min; 
running time, 15 min. The preparative-HPLC conditions were: C18 column with guard 
cartridge, 21.2 mm ID  150 mm (5 m); elution, isocratic mode with MeOH/H2O (35:65); 
flow rate, 6 mL/min; detection, UV 254 nm; room temperature; injection volume, 175 L 
per time; running time, 20 mins per injection; automatic fraction collector mode 
peak-based. The sample was dissolved in 1 mL MeOH and filtered with 0.45 m filter 
prior to injection. The eluates from 16.8-17.4 min were mixed and dried under high 
vacuum to afford compound 158. 
 
Analysis of their spectral data, together with comparison with data available in the 
literature,168 allowed to elucidate the structure of compound 158 as 2-phenylethyl 
-D-glucopyranoside. 
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2-Phenylethyl β-D-glucopyranoside 158: white powder; m.p. 118-119 C; ESI-MS m/z: 
343 [M+OAc]-; 1H NMR δ ppm (MeOH-d4, 300 MHz): 2.94 (2H, t-like, J = 7.2 Hz, H-7), 
3.15-3.40 (4H, m, H-2’, 3’, 4', 5’), 3.60-3.79 (1H, m, H-8a), 3.66 (1H, dd, J = 11.5, 5.2 Hz, 
H-6’a), 3.86 (1H, dd, J = 11.5, 1.7 Hz, H-6'b), 4.05-4.13 (1H, m, H-8b), 4.30 (1H, d, J = 7.7 
Hz, H-1'), 7.14-7.27 (5H, m, H-2, 3, 4, 5, 6); 13C NMR δ ppm (MeOH-d4, 75 MHz): 140.1 
(C-1), 130.0 (C-3 and C-5), 129.3 (C-2 and C-6), 127.2 (C-4), 104.4 (C-1’), 78.1 (C-5’), 78.0 
(C-3’), 75.1 (C-2’), 71.7 (C-8), 71.6 (C-4’), 62.7 (C-6’), 37.2 (C-7). 
 
2.2.3.3.6 Isolation of 3,3'-di-O-methylellagic acid 4-O-β-D-xylopyranoside 159 
Fr. C3-2-4 (40 mg) was submitted to chromatography over silica gel eluted by an isocratic 
solvent system CHCl3/MeOH (6:1). The similar fractions were combined and additionally 
purified by repeated column chromatography over Sephadex LH-20 gel eluted by 
MeOH/H2O (80:20) to afford a pure product (compound 159, 4.1 mg). 
 
Analysis of its spectral data, together with comparison with data available in the 
literature,170 allowed to elucidate the structure of compound 159 as 
3,3'-di-O-methylellagic acid 4-O-β-D-xylopyranoside. 
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3,3'-Di-O-methylellagic acid 4-O-β-D-xylopyranoside 159: white powder; m.p. 293-294 
C; ESI-MS m/z: 461 [M-H]-; 1H NMR δ ppm (DMSO-d6, 300 MHz): 10.87 (1H, brs, 4’-OH), 
7.72 (1H, s, H-5), 7.49 (1H, s, H-5’), 5.14 (1H, d, J = 6.6 Hz, H-1”), 4.06 (3H, s, 3-OCH3), 
4.03 (3H, s, 3’-OCH3), 3.36 (5H, under solvent, H-2”~5”). 
13C NMR δ ppm (DMSO-d6, 75 
MHz): 159.0 (C-7 and C-7’), 153.4 (C-4’), 151.8 (C-4), 142.4 (C-3), 142.2 (C-2’), 141.5 (C-2), 
140.7 (C-3’), 114.7 (C-1), 113.3 (C-6’), 112.4 (C-5), 112.4 (C-6), 112.2 (C-5’), 111.6 (C-1’), 
102.3 (C-1”), 76.7 (C-3”), 73.6 (C-2”), 69.8 (C-4”), 66.3 (C-5”), 62.2 (3-OCH3), 61.6 
(3’-OCH3). 
 
2.3 Results and Discussion 
G. bicolor is native to the tropics of East Asia and has been cultivated as a popular 
vegetable in China, Japan and even in Europe. As reported in the literature155, three 
anthocyanins were isolated and identified to be cyanidin 3-O-[-D-glucopyranoside]-7-O- 
[6-O-(E)-(4-O-(6-O-(E)-caffeoyl--D-glucopyranosyl)-caffeoyl)--D-glucopyranoside]-3’-O-
[6-O-(E)-caffeoyl--D-glucopyranoside] (bicolnin), cyanidin 3-O-[6-O-malonyl--D-gluco- 
pyranoside]-7-O-[6-O-(E)-(4-O-(6-O-(E)-caffeoyl--D-glucopyranosyl)-caffeoyl)--D-gluco-
pyranoside]-3’-O-[6-O-(E)-caffeoyl--D-glucopyr-anoside] (rubrocinerarin) and cyanidin 
3-O-[4,6-di-O-malonyl--D-glucopyranoside]-7-O-[6-O-(E)-(4-O-(6-O-(E)-caffeoyl--D-glu-
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copyranosyl)-caffeoyl)--D-glucopyranoside]-3’-O-[6-O-(E)-caffeoyl--D-glucopyranoside] 
(bicolmalonin) by MS and NMR analyses.  
 
In the present study, two terpenes (150 and 152), four megastigmane-type 
norisoprenoids (151, 153, 154 and 155), three glycosides (156, 158 and 159), one 
flavonoid (40), three phenolic acids (80, 79 and 157) and three other natural products 
(148, 78 and 149) were isolated from the aerial parts of G. bicolor. All the compounds 
were characterized by spectrometric methods (NMR, MS). It should be noted that all 
these compounds, except 4-hydroxybenzoic acid (79) and kaempferol (40) were isolated 
for the first time from this plant, and no evidence could be found of previous reported 
presence of megastigmane-type norisoprenoids in the genus Gynura. 
 
2.3.1 Megastigmane-type norisoprenoids from the aerial parts of G. bicolor 
2.3.1.1 C13-norisoprenoid compound: dehydrovomifoliol 151 
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Compound 151 was obtained as a colorless gum. The ESI mass spectrum of compound 
151 displayed a pseudomolecular ion peak at m/z 223 which may correspond to the 
fragment [M+H]+. The molecular formula of C13H18O3 was deduced. The 
1H NMR 
spectrum of 6 disclosed the presence of a vinyl proton at δ 5.96 (1H, s, H-4), two E-type 
olefinic protons at δ 6.47 (1H, d, J = 16.0 Hz, H-8) and 6.84 (1H, d, J = 16.0 Hz, H-7). In 
addition, protons of two gem-dimethyl groups at δ 1.11 (H-11) and 1.03 (H-12), protons 
of a methyl group at δ 1.89 (H-13) connected to a double bond, and a methyl group at δ 
2.31 adjacent to a carbonyl group were observed. A geminal coupling system ascribed to 
the two protons of methylene at δ 2.51 (d, J = 17.1 Hz, H-2b) and 2.34 (d, J = 17.1 Hz, 
H-2a). Their chemical shift suggested that this methylene was connected to a carbonyl 
group and that the gem-dimethyl unit was positioned at C-1. On the other hand, the 13C 
NMR spectrum of 151 exhibited two carbonyl signals at δ 197.4 (C-3) and 197.0 (C-9), 
four olefinic carbon signals at δ 127.9 (C-4), 130.4 (C-8), 145.0 (C-7), and 160.3 (C-5). 
Moreover, the observed signal at δ 79.4 (C-6) could be attributed to a quaternary carbon 
bearing the OH group. Based on all the above data, compound 151 was elucidated as the 
known (+)-dehydrovomifoliol. The assigned structure was in full agreement with data 
found in the literature (Table 2.38).161 
 
 
 
 
 
 
Study of the chemical constituents of the aerial parts of Gynura bicolor 
68 
Table 2.38 Comparison of characteristic 1H NMR (300 MHz, CDCl3) and 
13C NMR (75 MHz, CDCl3) 
data of dehydrovomifoliol 151 with literature data (500/125 MHz, CDCl3)
161 
Position 
This work Literature data 
1H 13C 1H 13C 
1 -- 41.5 -- 41.42 
2 
2.34 (1H, d, J = 17.1 Hz), 
2.51 (1H, d, J = 17.1 Hz) 
49.6 
2.33 (1H, d, J = 17.2 Hz), 
2.49 (1H, d, J = 17.2 Hz) 
49.59 
3 -- 197.4 -- 197.17 
4 5.96 (1H, s) 127.9 5.95 (1H, t-like) 127.87 
5 -- 160.3 -- 160.08 
6 -- 79.4 -- 79.32 
7 6.84 (1H, d, J = 16.0 Hz) 145.0 6.82 (1H, d, J = 15.7 Hz) 144.85 
8 6.47 (1H, d, J = 16.0 Hz) 130.4 6.45 (1H, d, J = 15.7 Hz) 130.40 
9 -- 197.0 -- 196.76 
10 2.31 (3H, s) 28.5 2.30 (3H, s) 28.36 
11 1.11 (3H, s) 24.4 1.10 (3H, s) 24.33 
12 1.03(3H, s) 23.0 1.02 (3H, s) 22.92 
13 1.89 (3H, s) 18.8 1.88 (3H, d, J = 1.4 Hz) 18.60 
 
2.3.1.2 C13-norisoprenoid compound: vomifoliol 153 
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Compound 153 was obtained as a colorless gum. The ESI mass spectrum of compound 
153 showed a molecular ion [M+OAc]- at m/z 283, suggesting a molecular formula of 
C13H20O3. The 
1H NMR spectrum of 153 contained signals (2H, ca. δ 5.81-5.85, H-7 and 
H-8), which were assigned to the protons on a trans-disubstituted double bond. The 
signal of the methyl protons at δ 1.31 (3H, d, J = 6.6 Hz, H-10) coupled to the multiplet 
signal at ca. δ 4.42 (H-9) which also coupled to one of the ethylenic protons at δ 
5.81-5.85. The presence of the moiety -CH=CH-CH(OH)CH3 was established. Additionally, 
two doublets at 2.46 (H-3b) and 2.25 (H-3a) each with a coupling constant of 17.1 Hz 
suggested a nonequivalent methylene adjacent to the carbonyl and connected to a 
tetrasubstituted carbon. Besides, two gem-dimethyl groups at δ 1.01 (H-11) and 1.09 
(H-12), a methyl group at δ 1.90 (H-13) connected to a double bond were observed. On 
the other hand, the 13C NMR spectrum of 153 exhibited one carbonyl signal at δ 198.1 
(C-4), four olefinic carbon signals at δ 127.0 (C-5), 129.0 (C-7), 135.8 (C-8), and 162.8 
(C-6). The observed signal at δ 19.0 (C-13) suggested the methyl substituent located on 
the -carbon of the ,-unsaturated carbonyl system. The carbon signals at δ 79.1 (C-1) 
and δ 68.1 (C-9) could be attributed to two carbons bearing the OH group, respectively. 
These spectral data led to conclude the structure of compound 153 as the known 
vomifoliol. The spectral data of the compound isolated in the present study match well 
with those reported earlier (Table 2.39).164 
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Table 2.39 Comparison of characteristic 1H NMR (300 MHz, CDCl3) and 
13C NMR (75 MHz, CDCl3) 
data of vomifoliol 153 with literature data (400/100 MHz, CDCl3)
164 
Position 
This work Literature data 
1H 13C 1H 13C 
1  79.1  78.9 
2  41.2  41.0 
3 
2.25 (1H, d, J = 17.1 Hz), 
2.46 (1H, d, J = 17.1 Hz) 
49.8 
2.25 (1H, d, J = 16.9 Hz), 
2.45 (1H, d, J = 16.9 Hz) 
49.6 
4  198.1  195.5 
5 5.91 (1H, m) 127.0 5.90 (1H, m) 127.9 
6  162.8  162.2 
7 5.81 (1H, m) 129.0 5.81 (1H, m) 129.0 
8 5.85 (1H, m) 135.8 5.84 (1H, m) 135.7 
9 4.37-4.47 (1H, m) 68.1 4.41 (1H, m) 68.1 
10 1.31 (3H, d, J = 6.6 Hz) 23.9 1.29 (3H, d, J = 6.4 Hz) 23.7 
11 1.01 (3H, s) 24.1 1.01 (3H, s) 24.0 
12 1.09 (3H, s) 23.0 1.08 (3H, s) 23.0 
13 1.90 (3H, d, J = 1.1 Hz) 19.0 1.89 (3H, s) 18.8 
 
2.3.1.3 C13-norisoprenoid compound: boscialin 154 
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Compound 154 was obtained as a colorless gum. ESI mass spectrometric analysis of 
compound 154 showed a molecular ion [M+OAc]- at m/z 285 and a molecular ion [M-H]- 
at m/z 225, thus indicating a molecular formula of C13H22O3. The 
1H NMR spectrum of 
154 showed two singlets (3H) at δ 0.88 (H-11) and 1.04 (H-12) probably attached to a 
quaternary C-atom as well as the presence of a doublet (3H) at 0.81 (H-13, J = 6.6 Hz). An 
E-configurated double bond was deduced from the signals at δ 6.76 (1H, H-7) and δ 6.37 
(1H, H-8) with a coupling constant of 16.0 Hz. The singlet (3H) at δ 2.29 (s, H-10) 
suggested a methyl adjacent to a carbonyl. The overlapping signals with signals from the 
solvent made it difficult to assign the rest of the proton signals. However, the 13C NMR 
spectrum of 154 exhibited one carbonyl signal at δ 197.9 (C-9), two olefinic carbon 
signals at δ 150.7 (C-7) and 130.4 (C-8). The observed signal at δ 45.1 (C-3), 40.0 (C-2), 
39.0 (C-5) and 34.0 (C-6) suggested a series of methylene, methine or quaternary C-atom 
signals. Analysis of the above spectral data, together with comparison with data 
available in the literature,165 allowed to elucidate the structure of compound 154 as the 
known boscialin. The spectral data of the compound isolated in the present study match 
well with those reported earlier (Table 2.40).165 
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Table 2.40 Comparison of characteristic 1H NMR (300 MHz, CDCl3) and 
13C NMR (75 MHz, CDCl3) 
data of boscialin 154 with literature data (400/100 MHz, CDCl3)
165 
Position 
This work Literature data 
1H 13C 1H 13C 
1  77.1  77.0 
2  40.0  39.9 
3 1.50-1.71 (2H, m) 45.1 
1.62 (t, J = 12 Hz, Hax-3), 
1.55 (Heq-3) 
45.1 
4 3.84-3.96 (1H, m) 66.5 3.89 (1H, m) 66.4 
5 
1.33 (1H, m, H-5a), 
1.81-1.89 (1H, m, H-5b) 
39.0 
1.34 (1H, q, J = 11.5 Hz, 
Hax-5), 1.83 (1H, br. dt, J = 
12.5, 4 Hz, Heq-5) 
39.0 
6 2.04 (1H, m) 34.0 2.08 (1H, m) 34.0 
7 6.76 (1H, d, J = 16.0 Hz) 150.7 6.75 (1H, d, J = 16.0 Hz) 150.5 
8 6.37 (1H, d, J = 16.0 Hz) 130.4 6.37 (1H, d, J = 16.0 Hz) 130.3 
9  197.9  197.5 
10 2.29 (3H, s) 28.3 2.28 (3H, s) 28.2 
11 0.88 (3H, s) 25.2 0.88 (3H, s) 25.2 
12 1.04 (3H, s) 24.7 1.04 (3H, s) 24.6 
13 0.81 (3H, d, J = 6.6 Hz) 16.0 0.81 (3H, d, J = 6.5 Hz) 15.9 
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Scheme 2.1 describes the complete isolation of compounds 151, 153 and 154 from the 
aerial parts of G. bicolor. 
 
Scheme 2.1 The complete isolation of compounds 151, 153 and 154 from G. bicolor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                       Extraction with 
                                       80% aqueous ethanol 
 
 
 
 
                                       Extraction with n-hexane, CH2Cl2, 
                                             EtOAc and MeOH, successively 
                                         
 
    n-Hexane extract      CH2Cl2 extract       EtOAc extract        MeOH extract 
          (0.8 g)                (3.4 g)                (7.7 g)                (121.3 g) 
                                   CC-Si: 
                                   CH2Cl2/MeOH Gradient 
                           
 
Fr. B1   Fr. B2   Fr. B3   Fr. B4   Fr. B5   Fr. B6 
 (600 mg) (655 mg) 
Auto. flash-C18: 
MeOH/H2O, 50-100% 
 
 
Fr. B2-1  Fr. B2-2  Fr. B2-3  Fr. B2-4   Fr. B3-1  Fr. B3-2  Fr. B3-3  Fr. B3-4 
(175 mg)                                (305 mg) 
  CC-MCI gel:                              CC-MCI gel: 
MeOH/H2O,                              MeOH/H2O, 
  20-100%                                 20-100% 
                                       
 
20% 40% 60% 80% 100% eluent        20% 40% 60% 80% 100% eluent 
                                          (92mg) 
                                              
93 mg                                  Prep-LC-C18: MeCN/H2O, 28:72 
CC-Si:                                      
PE/EtOAc, 10:1-1:1  
              
Prep-LC-C18:  
MeCN/H2O, 25:75 
                               
 
 
 
 
 
                    153 (1.2 mg)              154 (0.8 mg) 
                               
151 (0.5 mg) 
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2.3.1.4 C13-norisoprenoid compound: (6S,9S)-roseoside 155 
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Compound 155 was obtained as an amorphous powder. The ESI mass spectrum of 155 
showed an ion peak at m/z 445, which corresponded to [M+OAc]- and suggested a 
molecular formula of C19H30O8. In the 
1H NMR spectral data of compound 155, two 
olefinic protons in the side chain were confirmed by signals at δ 5.90 (H-7) and 5.64 (H-8) 
with J = 16 Hz indicating the trans configuration. The signal at δ 5.79 was assignable to a 
vinyl proton. The two methyl singlets at δ 0.95 and 0.93 were assigned to gem-dimethyl 
groups on a quaternary carbon. The signal (3H) at δ 1.86 corresponded to a methyl next 
to a double bond. A doublet signal for three protons at δ 1.20 could be attributed to a 
methyl proton (H-10) linked to an oxygenated methine at δ 4.45 (1H, m, H-9). Proton 
peaks at δ 2.53 (d, J = 17.1 Hz, H-2b) and 2.08 (d, J = 17.1 Hz, H-2a) were geminally 
coupled signals from a methylene attached to a carbonyl group. In the sugar part, an 
anomeric proton appeared at δ 4.18 (d, J = 7.7 Hz, H-1’) and its configuration could be 
deduced as  type. On the other hand, the 13C NMR spectrum exhibited a carbonyl signal 
at δ 201.3 (C-3), four olefinic carbon signals at 133.8 (C-7), 133.7 (C-8), 167.1 (C-5) and 
127.1 (C-4), two oxygenated carbon signals at δ 74.6 (C-9) and 80.0 (C-6). Moreover, the 
sugar moiety was identified as D-glucopyranoside when compared with the literature.171 
Thus, the structure of 155 was designated to roseoside. 
 
Although most natural roseosides have the (6S)-configuration, (6R)-configurated 
roseoside has been isolated as well.171 As reported in the literature, 1H and 13C NMR 
spectra of those epimers are so similar to each other that confirmation of 
stereochemistries of the natural glucosides from spectral data is not easy. The 
stereochemistry of C-9 was determined by comparing the chemical shift with reported 
data, which showed different signals at δ 77.0 and 74.7 for the 9R and 9S isomers, 
respectively.172 In the latter paper, the configuration of C-9 (δ 74.6) was assigned as S. In 
addition, after analysis of the chemical shift differences of the present isolated roseoside 
and roseosides resulting from stereocontrolled synthesis, compound 155 was tentatively 
determined to be (6S,9S)-roseoside.173 
 
The spectral data of the compound isolated in the present study match well with those 
reported earlier. The comparison of characteristic NMR data of compound 155 with 
literature data is listed in the Table 2.40.166 
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Table 2.40 Comparison of characteristic 1H NMR (300 MHz, CD3OD) and 
13C NMR (75 MHz, CD3OD) 
data of (6S,9S)-roseoside 155 with literature data (400/100 MHz, CD3OD)
166 
Position 
This work Literature data 
1H 13C 1H 13C 
1  42.4  42.4 
2 
2.08 (1H, d, J = 17.1 Hz), 2.53 (1H, 
d, J = 17.1 Hz) 
50.8 
2.10 (1H, d, J = 17.1 Hz) 2.54 (1H, 
d, J = 17.1 Hz) 
50.8 
3  201.3  201.3 
4 5.79 (1H, s) 127.1 5.80 (1H, s) 127.1 
5  167.1  167.1 
6  80.0  80.0 
7 5.90 (1H, d, J = 16 Hz) 133.8 5.91 (1H, d, J = 15.6 Hz) 133.8 
8 5.64 (1H, dd, J = 16, 7.2 Hz) 133.7 5.63 (1H, dd, J = 15.6, 7.3 Hz) 133.7 
9 4.41-4.49 (1H, m), 74.6 4.46 (1H, m) 74.6 
10 1.20 (3H, d, J = 6.1 Hz) 22.2 1.22 (3H, d, J = 6.3 Hz) 22.2 
11 0.93 (3H, s) 23.5 0.95 (3H, s) 23.5 
12 0.95 (3H, s) 24.7 0.97 (3H, s) 24.7 
13 1.86 (3H, d, J = 1.1 Hz) 19.6 1.87 (3H, d, J = 1.5 Hz) 19.6 
1’ 4.18 (1H, d, J = 7.7 Hz) 101.2 4.20 (1H, d, J = 7.8 Hz) 101.2 
2’ 
3.02-3.26 (4H, m, H-2’~5’) 
74.9 
3.06-3.38 (4H, m, H-2’~5’) 
74.9 
3’ 78.4 78.4 
4’ 71.7 71.7 
5’ 78.2 78.2 
6’ 
3.54 (1H, dd, J = 12.1, 6.1 Hz), 
3.77 (1H, dd, J = 12.1, 2.2 Hz) 
62.8 
3.56 (1H,dd, J = 11.7, 6.3 Hz), 
3.78 (1H, dd, J = 11.7, 2.0 Hz) 
62.8 
 
Scheme 2.2 describes the complete isolation of (6S,9S)-roseoside 155 from the aerial 
parts of G. bicolor. 
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Scheme 2.2 The complete isolation of (6S,9S)-roseoside 155 from G. bicolor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                       Extraction with 
                                       80% aqueous ethanol 
 
 
 
 
                                       Extraction with n-hexane, CH2Cl2, 
                                             EtOAc and MeOH, successively 
                                         
 
    n-Hexane extract      CH2Cl2 extract       EtOAc extract       MeOH extract 
          (0.8 g)                (3.4 g)                (7.7 g)               (121.3 g) 
                                                        CC-C18 
                                                        MeOH/H2O, 20-100% 
                           
 
Fr. C1      Fr. C2     Fr. C3    Fr. C4     Fr. C5 
      (1.3 g)       (0.7 g)      (2.1 g)     (2.9 g)      (0.5 g) 
            Auto. flash-C18: 
MeOH/H2O, 20-100% 
 
 
      Fr. C2-1      Fr. C2-2       Fr. C2-3       Fr. C2-4 
                (72 mg)        (510 mg)        (54 mg)         (30 mg) 
CC-Si: 
CHCl3/MeOH/H2O, 
                                      gradient 
                                                 
 
Fr. C2-2-1  Fr. C2-2-2  Fr. C2-2-3  Fr. C2-2-4  Fr. C2-2-5 
                      (190 mg)            (113 mg) 
                         CC-Si: 
            CHCl3/MeOH, 
                         100:1-6:1 
         
                         
Fr. C2-2-2-1  Fr. C2-2-2-2 Fr. C2-2-2-3 Fr. C2-2-2-4 Fr. C2-2-2-5 Fr. C2-2-2-6 
(15 mg)     (13 mg)   (12 mg)   (20 mg)  (26 mg)  (35 mg) 
             Prep-LC-C18: 
     MeOH/H2O, 
             36:64 
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2.3.2 Glycosides from the aerial parts of G. bicolor 
2.3.2.1 Glycoside compounds: 2-phenylethyl β-D-glucopyranoside 158 and benzyl 
β-D-glucopyranoside 156 
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158                                 156 
 
Compound 158 was isolated as a white powder. The ESI mass spectrum of 158 showed 
an ion peak at m/z 343, two ion peaks at m/z 319/321, which corresponded to [M+OAc]- 
and [M+Cl]-, suggesting a molecular formula of C14H20O6. The 
1H NMR spectrum 
exhibited a triplet signal at δ 2.94 (2H, J = 7.2 Hz, H-7) which could result from benzylic 
methylene protons. The proton signals from a sugar moiety were seen in the spectrum, 
moreover, the doublet signal due to an anomeric proton appeared at δ 4.30 (1H, d, J = 
7.7 Hz, H-1’) and its configuration was confirmed as  type. The aromatic protons at δ 
7.14-7.27 (5H, m, H-2~6) suggested a mono-substituted benzene ring in the molecule. 
The 13C NMR spectrum exhibited two methylene carbon signals at δ 37.2 (C-7) and 71.7 
(C-8). Comparison with data available in the literature allowed to elucidate the sugar 
moiety of the compound 158 as D-glucopyranoside.167 Moreover, these data allowed to 
conclude the structure of this compound to be 2-phenylethyl β-D-glucopyranoside. 
 
Compound 156 was isolated as a white powder. The ESI mass spectrum of 156 showed 
an ion peak at m/z 329, two ion peaks at m/z 305/307, which corresponded to [M+OAc]- 
and [M+Cl]-, suggesting a molecular formula of C13H18O6. The 
1H and 13C NMR data were 
almost the same as those of compound 158, except for the presence of a Ph-CH2 group 
at δ 2.94 in compound 158. Based on further comparison with published data,168 the 
structure of compound 156 was identified as benzyl β-D-glucopyranoside. 
 
The spectral data of the compounds isolated in the present study match well with those 
reported earlier.167,168 The comparison of characteristic NMR data of compounds 158 and 
156 with literature data is listed in the Table 2.41 and 2.42.168 
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Table 2.41 Comparison of characteristic 1H NMR (300 MHz, CD3OD) and 
13C NMR (75 MHz, CD3OD) 
data of 2-phenylethyl β-D-glucopyranoside 158 with literature data (300/75 MHz, CD3OD)
168 
Position 
This work Literature data 
1H 13C 1H 13C 
1  140.1  140.0 
2 
7.14-7.27 (5H, m, H-2~6) 
129.3 
7.15-7.26 (5H, m, Ph) 
129.3 
3 130.0 130.0 
4 127.2 127.1 
5 130.0 130.0 
6 129.3 129.3 
7 2.94 (2H, t-like, J = 7.2 Hz) 37.2 2.93 (2H, “t”) 37.2 
8 
3.60-3.79 (1H, m, H-8a) 
4.05-4.13 (1H, m, H-8b) 
71.7 
3.59-3.79 (1H, m, H-8a) 
4.05-4.13 (1H, m,H-8b) 
71.7 
1’ 4.30 (1H, d, J = 7.7 Hz) 104.4 4.30 (1H, d, J = 7.7 Hz) 104.3 
2’ 
3.15-3.40 (4H, m, H-2’~5’) 
75.1 
3.16-3.39 (4H, m, H-2’~5’) 
75.0 
3’ 78.0 77.9 
4’ 71.6 71.6 
5’ 78.1 78.0 
6’ 
3.66 (1H, dd, J = 11.5, 5.2 
Hz, H-6’a), 3.86 (1H, dd, J = 
11.5, 1.7 Hz, H-6'b) 
62.7 
3.65 (1H, dd, J = 12.0, 5.5 
Hz, H-6’a), 3.86 (1H, dd, J = 
12.0, 2.0 Hz, H-6’b) 
62.7 
 
Table 2.42 Comparison of characteristic 1H NMR (300 MHz, CD3OD) and 
13C NMR (75 MHz, CD3OD) 
data of benzyl β-D-glucopyranoside 156 with literature data (300/75 MHz, CD3OD)
168 
Position 
This work Literature data 
1H 13C 1H 13C 
1  139.1  139.0 
2 
7.24-7.44 (5H, m, H-2~6) 
129.2 
7.23-7.43 (5H, m, Ph) 
129.2 
3 129.3 129.25 
4 128.7 128.7 
5 129.3 129.25 
6 129.2 129.2 
7 
4.66 (1H, d, J = 11.6 Hz, H-7a), 
4.94 (1H, d, J = 11.6 Hz, H-7b) 
71.7 
4.65 (1H, d, J = 11.8 Hz,H-7a), 
4.93 (1H, d, J = 11.8 Hz, H-7b) 
71.7 
1’ 4.35 (1H, d, J = 7.7 Hz) 103.3 4.35 (1H, d, J = 7.6 Hz) 103.2 
2’ 
3.25-3.35 (4H, m, H-2’~5’) 
75.1 
3.22-3.38 (4H, m, H-2’~5’) 
75.1 
3’ 78.1 78.0 
4’ 71.7 71.6 
5’ 78.1 78.05 
6’ 
3.69 (1H, dd, J = 11.8, 5.5 Hz, 
H-6’a), 3.90 (1H, dd, J = 11.8, 1.9 
Hz, H-6'b) 
62.8 
3.69 (1H, dd, J = 12.0, 5.5 Hz, 
H-6’a), 3.89 (1h, dd, J = 12.0, 2.1 
Hz, H-6’b) 
62.8 
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Scheme 2.3 describes the complete isolation of 2-phenylethyl β-D-glucopyranoside 158 
from the aerial parts of G. bicolor. 
 
Scheme 2.3 The complete isolation of 2-phenylethyl β-D-glucopyranoside 158 from G. bicolor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.4 describes the complete isolation of benzyl β-D-glucopyranoside 156 from the 
aerial parts of G. bicolor. 
 
 
 
 
 
                                       Extraction with 
                                       80% aqueous ethanol 
 
 
 
 
                                       Extraction with n-hexane, CH2Cl2, 
                                             EtOAc and MeOH, successively 
                                         
 
    n-Hexane extract      CH2Cl2 extract       EtOAc extract       MeOH extract 
          (0.8 g)                (3.4 g)                (7.7 g)               (121.3 g) 
                                                        CC-C18 
                                                        MeOH/H2O, 20-100% 
                           
 
Fr. C1      Fr. C2     Fr. C3    Fr. C4     Fr. C5 
      (1.3 g)       (0.7 g)      (2.1 g)     (2.9 g)      (0.5 g) 
            Auto. flash-C18: 
MeOH/H2O, 20-100% 
 
 
      Fr. C2-1      Fr. C2-2       Fr. C2-3       Fr. C2-4 
                (72 mg)        (510 mg)        (54 mg)         (30 mg) 
CC-Si: 
CHCl3/MeOH/H2O, 
                                      gradient 
                                                 
 
Fr. C2-2-1  Fr. C2-2-2  Fr. C2-2-3  Fr. C2-2-4  Fr. C2-2-5 
                      (190 mg)            (113 mg) 
                         CC-Si: 
            CHCl3/MeOH, 
                         100:1-6:1 
         
                         
Fr. C2-2-2-1  Fr. C2-2-2-2 Fr. C2-2-2-3 Fr. C2-2-2-4 Fr. C2-2-2-5 Fr. C2-2-2-6 
(15 mg)     (13 mg)   (12 mg)   (20 mg)  (26 mg)  (35 mg) 
                      Prep-LC-C18: 
                      MeOH/H2O, 
                      36:64 
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Scheme 2.4 The complete isolation of benzyl β-D-glucopyranoside 156 from G. bicolor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.2.2 Ellagic acid derivatives: 3,3'-di-O-methylellagic acid 4-O-β-D-xylopyranoside 159 
 
 
 
 
 
 
159 
 
 
 
 
                                       Extraction with 
                                       80% aqueous ethanol 
 
 
 
 
                                       Extraction with n-hexane, CH2Cl2, 
                                             EtOAc and MeOH, successively 
                                         
 
    n-Hexane extract      CH2Cl2 extract       EtOAc extract       MeOH extract 
          (0.8 g)                (3.4 g)                (7.7 g)               (121.3 g) 
                                                        CC-C18 
                                                        MeOH/H2O, 20-100% 
                           
 
Fr. C1      Fr. C2     Fr. C3    Fr. C4     Fr. C5 
      (1.3 g)       (0.7 g)      (2.1 g)     (2.9 g)      (0.5 g) 
                       Auto. flash-C18: 
MeOH/H2O, 20-100% 
 
 
      Fr. C3-1      Fr. C3-2       Fr. C3-3       Fr. C3-4 
                (70 mg)       (1200 mg)        (318 mg)        (421 mg) 
CC-Si: 
CHCl3/MeOH/H2O, 
                                      gradient 
                                                 
 
Fr. C3-2-1  Fr. C3-2-2  Fr. C3-2-3  Fr. C3-2-4  Fr. C3-2-5  Fr. C3-2-6 
          (65 mg)   (70 mg)   (200 mg)   (40 mg)  (130 mg) 
                               CC-Si: 
                      CHCl3/MeOH, 
                      20:1-4:1 
 
 
     Fr. C3-2-3-1  Fr. C3-2-3-2  Fr. C3-2-3-3  Fr. C3-2-3-4 
(25 mg) 
                              Prep-LC-C18 
                                       MeOH/H2O 
35:65 
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Compound 159 was obtained as a white powder and its molecular formula C21H18O12 was 
deduced by the ESI mass spectrum (m/z 461 [M-H]-). The 1H NMR spectrum showed two 
singlets at δ 7.72 and 7.49 assignable to aromatic protons from the ellagic acid skeleton. 
An anomeric proton at δ 5.14 (1H, d, H-1”) indicated a sugar moiety and its configuration 
was proposed to be  type on the basis of the coupling constant of 6.6 Hz. Two methoxy 
groups were observed as well at δ 4.06 (3H, s) and 4.03 (3H, s). In the 13C NMR spectrum, 
two lactone carbonyls at δ 159.0 (C-7 and C-7’) and 12 aromatic carbon signals could be 
due to ellagic acid. The sugar part of the compound was determined as a xylose moiety 
by comparison with published data.170 Two remaining methoxy carbon signals appeared 
at 61.6 (3’-OCH3) and 62.2 (3-OCH3) suggesting two ortho-disubstituted methoxy groups 
in the structure. As consequence, the xylose was assigned to be linked with C-4 of ellagic 
acid. These data, together with comparison with data available in the literature,170 
allowed to elucidate the structure of compound 159 as the known 
3,3'-di-O-methylellagic acid 4-O-β-D-xylopyranoside. The spectral data of the compound 
isolated in the present study match well with those reported earlier (Table 2.43).170 
 
Table 2.43 Comparison of characteristic 1H NMR (300 MHz, DMSO-d6) and 
13C NMR (75 MHz, 
DMSO-d6) data of 3,3'-di-O-methylellagic acid 4-O-β-D-xylopyranoside 159 with literature data 
(300/75 MHz, DMSO-d6)
170 
Position 
This work Literature data 
1H 13C 1H 13C 
1  114.7  114.1 
2  141.5  140.8 
3  142.4  141.8 
4  151.8  151.1 
5 7.72 (1H, s) 112.4 7.74 (1H, s) 111.8 
6  112.4  111.8 
7  159.0  158.2 
1’  111.6  111.0 
2’  142.2  141.5 
3’  140.7  140.1 
4’ 10.87 (1H, brs) 153.4  152.7 
5’ 7.49 (1H, s) 112.2 7.52 (1H, s) 111.4 
6’  113.3  112.7 
7’  159.0  158.3 
1” 5.14 (1H, d, J = 6.6 Hz) 102.3 5.14 (1H, d, J =7.2 Hz) 101.6 
2” 
3.36 (4H, under solvent) 
73.6 3.33 72.9 
3” 76.7 3.32 76.0 
4” 69.8 3.38 69.1 
5” 66.3 3.82(dd, J = 10.0, 4.0 Hz)) 65.7 
3-OCH3 4.06 (3H, s) 62.2 4.06 61.5 
3’-OCH3 4.03 (3H, s) 61.6 4.03 60.9 
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Scheme 2.5 describes the complete isolation of 3,3'-di-O-methylellagic acid 
4-O-β-D-xylopyranoside 159 from the aerial parts of G. bicolor. 
 
Scheme 2.5 The complete isolation of 3,3'-di-O-methylellagic acid 4-O-β-D-xylopyranoside 159 
from G. bicolor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.3 Terpenes from the aerial parts of G. bicolor 
 
 
 
 
 
 
                                       Extraction with 
                                       80% aqueous ethanol 
 
 
 
 
                                       Extraction with n-hexane, CH2Cl2, 
                                             EtOAc and MeOH, successively 
                                         
 
    n-Hexane extract      CH2Cl2 extract       EtOAc extract       MeOH extract 
          (0.8 g)                (3.4 g)                (7.7 g)               (121.3 g) 
                                                        CC-C18 
                                                        MeOH/H2O, 20-100% 
                           
 
Fr. C1      Fr. C2     Fr. C3    Fr. C4     Fr. C5 
      (1.3 g)       (0.7 g)      (2.1 g)     (2.9 g)      (0.5 g) 
                       Auto. flash-C18: 
MeOH/H2O, 20-100% 
 
 
      Fr. C3-1      Fr. C3-2       Fr. C3-3       Fr. C3-4 
                (70 mg)       (1200 mg)        (318 mg)        (421 mg) 
CC-Si: 
CHCl3/MeOH/H2O, 
                                      gradient 
                                                 
 
Fr. C3-2-1  Fr. C3-2-2  Fr. C3-2-3  Fr. C3-2-4  Fr. C3-2-5  Fr. C3-2-6 
          (65 mg)   (70 mg)   (200 mg)   (40 mg)  (130 mg) 
                                       CC-Si: 
                              CHCl3/MeOH, 
                              6:1 
 
                                CC-Sephadex-LH 20 
                                          MeOH/H2O 
8:2 
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2.3.3.1 Monoterpene compound: Ficusic acid 150 
1
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150 
Compound 150 was isolated as a white powder. The ESI mass spectrum showed a 
molecular ion [M+H]+ at m/z 197, suggesting a molecular formula of C11H16O3. The 
1H 
NMR spectrum exhibited two geminal methyl singlets at δ 1.27 (3H, s, H-11), 1.31 (3H, s, 
H-12) and a methyl singlet at δ 1.59 (3H, s, H-8). The signal at 5.71 (1H, s, H-9) was 
attributable to an olefinic proton attached to one of the double bond carbons 
conjugated with the carboxylic acid. The signals of two methylene groups appeared at 
2.54 (1H, ddd, J = 11.7, 3.9, 2.2 Hz, H-3a), 1.51 (1H, t, J = 11.7 Hz, H-3b), 2.04 (1H, ddd, J 
= 12.1, 4.0, 2.2 Hz, H-5a) and 1.34 (1H, t, J = 12.1 Hz, H-5b), respectively. In those 
methylene signals, H-3a and H-5a exhibited a W-type coupling (J = 2.2 Hz) as well. The 
methine proton signal at ca. 4.10 (1H, m, H-4) was assigned to be geminal to an ether 
linkage and situated between two methylene groups (H-3 and H-5). In the 13C NMR 
spectrum, three signals at 181.5 (C-10), 172.0 (C-2) and 113.1 (C-9) were assigned to a 
carboxylic acid conjugated with a double bond. These data, together with comparison 
with data available in the literature,160 allowed to elucidate the structure of compound 
150 as the known ficusic acid. The spectral data of compound 150 isolated in the present 
study match well with those reported earlier (Table 2.44).160 
 
Table 2.44 Comparison of characteristic 1H NMR (300 MHz, CDCl3) and 
13C NMR (75 MHz, CDCl3) 
data of ficusic acid 150 with literature data (600/150 MHz, CDCl3)
160 
Position 
This work Literature data 
1H 13C 1H 13C 
1  86.9  86.4 
2  172.0  171.5 
3 
1.51 (1H, t, J = 11.7 Hz, H-3b), 2.54 
(1H, ddd, J = 11.7, 3.9, 2.2 Hz, 
H-3a) 
49.7 
2.54 (1H, ddd, J = 11.9, 3.7, 2.3 
Hz), 2.04 (1H, ddd, J = 12.8, 4.1, 
2.3 Hz) 
49.8 
4 4.06-4.19 (1H, m) 64.9 4.14 (1H, m) 65.1 
5 
1.34 (1H, t, J = 12.1 Hz, H-5b), 2.04 
(1H, ddd, J = 12.1, 4.0, 2.2 Hz, 
H-5a) 
47.9 
1.51 (1H, t, J = 11.9 Hz), 1.33 
(1H, t, J = 12.4 Hz) 
47.9 
6  35.2  35.0 
8 1.59 (3H, s) 30.0 1.59 (3H, s) 30.0 
9 5.71 (1H, s) 113.1 5.72 (1H, s) 113.3 
10  181.5  180.7 
11 1.27 (3H, s) 25.1 1.27 (3H, s) 25.1 
12 1.31 (3H, s) 25.6 1.32 (3H, s) 25.6 
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2.3.3.2 Monoterpene compound: loliolide 152 
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Compound 152 was obtained as colorless needles. A quasi-molecular ion peak at m/z 
197 [M+H]+ was observed in the ESI mass spectrum, suggesting that the molecular 
formula of 7 was C11H16O3. In the 
1H NMR spectrum, three singlets at 1.27 (3H, s, H-9), 
1.47 (3H, s, H-10) and 1.79 (3H, s, H-11) were observed, which indicated the presence of 
three methyl groups. In the olefinic region, only one sharp singlet at 5.70 appeared. The 
signals of two methylene groups were observed at 1.53 (1H, dd, J = 14.3, 3.9 Hz, H-2a), 
1.98 (1H, dt, J = 14.9, 2.8 Hz, H-2b), 1.78 (1H, dd, J = 13.5, 4.1 Hz, H-4a) and 2.47 (1H, dt, 
J = 14.3, 2.8 Hz, H-4b) as well as one oxygenated methine at ca. 4.34, suggesting a 
CH2-CH(OH)-CH2 group of compound 152. In addition, a carbonyl function (182.5, C-6), 
one trisubstituted double bond (172.0, C-8 and 113.0, C-7), one oxygenated quaternary 
carbon (86.8, C-1), one oxygenated methine (66.9, C-3) from the 13C NMR spectrum, 
could be assigned also. Compared with the previous literature data reported (Table 2.45), 
162 compound 152 was identified as the known loliolide. 
 
Table 2.45 Comparison of characteristic 1H NMR (300 MHz, CDCl3) and 
13C NMR (75 MHz, CDCl3) 
data of loliolide 152 with literature data (300/75 MHz, CDCl3)
162 
Position 
This work Literature data 
1H 13C 1H 13C 
1  86.8  86.7 
2 
1.53 (1H, dd, J = 14.3, 3.9 Hz, H-2a), 
1.98 (1H, dt, J = 14.3, 2.8 Hz, H-2b) 
47.4 
1.50 (1H, dd, J = 15.0, 3.6 Hz) 
1.94 (1H, dt, J = 14.7, 3.0 Hz) 
47.3 
3 4.30-4.37 (1H, m) 66.9 4.31 (1H, quintet, J = 3.6 Hz) 66.8 
4 
1.78 (1H, dd, J = 14.3, 3.9 Hz, H-4a), 
2.47 (1H, dt, J = 14.3, 2.8 Hz, H-4b) 
45.7 
1.78 (1H, dd, J = 13.2, 3.9 Hz) 
2.43 (1H, dt, J = 14.1, 3.0 Hz) 
45.6 
5  36.0  35.9 
6  182.5  182.4 
7 5.70 (1H, s) 113.0 5.67 (1H, s) 112.9 
8  172.0  171.9 
9 1.27 (3H, s) 30.7 1.25 (3H, s) 30.6 
10 1.47 (3H, s) 26.6 1.45 (3H, s) 26.5 
11 1.79 (3H, s) 27.1 1.76 (3H, s) 27.0 
 
Scheme 2.6 describes the complete isolation of ficusic acid 150 and loliolide 152 from 
the aerial parts of G. bicolor. 
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Scheme 2.6 The complete isolation of ficusic acid 150 and loliolide 152 from G. bicolor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.4 Flavonoids from the aerial parts of G. bicolor 
2.3.4.1 Flavonoid compound: kaempferol 40 
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40 
 
 
 
 
                                       Extraction with 
                                       80% aqueous ethanol 
 
 
 
 
                                       Extraction with n-hexane, CH2Cl2, 
                                             EtOAc and MeOH, successively 
                                         
 
    n-Hexane extract      CH2Cl2 extract       EtOAc etract        MeOH extract 
          (0.8 g)                (3.4 g)                (7.7 g)                (121.3 g) 
                                   CC-Si: 
                                   CH2Cl2/MeOH Gradient 
                           
 
Fr. B1   Fr. B2   Fr. B3   Fr. B4   Fr. B5   Fr. B6 
 (600 mg)  
Auto. flash-C18: 
       MeOH/H2O, 50-100% 
 
 
      Fr. B2-1       Fr. B2-2      Fr. B2-3       Fr. B2-4 
     (248 mg)      (175 mg)      (64 mg)       (83 mg) 
CC-MCI gel: 
MeOH/H2O,                        CC-MCI gel: 
20-100%                          MeOH/H2O, 
                                      20-100% 
 
20% 40% 60% 80% 100% eluent 
       (56 mg)              20% 40% 60% 80% 100% eluent 
CC-Si: 
CH2Cl2/MeOH,                     
100:1-10:1                  93 mg   
                              CC-Si: 
Prep-LC-C18: MeCN/H2O,          PE/EtOAc, 10:1-1:1 
25:75 
                        Prep-LC-C18: MeCN/H2O, 
                              25:75 
 
 
 
 
 
 
 
150 (2.2 mg)                          
                      152 (4.0 mg) 
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Compound 40 was obtained as a yellow powder. In the ESI mass spectrum, a 
quasi-molecular ion peak [M-H]− at m/z 285 was observed suggesting the molecular 
formula of 40 was C15H10O6. The 
1H NMR spectrum showed two doublets at δ 6.18 (1H, d, 
J = 2.2 Hz, H-6) and 6.43 (1H, d, J = 2.2 Hz, H-8) corresponding to the meta-coupled 
protons on A-ring of a flavonoid. In addition, a typical A2X2 system was observed at δ 
8.04 (2H, d, J = 9.1 Hz, H-2’, 6’) and 6.92 (2H, d, J = 9.1 Hz, H-3’, 5’), which could be 
assigned to the protons on a para-substituted phenyl ring. In the 13C NMR spectrum, six 
aromatic methine carbons at δ 98.8 (C-6), 94.0 (C-8), 130.1 (C-2’, 6’), 116.0 (d, C-3’, 5’), 
eight aromatic quaternary carbons and a carbonyl carbon at δ 176.4 (C-4), were 
observed. Analysis of these data allowed to conclude the structure of 40 as the known 
kaempferol. The spectral data of the compound isolated in the present study match well 
with those reported earlier (Table 2.46).169 
 
Table 2.46 Comparison of characteristic 1H NMR (300 MHz, DMSO-d6) and 
13C NMR (75 MHz, 
DMSO-d6) data of kaempferol 40 with literature data (400/100 MHz, CD3OD)
169 
Position 
This work Literature data 
1H 13C 1H 13C 
1     
2  147.3  148.0 
3  136.2  137.1 
3-OH 9.42 (1H, brs)    
4  176.4  177.4 
5  156.7  162.5 
5-OH 12.48 (1H, s)    
6 6.18 (1H, d, J = 2.2 Hz) 98.8 6.17 (1H, d, J = 1.4 Hz) 99.2 
7  164.5  165.6 
7-OH 10.12 (1H, brs)    
8 6.43 (1H, d, J = 2.2 Hz) 94.0 6.38 (1H, s) 94.4 
9  161.3  160.5 
10  103.5  104.5 
1’  122.2  123.7 
2’ 8.04 (1H, d, J = 9.1 Hz) 130.1 8.07 (1H, d, J = 8.7 Hz) 130.7 
3’ 6.92 (1H, d, J = 9.1 Hz) 116.0 6.89 (1H, d, J = 8.7 Hz) 116.3 
3’-OH 10.80 (1H, brs)    
4’  159.8  158.2 
5’ 6.92 (1H, d, J = 8.8 Hz) 116.0 6.89 (1H, d, J = 8.7 Hz) 116.2 
6’ 8.04 (1H, d, J = 9.4 Hz) 130.1 8.07 (1H, d, J = 8.7 Hz) 130.7 
 
Scheme 2.7 describes the complete isolation of kaempferol 40 from the aerial parts of G. 
bicolor. 
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Scheme 2.7 The complete isolation of kaempferol 40 from G. bicolor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.5 Phenolic acids from the aerial parts of G. bicolor 
2.3.5.1 Phenolic acid compound: vanillic acid 80, 4-hydroxybenzoic acid 79 and 
protocatechuic acid 157 
 
 
 
 
                                       Extraction with 
                                       80% aqueous ethanol 
 
 
 
 
                                       Extraction with n-hexane, CH2Cl2, 
                                             EtOAc and MeOH, successively 
                                         
 
    n-Hexane extract      CH2Cl2 extract       EtOAc extract       MeOH extract 
          (0.8 g)                (3.4 g)                (7.7 g)               (121.3 g) 
                                                        CC-C18 
                                                        MeOH/H2O, 20-100% 
                           
 
Fr. C1      Fr. C2     Fr. C3    Fr. C4     Fr. C5 
      (1.3 g)       (0.7 g)      (2.1 g)     (2.9 g)      (0.5 g) 
                       Auto. flash-C18: 
MeOH/H2O, 20-100% 
 
 
      Fr. C3-1      Fr. C3-2       Fr. C3-3       Fr. C3-4 
                (70 mg)       (1200 mg)        (318 mg)        (421 mg) 
CC-Si: 
CHCl3/MeOH/H2O, 
                                      gradient 
                                                 
 
Fr. C3-2-1  Fr. C3-2-2  Fr. C3-2-3  Fr. C3-2-4  Fr. C3-2-5  Fr. C3-2-6 
          (65 mg)   (70 mg)   (200 mg)   (40 mg)  (130 mg) 
                      CC-Si: 
             CHCl3/MeOH, 
             10:1 
 
                     CC-Sephadex-LH 20 
                         MeOH/H2O 
8:2 
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Compounds 80, 79 and 157 were all isolated as white powder. Their ESI Mass spectram 
suggested their molecular formula as C8H8O4, C7H6O3 and C7H6O4, respectively. In the 
1H 
NMR spectra of compounds 80 and 157, three aromatic proton signals with an ABX 
coupling system were observed. In the 1H NMR spectrum of compound 79, two doublets 
of doublets at δ 7.77 (2H, J = 8.8, 3.9 Hz, H-2, 6) and δ 6.80 (2H, J = 8.8, 3.9 Hz, H-3, 5) 
were present, indicative of a 1,4-disubstituted aromatic ring. By comparison of the 
spectroscopic data with those reported in literature159, the structures of 80, 79 and 157 
could be determined as vanillic acid, 4-hydroxybenzoic acid and protocatechuic acid, 
respectively (Table 2.47). 
 
Table 2.47 Comparison of characteristic 1H NMR (300 MHz, CD3OD) and 
13C NMR (75 MHz, 
DMSO-d6) data of compounds 80, 79 and 157 with literature data (300/75 MHz, DMSO-d6)
159 
Position 
This work Literature data 
1H 13C 1H 13C 
Compound 80     
1  123.0  121.7 
2 7.55 (1H, d, J = 1.8 Hz) 115.8 7.43 ( 1H, s) 115.1 
3  148.7  147.3 
4  152.7 9.85 (1H, s) 151.1 
5 6.84 (1H, d, J = 8.3 Hz) 113.8 6.84 (1H, d, J = 8.7 Hz) 112.8 
6 7.56 (1H, dd, J = 8.3, 1.8 Hz) 125.3 7.45 (1H, d, J = 8.7 Hz) 123.5 
COOH  170.0 12.48 (1H,s) 167.3 
OCH3 3.90 (3H, s) 56.4 3.80 (3H, s) 55.6 
Compound 79     
1  122.0  121.5 
2, 6 7.77 (2H, dd, J = 8.8, 3.9 Hz) 132.1 7.80 (2H, dd) 131.6 
3, 5 6.80 (2H, dd, J = 8.8, 3.9 Hz) 115.7 6.83 (2H, dd) 115.2 
4  162.1  161.7 
COOH  167.7 11.28 (1H, s) 167.3 
Compound 157     
1  121.8  121.8 
2 7.34 (1H, s) 116.4 7.46 (1H, d, J = 2.0 Hz) 116.7 
3  144.8  145.0 
4  150.2  150.1 
5 6.69 (1H, d, J = 8.8 Hz) 114.4 6.80 (1H, d, J = 8.1 Hz) 115.3 
6 7.32 (1H, dd, J = 7.2, 1.7 Hz) 122.6 7.30 (1H, dd, J = 2.0, 8.1 Hz) 122.0 
COOH  168.9  167.5 
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Scheme 2.8 describes the complete isolation of vanillic acid 80 from the aerial parts of G. 
bicolor. 
 
Scheme 2.8 The complete isolation of vanillic acid 80 from G. bicolor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                       Extraction with 
                                       80% aqueous ethanol 
 
 
 
 
                                       Extraction with n-hexane, CH2Cl2, 
                                             EtOAc and MeOH, successively 
                                         
 
    n-Hexane extract      CH2Cl2 extract       EtOAc extract       MeOH extract 
          (0.8 g)                (3.4 g)                (7.7 g)               (121.3 g) 
                                   CC-Si: 
                                   CH2Cl2/MeOH Gradient 
                           
 
Fr. B1   Fr. B2   Fr. B3   Fr. B4   Fr. B5   Fr. B6 
    (1050 mg)  
                   CC-C18: 
MeOH/H2O, 50-100% 
 
 
      Fr. B1-1      Fr. B1-2       Fr. B1-3       Fr. B1-4 
                (176 mg)     (105 mg)     (144 mg)      (133 mg) 
CC-MCI gel: 
MeOH/H2O, 
20-100% 
                                                 
 
20% 40% 60% 80% 100% eluent 
                                      (32 mg) 
                                          CC-Si: 
                             CH2Cl2/MeOH, 
                                          20:1 
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Scheme 2.9 describes the complete isolation of 4-hydroxybenzoic acid 79 from the aerial 
parts of G. bicolor. 
 
Scheme 2.9 The complete isolation of 4-hydroxybenzoic acid 79 from G. bicolor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                       Extraction with 
                                       80% aqueous ethanol 
 
 
 
 
                                       Extraction with n-hexane, CH2Cl2, 
                                             EtOAc and MeOH, successively 
                                         
 
    n-Hexane extract      CH2Cl2 extract       EtOAc extract       MeOH extract 
          (0.8 g)                (3.4 g)                (7.7 g)               (121.3 g) 
                                                        CC-C18 
                                                        MeOH/H2O, 20-100% 
                           
 
Fr. C1      Fr. C2     Fr. C3    Fr. C4     Fr. C5 
      (1.3 g)       (0.7 g)      (2.1 g)     (2.9 g)      (0.5 g) 
            Auto. flash-C18: 
MeOH/H2O, 20-100% 
 
 
      Fr. C2-1      Fr. C2-2       Fr. C2-3       Fr. C2-4 
                (72 mg)        (510 mg)        (54 mg)         (30 mg) 
CC-Si: 
CHCl3/MeOH/H2O, 
                                      gradient 
                                                 
 
Fr. C2-2-1  Fr. C2-2-2  Fr. C2-2-3  Fr. C2-2-4  Fr. C2-2-5 
                      (190 mg)            (113 mg) 
                                        Auto. flash-C18: 
                           MeOH/H2O, 
                                        50:50 
                                56 mg 
                                   CC-Si: 
                                   CHCl3/MeOH, 
                                   9:1 
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Scheme 2.10 describes the complete isolation of protocatechuic acid 157 from the aerial 
parts of G. bicolor. 
 
Scheme 2.10 The complete isolation of protocatechuic acid 157 from G. bicolor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.6 Other natural products from the aerial parts of G. bicolor 
2.3.6.1 Sugar derivative: 5-(hydroxymethyl)furfural 148 
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                                       Extraction with 
                                       80% aqueous ethanol 
 
 
 
 
                                       Extraction with n-hexane, CH2Cl2, 
                                             EtOAc and MeOH, successively 
                                         
 
    n-Hexane extract       CH2Cl2 extract       EtOAc extract       MeOH extract 
          (0.8 g)                (3.4 g)                (7.7 g)               (121.3 g) 
                                                        CC-C18 
                                                        MeOH/H2O, 20-100% 
                           
 
Fr. C1      Fr. C2     Fr. C3    Fr. C4     Fr. C5 
      (1.3 g)       (0.7 g)      (2.1 g)     (2.9 g)      (0.5 g) 
                       Auto. flash-C18: 
MeOH/H2O, 20-100% 
 
 
      Fr. C3-1      Fr. C3-2       Fr. C3-3       Fr. C3-4 
                (70 mg)       (1200 mg)        (318 mg)        (421 mg) 
CC-Sephadex LH-20: 
MeOH/H2O, 
                       9:1 
                                                 
 
Fr. C3-1-1     Fr. C3-1-2      Fr. C3-1-3 
                 (46 mg) 
                    CC-Si: 
           CHCl3/MeOH, 
           8:1 
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Compound 148 was obtained as a colorless oil. A quasi-molecular ion peak [M+H]+ was 
observed with m/z 127 in the ESI mass spectrum suggesting that the molecular formula 
of 148 was C6H6O3. In the 
1H NMR spectrum, the proton at δ 9.53 suggested an aldehyde 
group, two doublets at δ 6.59 and 7.48 (each 1H, d, J = 3.3 Hz) were attributed to  
protons from a furan ring. In addition, the protons of an oxygenated methylene group 
were observed at δ 4.49. These data allowed to assign the structure of 148 as the known 
5-(hydroxymethyl)furfural. 
 
The spectral data of compound 148 in the present study match well with those reported 
earlier.156 The comparison of characteristic NMR data of compound 148 with literature 
data is listed in the Table 2.48. 
 
Table 2.48 Comparison of characteristic 1H NMR (300 MHz, DMSO-d6) and 
13C NMR (75 MHz, 
DMSO-d6) data of 5-(hydroxymethyl)furfural 148 with literature data (400/100 MHz, DMSO-d6)
156 
Position 
This work Literature data 
1H 13C 1H 13C 
1     
2  152.3  152.1 
3 7.48 (1H, d, J = 3.3 Hz) 110.3 7.42 (1H, d, J = 3.4 Hz) 110.0 
4 6.59 (1H, d, J = 3.3 Hz) 125.0 6.53 (1H, d, J = 3.4 Hz) 124.8 
5  162.8  163.2 
6 9.53 (1H, s) 178.6 9.45 (1H, s) 178.3 
7 4.49 (2H, s) 56.5 4.43 (2H, s) 56.0 
 
2.3.6.2 Benzoic acid 78 
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Compound 78 was obtained as a white powder. A quasi-molecular ion peak [M-H]- 
appeared at m/z 121 in the negative ESI mass spectrum suggesting that the molecular 
formula of 78 was C7H6O2. The 
1H NMR spectrum of 78 displayed two aromatic system at 
ca. δ 7.49 (2H) and 7.63 (1H), one aromatic doublet at δ 8.12 (2H), respectively. The 13C 
NMR spectrum also exhibited four aromatic signals at δ 133.9 (C-4), 130.3 (C-2 and C-6), 
129.3 (C-1), 128.6 (C-3 and C-5) and one carbonyl signal at δ 171.7. Based on this, the 
structure of compound 78 was elucidated as benzoic acid. The spectral data of the 
compound isolated in the present study match well with those reported earlier (Table 
2.49).157 
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Table 2.49 Comparison of characteristic 1H NMR (300 MHz, CDCl3) and 
13C NMR (75 MHz, CDCl3) 
data of benzoic acid 78 with literature data (90/22.5 MHz, CDCl3)
157 
Position 
This work Literature data 
1H 13C 1H 13C 
1  129.3  129.44 
2, 6 8.12 (2H, d, J = 7.2 Hz) 130.3 8.12 (2H, m) 130.28 
3, 5 7.46-7.52 (2H, m) 128.6 7.45 (2H, m) 128.49 
4 7.60-7.65 (1H, m) 133.9 7.62 (1H, m) 133.83 
7  171.7  172.77 
 
2.3.6.3 4-Hydroxybenzaldehyde 149 
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Compound 149 was obtained as a white powder. A quasi-molecular ion peak [M-H]- 
appeared at m/z 121 in the negative ESI mass spectrum suggesting that the molecular 
formula of 149 was C7H6O2. The 
1H NMR spectra of compound 149 showed the 
characteristic pattern of a 1,4-disubstituted benzene ring with two doublets at δ 7.76 (2H, 
d, J = 8.5 Hz, H-2, 6) and 6.89 (2H, d, J = 8.5 Hz, H-3, 5). At the same time, an aldehyde 
proton was observed at 9.74 as well. Moreover, the 13C NMR data were consistent with 
4-hydroxybenzaldehyde (Table 2.50).158 
 
Table 2.50 Comparison of characteristic 1H NMR (300 MHz, MeOH-d4) and 
13C NMR (75 MHz, 
MeOH-d4) data of 4-hydroxybenzaldehyde 149 with literature data (400/100 MHz, DMSO-d6)
158 
Position 
This work Literature data 
1H 13C 1H 13C 
1  130.1  128.5 
2, 6 7.76 (2H, d, J = 8.5 Hz) 132.5 7.79 (2H, d) 132.0 
3, 5 6.89 (2H, d, J = 8.5 Hz) 116.0 6.97 (2H, d) 115.8 
4  161.4  163.3 
7 9.74 (1H, s) 190.9 9.82 (1H, s) 190.8 
 
Scheme 2.11 describes the complete isolation of compounds 148, 78, 149 from the aerial 
parts of G. bicolor. 
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Scheme 2.11 The complete isolation of compounds 148, 78, 149 from G. bicolor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                       Extraction with 
                                       80% aqueous ethanol 
 
 
 
 
                                       Extraction with n-hexane, CH2Cl2, 
                                             EtOAc and MeOH, successively 
                                         
 
    n-Hexane extract      CH2Cl2 extract       EtOAc extract       MeOH extract 
          (0.8 g)                (3.4 g)                (7.7 g)               (121.3 g) 
                                   CC-Si: 
                                   CH2Cl2/MeOH Gradient 
                           
 
Fr. B1   Fr. B2   Fr. B3   Fr. B4   Fr. B5   Fr. B6 
    (1050 mg)  
                   CC-C18: 
MeOH/H2O, 50-100% 
 
 
      Fr. B1-1      Fr. B1-2       Fr. B1-3       Fr. B1-4 
                (176 mg)     (105 mg)     (144 mg)      (133 mg) 
CC-MCI gel: 
MeOH/H2O,                        Auto. flash-Si: 
20-100%                          CH2Cl2/MeOH, 
                                                0-8% 
 
20% 40% 60% 80% 100% eluent 
        
 
(102 mg) 
                 CC-Si:                
        CH2Cl2/MeOH, 
100:1-10:1                       148 (7.3 mg) 
100:1, 100:2 eluent 
(28 mg) 
Prep-LC-C18: 
MeOH/H2O, 
        35:65 
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STUDY OF THE CHEMICAL CONSTITUENTS OF THE 
AERIAL PARTS OF GYNURA DIVARICATA 
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3.1 Introduction 
Gynura divaricata (Linnaeus) Candolle is a herb with erect stems, glabrous or shortly 
pubescent, about 30-60 cm high and purplish; their leaves are ovate or 
half-moon-shaped, dentate auricle at base; blade adaxially purplish while abaxially green, 
which is reverse compared with Gynura bicolor (Figure 3.1). Capitula are numerous, 
peduncles are 1-15 cm; involucres campanulate; florets are orange-yellow; corolla 
slightly exceeding involucres, 11-15 mm; tube 9-10 mm; lobes are oblong-ovate, while 
anthers are obtuse. Style branches are slender. Achenes are brown, cylindric, 10-ribbed. 
Pappus white and silky. The flower time is from August to October.12 
 
   
Figure 3.1. Gynura divaricata (Linnaeus) Candolle 
 
Gynura divaricata is a traditional Chinese medicine, which can be used for the treatment 
of bronchitis, pulmonary tuberculosis, pertussis, sore eye, toothache and rheumatic 
arthralgia.174 G. divaricata is also known as an antidiabetic plant. It is used in folk recipes 
for the treatment of diabetes mellitus in Jiangsu, Zhejiang and Sichuan province in south 
China. In our investigation of natural medicines used in the traditional Chinese medical 
system for treatment of diabetes,52,151 a tea made from the fresh leaves of G. divaricata 
was found to have excellent hypoglycemia effects. Our previous pharmacological tests 
proved that the ethyl acetate and n-butanol extracts of the aerial parts of the plant had 
significant effects on lowering blood glucose level in normal and alloxan diabetic mice.151 
However, there are few reported phytochemical investigations of this species, despite 
the possible relationship between the hypoglycemic activity and the natural products 
from this species. One literature disclosure reported two pyrrolizidine alkaloids from this 
species22 and other researchers found cerebrosides41,42,43 and flavonoids31 from this plant. 
Therefore, this further research on the isolation and identification of the active chemical 
constituents from G. divaricata was conducted. The biological testing of the isolated 
compounds on potential hypoglycemic activity, en route towards the development of 
natural products for the treatment of diabetes mellitus, was planned to be studied as 
well. 
 
3.2 Experimental 
3.2.1 Plant materials 
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The aerial parts of G. divaricata for chemical constituent investigation were collected in 
June 2010 in Nanjing Botanical Garden Mem. Sun Yat-sen, in the south of the Zijin 
Mountain, Nanjing, China. The plant was identified by Professor Guo Rong-lin at the 
Institute of Botany, Jiangsu Province and Chinese Academy of Sciences. A voucher 
specimen (No. 510310-2) was deposited in the herbarium, Institute of Botany, Jiangsu 
Province and Chinese Academy of Sciences. 
 
3.2.2 Instrumentation 
Silica gel 60 (0.015-0.040 mm for column chromatography; Merck) was used as normal 
phase, whereas LiChroprep RP-18 (40-63 m particle size; Merck) was used as reversed 
phase column material. MCI gel CHP20P (75-150m, 400-600 Å mean pore size; 
Mitsubishi Chemical Corp.) and Sephadex LH-20 (GE healthcare) were used for column 
chromatography as well. TLC analyses were carried out on silica gel plates (KG60-F254, 
Merck). The melting point was measured with an X-6 micro-melting point apparatus 
(Beijing Tech). 1H and 13C NMR spectra were obtained on a JEOL 300 spectrometer. The 
HPLC instrument consisted of an Agilent (Waldbronn, Germany) model 1100 liquid 
chromatograph with diode array detector. The HPLC-MS consisted of Agilent LC/MSD 
1100 series, and the prep-LC consisted of Agilent 1100 serious equipped with VWD 
detector and automatic fraction collector. Automatic flash chromatography was 
performed by The Reveleris Flash System from GRACE, United States. 
 
3.2.3 Extraction and purification 
3.2.3.1 Extraction 
Dry aerial parts of G. divaricata (7.5 kg) were cut into small pieces and extracted with 80% 
aqueous ethanol at 70 C twice to afford 900 g of crude extract after evaporation in 
vacuo of the solvent. The crude extract was suspended in water (4.5 L), then liquid-liquid 
partitioned successively by n-hexane, EtOAc and n-butanol, respectively. The extracts 
were filtered and concentrated by evaporation under reduced pressure with a rotavapor 
at 40 C to afford a dark green n-hexane residue, a dark brown EtOAc residue (47.5 g, 
6.33 % yield), and a dark brown n-butanol residue. 
 
3.2.3.2 Study of the ethyl acetate extract of the aerial parts of G. divaricata 
The EtOAc extract (47.5 g) was adsorbed on 50 g of silica gel and further fractionated by 
column chromatography over silica gel, eluted with a gradient solvent system 
(n-hexane/EtOAc/acetone, Table 3.1). The fractions were collected in 100 mL tubes and 
after monitoring by TLC under UV, a total of seven different combined fractions (Fr. D1-7) 
were obtained (Table 3.2). 
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Table 3.1 Programme for fractionation of the EtOAc extract of the aerial parts of G. divaricata by 
column chromatography 
Mobile phase Gradient elution Solvent volume (mL) 
n-hexane 100 500 
n-hexane/EtOAc 100:10 1100 
n-hexane/EtOAc 100:25 2500 
n-hexane/EtOAc 50:50 3000 
n-hexane/EtOAc 50:100 4500 
EtOAc 100 2400 
EtOAc/acetone 100:25 2500 
EtOAc/acetone 100:50 1500 
EtOAc/acetone 50:50 1000 
acetone (clean up) 100 1000 
 
Table 3.2 Column chromatography fractionation of the EtOAc extract of G. divaricata 
Fraction Weight (mg) 
Fr. D1 0.8 g 
Fr. D2 2.1 g 
Fr. D3 7.0 g 
Fr. D4 7.6 g 
Fr. D5 11.3 g 
Fr. D6 8.1 g 
Fr. D7 --- 
 
3.2.3.2.1 Isolation of succinic acid 94 
Fr. D3 (7.0 g) was adsorbed on silica gel (12 g) and chromatographed over a normal 
phase column. Upon elution by a gradient of petroleum ether/EtOAc/acetone (Table 3.3) 
and monitoring by TLC, five combined fractions (Fr. D3-1~5) were obtained (Table 3.4). 
 
Table 3.3 Programme for separation of fraction Fr. D3 of the aerial parts of G. divaricata by 
column chromatography 
Mobile phase Gradient elution Solvent volume (mL) 
PE/EtOAc/acetone 100:5:5 1000 
PE/EtOAc/acetone 100:8:8 1000 
PE/EtOAc/acetone 100:10:10 1000 
PE/EtOAc/acetone 100:20:20 2000 
PE/EtOAc/acetone 100:25:25 1500 
PE/EtOAc/acetone 100:50:50 1500 
acetone (clean up) 100 800 
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Table 3.4 Column chromatography fractionation of Fr. D3 of G. divaricata 
Fraction Weight (mg) 
Fr. D3-1 220 
Fr. D3-2 540 
Fr. D3-3 1600 
Fr. D3-4 3500 
Fr. D3-5 800 
 
Fr. D3-3 (1.6 g) was dissolved in a small amount of hot EtOAc to fully dissolve the mixture 
and then filtered to obtain a clear solution. After cooling overnight, it resulted in 
compound 94 (1.1 g) which crystallized from the solvent. The solid crystals were 
collected by filtration as colorless needles. 
 
By comparison of the 1H, 13C NMR and ESI-MS spectral data with those reported,175 the 
compound 94 was identified as succinic acid. 
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Succinic acid 94: colorless needles; m.p. 176-177 C; ESI-MS m/z: 117 [M-H]-; 1H NMR δ 
ppm (D2O, 300 MHz): 2.57 (4H, s, H-2 and H-3); 
13C NMR δ ppm (D2O, 75 MHz): 174.1 
(C-1 and C-4), 29.3 (C-2 and C-3). 
 
3.2.3.2.2 Isolation of salicylic acid 160 and ethyl methyl succinate 161 
Fr. D3-4 (3.5 g) was subjected to column chromatography over silica gel eluted by a 
gradient of petroleum ether/EtOAc/acetone for further separation (Table 3.5). After 
monitoring by TLC, four combined fractions (Fr. D3-4-1~4) were obtained (Table 3.6). 
 
Table 3.5 Programme for separation of fraction Fr. D3-4 of G. divaricata by column chromatography 
Mobile phase Gradient elution Solvent volume (mL) 
PE/EtOAc/acetone 10:1:1 1800 
PE/EtOAc/acetone 8:1:1 1500 
PE/EtOAc/acetone 5:1:1 1400 
PE/EtOAc/acetone 4:1:1 1200 
PE/EtOAc/acetone 2:1:1 1200 
 
Table 3.6 Column chromatography fractionation of Fr. D3 of G. divaricata 
Fraction Weight (mg) 
Fr. D3-4-1 150 
Fr. D3-4-2 1300 
Fr. D3-4-3 800 
Fr. D3-4-4 500 
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Fr. D3-4-2 (1300 mg) was fractionated with an automatic flash chromatography system 
on a normal phase column eluted by a gradient of CH2Cl2 and methanol (0-9 %). The 
automatic flash chromatography conditions were (Table 3.7 and 3.8):  
 
Table 3.7 Automatic flash chromatography conditions of Fr. D3-4-2 of G. divaricata 
Run conditions 
Cartridge: Reveleris 40 g 
Solvent A: CH2Cl2 
Solvent B: Methanol  
Flow rate: 50 mL/min 
UV1 wavelength: 254 nm 
UV2 wavelength: 280 nm 
ELSD carrier Isopropanol 
Injection type: Dry sample 
 
Table 3.8 Automatic flash chromatography gradient method of Fr. D3-4-2 of G. divaricata 
Gradient method 
Step Time (min.) %B 
1 0 0 
2 90 9 
 
The eluates from 3.6-5.1 and 10.2-12.4 min were collected separately, concentrated by 
evaporation under reduced pressure with a rotavapor and finally dried under high 
vacuum. In this way, two pure compounds 160 (3.0 mg) and 161 (6.7 mg) were yielded. 
 
Besides the above two collected eluates, the others were collected as well and 
concentrated by evaporation under reduced pressure with a rotavapor, after monitoring 
by TLC under UV, four combined fractions (Fr. D3-4-2-1~4) were obtained (Table 3.9). 
 
Table 3.9 Column chromatography fractionation of Fr. D3-4-2 of G. divaricata 
Fraction Weight (mg) 
Fr. D3-4-2-1 103 
Fr. D3-4-2-2 52 
Fr. D3-4-2-3 89 
Fr. D3-4-2-4 170 
 
Analysis of their spectral data, together with comparison with data available in the 
literature,175,176,177 allowed to elucidate the structure of compounds 160 and 161 and to 
identify them as salicylic acid and ethyl methyl succinate, respectively. 
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Salicylic acid 160: white powder; m.p. 154-155 C; ESI-MS: m/z 137 [M-H]-; 1H NMR  
ppm (MeOH-d4, 300 MHz): 7.85 (1H, dd, J = 8.2, 1.7 Hz, H-6), 7.46 (1H, ddd, J = 8.3, 7.2, 
1.7 Hz, H-4), 6.91 (1H, ddd, J = 8.2, 7.2, 1.1 Hz, H-5), 6.87 (1H, dd, J = 8.3, 1.1 Hz, H-3); 13C 
NMR  ppm (MeOH-d4, 75 MHz): 173.5 (-COOH), 163.2 (C-2), 136.6 (C-4), 131.5 (C-6), 
120.1 (C-5), 118.1 (C-3), 113.9 (C-1). 
 
Ethyl methyl succinate 161: colorless liquid; 1H NMR δ ppm (CDCl3, 300 MHz): 4.16 (2H, 
q, J = 7.2 Hz, -OCH2), 3.71 (3H, s, OCH3), 2.60-2.73 (4H, m, 2  -COCH2), 1.27 (3H, t, J = 7.2 
Hz, -CH2CH3); 
13C NMR δ ppm (CDCl3, 75 MHz): 172.8 (C-4), 172.3 (C-1), 61.0 (OCH2), 52.1 
(OCH3), 28.9 (C-2 and C-3), 14.2 (-CH2CH3). 
 
3.2.3.2.3 Isolation of methyl succinate 162 and ethyl succinate 163 
Fr. D3-4-2-4 (170 mg) was subjected to column chromatography over Sephadex LH-20 gel 
eluted with methanol for further separation. The collected fractions were combined 
according to their chromatographic behavior on the TLC using CH2Cl2/MeOH (10:1) as 
eluent. The fraction with Rf 0.34 (30.2 mg) was additionally purified by prep-HPLC. The 
prep-HPLC conditions were: C18 column with guard cartridge, 21.2 mm ID  150 mm (5 
m); solvent isocratic 28% MeCN in water; flow rate 6 mL/min; detection UV 210 nm; 
room temperature; injection volume 150 L per time; running time 20 mins per injection; 
automatic fraction collector mode peak-based. 
 
The eluent from 8.7 to 9.9 min and 10.0 to 11.2 min were collected, respectively. Solvent 
removal by evaporation under reduced pressure yielded two pure compounds (162, 4.3 
mg and 163, 3.2 mg).  
By comparison of their 1H, 13C NMR and ESI-MS spectral data with those reported,175 the 
two compounds were identified as methyl succinate 162 and ethyl succinate 163, 
respectively. 
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Methyl succinate 162: white powder; m.p. 54-55 C; ESI-MS m/z: 131 [M-H]-; 1H NMR δ 
ppm (MeOH-d4, 300 MHz): 3.57 (3H, s, -OCH3), 2.49-2.51 (4H, m, H-2 and H-3); 
13C NMR 
δ ppm (75 MHz, MeOH-d4): 174.8 (C-4), 173.5 (C-1), 50.9 (OCH3), 28.5 (C-2 and C-3). 
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Ethyl succinate 163: white powder; m.p. 53-54 C; ESI-MS m/z: 145 [M-H]-; 1H NMR δ 
ppm (CDCl3, 300 MHz): 4.16 (2H, q, J = 6.9 Hz, -OCH2), 2.38-2.69 (4H, m, H-2 and H-3), 
1.26 (3H, t, J = 6.9 Hz, -CH3); 
13C NMR δ ppm (CDCl3, 75 MHz): 176.4 (C-1 and C-4), 60.9 
(OCH2), 28.5 (C-2 and C-3), 14.1 (-CH3). 
 
3.2.3.2.4 Isolation of isovanillic acid 164 
Fr. D3-4-4 (500 mg) was fractionated with column chromatography over silica gel eluted 
by CH2Cl2/methanol (10:1). The collected fractions were concentrated by evaporation 
under reduced pressure with a rotavapor and after monitoring by TLC with UV detection, 
three combined fractions (Fr. D3-4-4-1~3) were obtained (Table 3.10). 
 
Table 3.10 Column chromatography fractionation of Fr. D3-4-4 of G. divaricata 
Fraction Weight (mg) 
Fr. D3-4-4-1 62 
Fr. D3-4-4-2 182 
Fr. D3-4-4-3 55 
 
Fr. D3-4-4-2 (182 mg) was dissolved in a small amount of hot CH2Cl2/acetone to fully 
dissolve the mixture. After cooling overnight, this resulted in compound 164 (23.1 mg) 
which crystallized from the solvent.  
 
Analysis of the spectral data, together with comparison with data available in the 
literature,178 allowed to elucidate the structure of compound 164 and to identify it as 
isovanillic acid. 
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Isovanillic acid 164: white powder; m.p. 248-249 °C; ESI-MS m/z: 167 [M-H]-; 1H NMR δ 
ppm (300 MHz, MeOH-d4): 7.48 (1H, dd, J = 8.7, 1.7, H-6), 7.47 (1H, d, J = 1.7 Hz, H-2), 
6.75 (1H, d, J = 8.7 Hz, H-5), 3.81 (3H, s, -OCH3); 
13C NMR δ ppm (75 MHz, MeOH-d4): 
168.8 (-COOH), 151.3 (C-4), 147.3 (C-3), 123.9 (C-6), 121.8 (C-1), 114.5 (C-2), 112.4 (C-5), 
55.0 (-OCH3). 
 
3.2.3.2.5 Isolation of 4-hydroxybenzoic acid 79 and p-coumaric acid 165 
Fr. D3-4-4-3 (55 mg) was additionally purified by prep-HPLC. The prep-HPLC conditions 
were: C18 column with guard cartridge, 21.2 mm ID  150 mm (5 m); solvent isocratic 
26% MeCN in water; flow rate 6 mL/min; detection UV 254 nm; room temperature; 
injection volume 150 L per time; running time 15 mins per injection; automatic fraction 
collector mode peak-based. 
Chapter 3 
101 
The eluents from 9.3-11.1 min and 11.4-12.7 min were collected, respectively. Solvent 
removal by evaporation under reduced pressure yielded two pure compounds (79, 5.6 
mg; 165, 4.8 mg).  
 
By comparison of their 1H, 13C NMR and ESI-MS spectral data with those reported,179 the 
two compounds were identified as 4-hydroxybenzoic acid 79 and p-coumaric acid 165, 
respectively. 
4
3
1
6
5
2
O OH
OH                    
4
3
1
6
5 OH
O
HO
2
7
8
9
 
79                                165 
 
4-Hydroxybenzoic acid 79: white powder; m.p. 211-212 °C; ESI-MS m/z: 137 [M-H]-; 1H 
NMR δ ppm (MeOH-d4, 300 MHz): 7.77 (2H, d, J = 8.3 Hz, H-2 and H-6), 6.71 (2H, d, J = 
8.3 Hz, H-3 and H-5); 13C NMR δ ppm (MeOH-d4, 75 MHz): 169.0 (-COOH), 161.9 (C-4), 
131.7 (C-2 and C-6), 121.7 (C-1), 114.7 (C-3 and C-5). 
 
p-Coumaric acid 165: white powder; m.p. 209-210 °C; ESI-MS m/z: 163 [M-H]-; 1H NMR δ 
ppm (MeOH-d4, 300 MHz): 7.52 (1H, d, J = 15.9 Hz, H-7), 7.37 (2H, d, J = 8.8 Hz, H-2, 6), 
6.73 (2H, d, J = 8.8 Hz, H-3, 5), 6.20 (1H, d, J = 15.9, H-8); 13C NMR δ ppm (MeOH-d4, 75 
MHz): 169.7 (COOH), 159.9 (C-4), 145.3 (C-7), 129.8 (C-2 and C-6), 125.9 (C-1), 115.5 (C-3 
and C-5), 114.3 (C-8). 
 
3.2.3.2.6 Isolation of esculetin 166 
Fr. D3-5 (800 mg) was further separated by column chromatography over silica eluted by 
a gradient of CH2Cl2 and methanol (Table 3.11) resulting in three fractions (Fr. D3-5-1~3) 
(Table 3.12). Fr. D3-5-2 (177 mg) was recrystallized in acetone to yield compound 166 
(12.7 mg).  
 
Table 3.11 Programme for separation of Fr. D3-5 of G. divaricata 
Mobile phase Gradient elution Solvent volume (mL) 
CH2Cl2 100 300 
CH2Cl2/MeOH 100:2 1530 
CH2Cl2/MeOH 100:5 525 
CH2Cl2/MeOH 100:10 550 
CH2Cl2/MeOH 100:20 600 
 
Table 3.12 Column chromatography fractionation of Fr. D3-5 of G. divaricata 
Fraction Weight (mg) 
Fr. D3-5-1 153 
Fr. D3-5-2 177 
Fr. D3-5-3 86 
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Analysis of the spectral data, together with comparison with data available in the 
literature,180 allowed to elucidate the structure of compound 166 as esculetin. 
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Esculetin 166: yellow crystals; m.p. 266-267 °C; ESI-MS m/z: 177 [M-H]-; 1H NMR δ ppm 
(MeOH-d4, 300 MHz): 7.70 (1H, d, J = 9.9 Hz, H-4), 6.85 (1H, s, H-5), 6.67 (1H, s, H-8), 
6.09 (1H, d, J = 9.9 Hz, H-3); 13C NMR δ ppm (MeOH-d4, 75 MHz): 163.0 (C-2), 150.7 (C-7), 
149.1 (C-9), 144.7 (C-4), 143.2 (C-6), 111.7 (C-5), 111.5 (C-3), 111.2 (C-10), 102.3 (C-8). 
 
3.2.3.2.7 Isolation of rutin 38 
Fr. D4 (7.6 g) was subjected to column chromatography over MCI gel, eluted with water 
containing increasing concentrations of MeOH (Table 3.13). After monitoring by TLC, a 
total of five different combined fractions (Fr. D4-1~5) were obtained (Table 3.14). 
 
Table 3.13 Programme for fractionation of Fr. D4 of G. divaricata by column chromatography 
Mobile phase Gradient elution Solvent volume (mL) 
MeOH/H2O 20:80 800 
MeOH/H2O 40:60 2000 
MeOH/H2O 60:40 2000 
MeOH/H2O 80:20 1500 
MeOH (clean up) 100 500 
 
Table 3.14 Column chromatography fractionation of Fr. D4 of G. divaricata 
Fraction Weight (g) 
  
Fr. D4-2 1.3 
Fr. D4-3 0.9 
Fr. D4-4 0.8 
Fr. D4-5 1.1 
 
Fr. D4-2 (1.3 g) was further fractionated with an automatic flash chromatography system 
on a reversed-phase column (C-18, 40 g) eluted by a gradient of water and methanol 
(20-100%). The automatic flash chromatography conditions were (Table 3.15 and 3.16):  
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Table 3.15 Automatic flash chromatography conditions of Fr. D4-2 of G. divaricata 
Run conditions 
Cartridge: Reveleris 40 g C18 
Solvent A: Water 
Solvent B: Methanol  
Flow rate: 25 mL/min 
UV1 wavelength: 254 nm 
UV2 wavelength: 280 nm 
ELSD carrier Isopropanol 
Injection type: Dry sample 
 
Table 3.16 Automatic flash chromatography gradient method of Fr. D4-2 of G. divaricata 
Gradient method 
Step Time (min.) %B 
1 0 20 
2 60 100 
 
Upon monitoring by TLC under UV, four different fractions (Fr. D4-2-1~4) were obtained 
(Table 3.17), after concentration by evaporation under reduced pressure with a 
rotavapor. 
 
Table 3.17 Column chromatography fractionation of Fr. D4-2 of G. divaricata 
Fraction Weight (mg) 
Fr. D4-2-1 315 
Fr. D4-2-2 208 
Fr. D4-2-3 136 
Fr. D4-2-4 46 
 
Fr. D4-2-2 (208 mg) was further subjected to column chromatography over silica gel 
eluted by a solvent system consisting of CHCl3/MeOH (4:1). The collected fraction was 
finally purified by column chromatography over Sephadex LH-20 eluted with methanol to 
yield a pure compound (38, 8.9 mg). 
 
Analysis of its spectral data, together with comparison with data available in the 
literature,181 allowed to elucidate the structure of compound 38 as quercetin 
3-O-rutinoside (rutin). 
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Rutin 38: yellow powder; m.p. 197-198 °C; ESI-MS m/z: 609 [M-H]-; 1H NMR  ppm (300 
MHz, MeOH-d4): 7.57 (1H, d, J = 2.2 Hz, H-2), 7.54 (1H, dd, J = 8.7, 2.2 Hz, H-6), 6.78 (1H, 
d, J = 8.7 Hz, H-5), 6.31 (1H, s, H-8), 6.12 (1H, s, H-6), 5.01 (1H, d, J = 7.2 Hz, H-1), 4.42 
(1H, brs), 3.26-3.73 (11H, m, H-sugar), 1.02 (3H, d, J = 5.4 Hz, -CH3); 
13C NMR δ ppm 
(MeOH-d4, 75 MHz): 178.1 (C-4), 164.7 (C-7), 161.7 (C-5), 158.0 (C-2), 157.2 (C-9), 148.5 
(C-4), 144.5 (C-3), 134.3 (C-3), 122.2 (C-6), 121.8 (C-1), 116.4 (C-5), 114.7 (C-2), 104.3 
(C-10), 103.4 (C-1”), 101.1 (C-1”), 98.6 (C-6), 93.5 (C-8), 76.9 (C-5”), 75.9 (C-3”), 74.4 
(C-2”), 72.6 (C-4”), 70.9 (C-4”), 70.8 (C-2”), 70.1 (C-3”), 68.4 (C-5”), 67.2 (C-6”), 16.6 
(CH3). 
 
3.2.3.2.8 Isolation of quercetin 3-O-β-D-glucoside 36 and kaempferol 3-O-β-D-glucoside 
41 
 
Fr. D4-2-3 (136 mg) was further subjected to column chromatography over silica gel 
eluted by a solvent system consisted of CHCl3/MeOH (6:1). Based on TLC analysis, the 
combined eluent (37 mg) was finally purified by prep-HPLC on a RP-C18 column to afford 
two pure products. The preparative-HPLC conditions were: C18 column with guard 
cartridge, 21.2 mm ID  150 mm (5 m); elution, isocratic mode with MeOH/H2O (55:45); 
flow rate, 6 mL/min; detection, UV 254 nm; room temperature; injection volume, 150 L 
per time; running time, 12.5 mins per injection; automatic fraction collector mode 
peak-based. The sample was dissolved in 1 mL MeOH and filtered with 0.45 m filter 
prior to injection. The eluates from 8.6-9.7 and 11.0-12.2 min were collected, dried 
under high vacuum to afford compound 36 (2.5 mg) and 41 (2.8 mg), respectively. 
 
Analysis of their spectral data, together with comparison with data available in the 
literatures,182,183 allowed to elucidate the structure of the compound 36 and 41 as 
quercetin 3-O-β-D-glucoside and kaempferol 3-O-β-D-glucoside, respectively. 
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Quercetin 3-O-β-D-glucoside 36: yellow powder; m.p. 217-218 °C; ESI-MS m/z: 463 
[M-H]-; 1H NMR δ ppm (MeOH-d4, 300 MHz): 7.60 (1H, d, J = 2.2 Hz, H-2), 7.49 (1H, dd, J 
= 8.8, 2.2 Hz, H-6), 6.77 (1H, d, J = 8.8 Hz, H-5), 6.27 (1H, d, J = 1.9 Hz, H-8), 6.08 (1H, d, 
J = 1.9 Hz, H-6), 5.13 (1H, d, J = 7.2 Hz, H-1), 3.30-3.64 (6H, m, H-2-6); 13C NMR δ ppm 
(MeOH-d4, 100 MHz): 179.5 (C-4), 166.5 (C-7), 163.1 (C-5), 159.0 (C-9), 158.5 (C-2), 149.9 
(C-4’), 147.0 (C-3’), 135.6 (C-3), 123.2 (C-1’), 123.1 (C-6’), 117.5 (C-5’), 116.0 (C-2’), 105.6 
(C-10), 104.3 (C-1”), 100.0 (C-6), 94.8 (C-8), 78.4 (C-5”), 78.1 (C-3”), 75.7 (C-2”), 71.2 
(C-4”), 62.6 (C-6”). 
 
Kaempferol 3-O-β-D-glucoside 41: yellow powder; m.p. 207-208 °C; ESI-MS m/z: 447 
[M-H]-; 1H NMR δ ppm (MeOH-d4, 300 MHz): 7.96 (2H, d, J = 8.8 Hz, H-2, 6), 6.79 (2H, d, 
J = 8.8 Hz, H-3, 5), 6.25 (1H, d, J = 1.8 Hz, H-8), 6.07 (1H, d, J = 1.8 Hz, H-6), 5.12 (1H, d, J 
= 6.9 Hz, H-1), 3.30-3.62 (6H, m, H-2-6). 
 
3.2.3.2.9 Isolation of quercetin 35 and kaempferol 40 
Fr. D4-3 (0.9 g) was further subjected to column chromatography over silica gel eluted by 
a gradient of CH2Cl2 and methanol (100:5-8:1) (Table 3.18). Five fractions (Table 3.19) 
were obtained and two of them were combined for subsequent purification.  
 
Table 3.18 Programme for separation of Fr. D4-3 of G. divaricata 
Mobile phase Gradient elution Solvent volume (mL) 
CH2Cl2/MeOH 100:5 550 
CH2Cl2/MeOH 100:10 1100 
CH2Cl2/MeOH 90:10 500 
CH2Cl2/MeOH 80:10 450 
 
Table 3.19 Column chromatography fractionation of Fr. D4-3 of G. divaricata 
Fraction Weight (mg) 
Fr. D4-3-1 164 
Fr. D4-3-2 76 
Fr. D4-3-3 65 
Fr. D4-3-4 51 
Fr. D4-3-5 29 
 
Fr. D4-3-2 and Fr. D4-3-3 were combined (141 mg) and chromatographed on a Sephadex 
LH-20 column eluted with chloroform-methanol (1:1) to afford two pure compounds 35 
(10.2 mg) and 40 (8.8 mg), respectively. 
 
Analysis of their spectral data, together with comparison with data available in the 
literatures,182,183 allowed to elucidate the structure of compound 35, 40 as quercetin and 
kaempferol, respectively. 
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Quercetin 35: yellow powder; m.p. 310-311 °C; ESI-MS m/z: 301 [M-H] -; 1H NMR δ ppm 
(MeOH-d4, 300 MHz): 7.63 (1H, d, J = 2.1 Hz, H-2), 7.53 (1H, dd, J = 8.1, 2.1 Hz, H-6), 
6.78 (1H, d, J = 8.1 Hz, H-5), 6.29 (1H, d, J = 1.8 Hz, H-8), 6.08 (1H, d, J = 1.8 Hz, H-6); 13C 
NMR δ ppm (MeOH-d4, 75 MHz): 176.0 (C-4), 164.2 (C-7), 161.2 (C-9), 156.9 (C-5), 147.4 
(C-4), 146.7 (C-2), 144.9 (C-3), 135.9 (C-3), 122.8 (C-1), 120.3 (C-6), 114.9 (C-5), 114.7 
(C-2), 103.2 (C-10), 97.9 (C-6), 93.1 (C-8). 
 
Kaempferol 40: yellow powder; m.p. 275-276 °C; ESI-MS m/z: 287 [M+H]+; 1H NMR δ 
ppm (MeOH-d4, 300 MHz): 7.99 (2H, d, J = 9.1 Hz, H-2, 6), 6.81 (2H, d, J = 9.1 Hz, H-3, 
5), 6.30 (1H, d, J = 2.1 Hz, H-8), 6.08 (1H, d, J = 2.1 Hz, H-6); 13C NMR δ ppm (MeOH-d4, 
75 MHz): 175.8 (C-4), 164.3 (C-7), 161.2 (C-9), 159.1 (C-4), 156.9 (C-5), 146.6 (C-2), 135.9 
(C-3), 129.4 (C-2 and C-6), 122.2 (C-1), 115.0 (C-3 and C-5), 103.2 (C-10), 97.9 (C-6), 
93.1 (C-8). 
 
3.2.3.2.10 Isolation of 3,4-dicaffeoylquinic acid 167, 3,5-dicaffeoylquinic acid 72, 
4,5-dicaffeoylquinic acid 73, methyl 3,4-dicaffeoylquinate 168, methyl 
3,5-dicaffeoylquinate 169 and methyl 4,5-dicaffeoylquinate 170 
 
Fr. D5 (11.3 g) was subjected to column chromatography over MCI gel, eluted with water 
containing increasing concentrations of MeOH (Table 3.20). After monitoring by TLC, a 
total of four different combined fractions (Fr. D5-1~4) were obtained (Table 3.21). 
 
Table 3.20 Programme for fractionation of Fr. D5 of the aerial parts of G. divaricata by column 
chromatography 
Mobile phase Gradient elution Solvent volume (mL) 
MeOH/H2O 20:80 1200 
MeOH/H2O 40:60 2500 
MeOH/H2O 60:40 3000 
MeOH/H2O 80:20 2500 
MeOH (clean up) 100 800 
 
Table 3.21 Column chromatography fractionation of Fr. D5 of G. divaricata 
Fraction Weight (g) 
Fr. D5-1 2.4 
Fr. D5-2 1.3 
Fr. D5-3 6.2 
Fr. D5-4 0.8 
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Fr. D5-3 (6.2 g) was divided into four equal parts and each part was fractionated with an 
automatic flash chromatography system on a reversed-phase column (C-18, 40 g) eluted 
by a gradient of water and methanol (20-100%). The automatic flash chromatography 
conditions were (Table 3.22 and 3.23):  
 
Table 3.22 Automatic flash chromatography conditions of Fr. D5-3 of G. divaricata 
Run conditions 
Cartridge: Reveleris 40 g C18 
Solvent A: Water 
Solvent B: Methanol  
Flow rate: 25 mL/min 
UV1 wavelength: 254 nm 
UV2 wavelength: 280 nm 
ELSD carrier Isopropanol 
Injection type: Dry sample 
 
Table 3.23 Automatic flash chromatography gradient method of Fr. D5-3 of G. divaricata 
Gradient method 
Step Time (min.) %B 
1 0 20 
2 60 100 
 
Upon monitoring by TLC under UV, five different fractions (Fr. D5-3-1~5) were obtained 
(Table 3.24), after concentration by evaporation under reduced pressure with a 
rotavapor. 
 
Table 3.24 Column chromatography fractionation of Fr. D5-3 of G. divaricata 
Fraction Weight (mg) 
Fr. D5-3-1  
Fr. D5-3-2 1530 
Fr. D5-3-3 610 
Fr. D5-3-4 380 
Fr. D5-3-5 750 
 
Fr. D5-3-2 (1530 mg) was dissolved in a small amount of methanol, and 
chromatographed over Sephadex LH-20 gel column eluting with a methanol/water 
gradient (50-100%) as solvent to afford three fractions (Fr. D5-3-2-1~3, Table 3.25).  
 
Table 3.25 Column chromatography fractionation of Fr. D5-3-2 of G. divaricata 
Fraction Weight (mg) 
Fr. D5-3-2-1 450 
Fr. D5-3-2-2 680 
Fr. D5-3-2-3 320 
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An analytical HPLC method was developed to analyse the constituents in the Fr. D5-3-2-2. 
In the HPLC spectrum (Figure 3.2), six major peaks were observed which were separated 
from each other well. The analytical HPLC conditions were the following: column, inertsil 
ODS-SP, 5 m 4.6  250 mm, Shimadzu; solvents for the mobile phase, water-0.1% 
formic acid (A) and MeCN (B); elution, linear gradient mode 10-30% B in 0-30 min, 
30-100% B in 30-45 min, 100-10% in 45-50 min; flow rate, 0.8 mL/min; detection, UV 325 
nm; running time, 50 min.  
 
Figure 3.2 HPLC chromatogram of the constituents in Fr. D5-3-2-2 of G. divaricata 
 
 
To isolate these six compounds, a preparative-HPLC method was developed. The 
preparative-HPLC conditions were: C18 column with guard cartridge, 21.2 mm ID  150 
mm (5 m); solvents for the mobile phase, water-0.1% formic acid (A) and MeCN (B); 
elution, isocratic mode 20% B in 0-30 min, linear gradient mode 20-30% B in 30-55 min, 
30-20% in 55-57 min; flow rate, 6 mL/min; detection, UV 325 nm; room temperature; 
injection volume, 250 L per time; running time, 57 mins per injection; automatic 
fraction collector mode peak-based. About 100 mg of sample was dissolved in 1 mL 
MeOH and filtered with 0.45 m filter prior to injection. Six eluates were collected and 
dried under high vacuum to afford compound 167 (44.3 mg), 72 (38.2 mg), 73 (26.3 mg), 
168 (13.6 mg), 169 (9.4 mg) and 170 (10.5 mg), respectively. 
 
Analysis of their spectral data, together with comparison with data available in the 
literature,184,185,186,187 allowed to elucidate the structure of the compounds 167, 72-73 
and 168-170 as 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, 4,5-dicaffeoylquinic 
acid, methyl 3,4-dicaffeoylquinate, methyl 3,5-dicaffeoylquinate and methyl 
4,5-dicaffeoylquinate, respectively. 
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Compound Name R1 R2 R3 R4 
167 3,4-dicaffeoylquinic acid H caffeoyl caffeoyl H 
72 3,5-dicaffeoylquinic acid caffeoyl H caffeoyl H 
73 4,5-dicaffeoylquinic acid caffeoyl caffeoyl H H 
168 methyl 3,4-dicaffeoylquinate H caffeoyl caffeoyl Me 
169 methyl 3,5-dicaffeoylquinate caffeoyl H caffeoyl Me 
170 methyl 4,5-dicaffeoylquinate H caffeoyl caffeoyl Me 
 
3,4-Dicaffeoylquinic acid 167: pale green powder; m.p. 168-169 °C; ESI-MS m/z: 515 
[M-H]-; 1H NMR δ ppm (MeOH-d4, 300 MHz): 7.57, 7.55 (2H, d, J = 16 Hz, H-7’, 7”), 7.04, 
7.02 (2H, d, J = 2 Hz, H-2’, 2”), 6.93, 6.88 (2H, dd, J = 8, 2 Hz, H-6’, 6”), 6.77, 6.73 (2H, d, J 
= 8 Hz, H-5’, 5”), 6.29, 6.26 (2H, d, J = 16 Hz, H-8’, 8”), 5.60-5.67 (1H, m, H-3), 5.00 (1H, dd, 
J = 3.3, 9 Hz, H-4), 4.31-4.41 (1H, m, H-5), 1.99-2.38 (4H, m, H-2 and H-6); 13C NMR δ 
ppm (MeOH-d4, 75 MHz): 178.5 (COOH), 168.9 (C-9’, 9”), 149.7 (C-4’, 4”), 147.6 (C-7’, 7”), 
146.9 (C-3’, 3”), 128.0 (C-1’, 1”), 123.5 (C-6’, 6”), 116.7 (C-5’, 5”), 115.4 (C-2’, 2”), 115.2 
(C-8’, 8”), 76.6 ( C-4), 75.6 (C-1), 70.4 (C-3), 66.1 (C-5), 42.0 (C-2), 37.2 (C-6). 
 
3,5-Dicaffeoylquinic acid 72: pale green powder; m.p. 169-170 °C; ESI-MS m/z: 515 
[M-H]-; 1H NMR δ ppm (MeOH-d4, 300 MHz): 7.62, 7.59 (2H, d, J = 16 Hz, H-7’, 7”), 7.07 
(2H, s, H-2’, 2”), 6.97, 6.96 (2H, dd, J = 8.3, 2.2 Hz, H-6’, 6”), 6.79, 6.77 (2H,d, J = 8.3 Hz, 
H-5’, 5”), 6.36, 6.27 (2H, d, J = 16 Hz, H-8’, 8”), 5.34-5.46 (2H, m, H-3 and H-5), 3.97 (1H, 
dd, J = 2.7, 7.5 Hz, H-4), 2.04-2.34 (4H, m, H-2 and H-6). 13C NMR δ ppm (MeOH-d4, 75 
MHz): 177.6 (COOH), 168.9, 168.4 (C-9’, 9”), 149.6, 149.5 (C-4’, 4”), 147.3, 147.0 (C-7’, 7”), 
146.8 (C-3’, 3”), 127.9, 127.8 (C-1’, 1”), 123.1, 123.0 (C-6’, 6”), 116.4 (C-5’, 5”), 115.6, 
115.2 (C-2’, 2”), 115.1 (C-8’, 8”), 74.8 (C-1), 72.6 (C-3), 72.1 (C-5), 70.7 ( C-4), 37.7 (C-6), 
36.1 (C-2). 
 
4,5-Dicaffeoylquinic acid 73: pale green powder; m.p. 170-171 °C; ESI-MS m/z: 515 
[M-H]-; 1H NMR δ ppm (MeOH-d4, 300 MHz): 7.56, 7.47 (2H, d, J = 16 Hz, H-7’, 7”), 6.96 
(2H, s, H-2’, 2”), 6.86, 6.84 (2H, d, J = 7.2 Hz, H-6’, 6”), 6.72, 6.69 (2H, d, J = 7.2 Hz, H-5’, 
5”), 6.25, 6.15 (2H, d, J = 16 Hz, H-8’, 8”), 5.50-5.68 (1H, m, H-5), 5.00-5.20 (1H, m, H-4), 
4.27-4.42 (1H, m, H-3), 1.93-2.38 (4H, m, H-2 and H-6). 13C NMR δ ppm (MeOH-d4, 75 
MHz): 177.1 (COOH), 168.5, 168.3 (C-9’, 9”), 149.6 (C-4’, 4”), 147.7, 147.5 (C-7’, 7”), 146.6 
(C-3’, 3”), 127.6 (C-1’, 1”), 123.1 (C-6’, 6”), 116.4 (C-5’, 5”), 115.2 (C-2’, 2”), 114.7 (C-8’, 8”), 
76.2 ( C-4), 75.8 (C-1), 69.4 (C-3), 69.0 (C-5), 39.4 (C-6), 38.3 (C-2). 
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Methyl 3,4-dicaffeoylquinate 168: pale yellow powder; m.p. 142-143 °C; ESI-MS m/z: 
529 [M-H]-; 1H NMR δ ppm (MeOH-d4, 300 MHz): 7.55, 7.50 (2H, d, J = 16 Hz, H-7’, 7”), 
7.01 (2H, s, H-2’, 2”), 6.87 (2H, d, J = 7.7 Hz, H-6’, 6”), 6.74 (2H, d, J = 7.7 Hz, H-5’, 5”), 
6.27, 6.22 (2H, d, J = 16 Hz, H-8’, 8”), 5.52-5.66 (1H, m, H-3), 4.95-5.15 (1H, m, H-4), 
4.20-4.35 (1H, m, H-5), 3.73 (3H, s, COOCH3), 1.96-2.35 (4H, m, H-2 and H-6); 
13C NMR δ 
ppm (MeOH-d4, 75 MHz): 176.1 (COOCH3), 168.5 (C-9’, 9”), 149.6 (C-4’, 4”), 147.3 (C-7’, 
7”), 146.8 (C-3’, 3”), 127.7 (C-1’, 1”), 123.2, 123.1 (C-6’, 6”), 116.4 (C-5’, 5”), 115.1 (C-2’, 
2”), 115.0, 114.8 (C-8’, 8”), 75.6 ( C-4), 75.2 (C-1), 69.8 (C-3), 69.8 (C-5), 41.3 (C-2), 36.8 
(C-6). 
 
Methyl 3,5-dicaffeoylquinate 169: pale yellow powder; m.p. 143-144 °C; ESI-MS m/z: 
529 [M-H]-; 1H NMR δ ppm (MeOH-d4, 300 MHz): 7.62, 7.55 (2H, d, J = 16 Hz, H-7’, 7”), 
7.07 (2H, d, J = 2 Hz, H-2’, 2”), 6.99, 6.96 (2H, d, J = 8 Hz, H-6’, 6”), 6.80, 6.77 (2H, d, J = 8 
Hz, H-5’, 5”), 6.35, 6.22 (2H, d, J = 16 Hz, H-8’, 8”), 5.36-5.43 (1H, m, H-5), 5.27-5.35 (1H, 
m, H-3), 3.98 (1H, dd, J = 7.5, 2.7 Hz, H-4), 3.69 (3H, s, COOCH3), 2.11-2.36 (4H, m, H-2 
and H-6); 13C NMR δ ppm (MeOH-d4, 75 MHz): 175.6 (COOCH3), 168.7, 167.9 (C-9’, 9”), 
149.8, 149.6 (C-4’, 4”), 147.4, 147.1 (C-7’, 7”), 146.9, 146.8 (C-3’, 3”), 127.9, 127.6 (C-1’, 
1”), 123.1, 123.0 (C-6’, 6”), 116.6, 116.5 (C-5’, 5”), 115.5, 115.1 (C-2’, 2”), 115.1, 114.8 
(C-8’, 8”), 74.6 (C-1), 72.2 (C-3), 72.0 (C-5), 69.7 ( C-4), 53.0 (COOCH3), 37.0 (C-6), 35.6 
(C-2). 
 
Methyl 4,5-dicaffeoylquinate 170: pale yellow powder; m.p. 145-146 °C; ESI-MS m/z: 
529 [M-H]-; 1H NMR δ ppm (MeOH-d4, 300 MHz): 7.61, 7.51 (2H, d, J = 16 Hz, H-7’, 7”), 
7.03 (2H, s, H-2’, 2”), 6.91-6.93 (2H, m, H-6’, 6”), 6.78, 6.75 (2H, d, J = 8 Hz, H-5’, 5”), 6.30, 
6.18 (2H, d, J = 16 Hz, H-8’, 8”), 5.48-5.59 (1H, m, H-5), 5.08-5.15 (1H, m, H-4), 4.30-4.39 
(1H, m, H-3), 3.72 (3H, s, COOCH3), 1.99-2.36 (m, H-2 and H-6). 
13C NMR δ ppm 
(MeOH-d4, 75 MHz): 175.2 (COOCH3), 168.5, 167.9 (C-9’, 9”), 149.8, 149.7 (C-4’, 4”), 
147.7 (C-7’, 7”), 146.8 (C-3’, 3”), 127.7, 127.5 (C-1’, 1”), 123.2 (C-6’, 6”), 116.5 (C-5’, 5”), 
115.1 (C-2’, 2”), 114.7, 114.5 (C-8’, 8”), 75.8 ( C-4), 74.8 (C-1), 69.1 (C-3), 68.6 (C-5), 53.1 
(COOCH3), 38.5 (C-6), 38.4 (C-2). 
 
3.2.3.2.11 Isolation of 5-O-p-coumaroylquinic acid 171, methyl 5-O-caffeoylquinate 172 
and 5-O-feruloylquinic acid 173 
 
Fr. D5-3-2-1 (450 mg) was subjected to column chromatography over silica gel eluted by 
a solvent gradient system consisting of CHCl3-MeOH (Table 3.26) to yield three fractions 
(Fr. D5-3-2-1-1~3, Table 3.27). 
 
Table 3.26 Programme for fractionation of Fr. D5-3-2-1 of G. divaricata by column 
chromatography 
Mobile phase Gradient elution Solvent volume (mL) 
CHCl3/MeOH 10:1 1100 
CHCl3/MeOH 8:1 1350 
CHCl3/MeOH 8:2 800 
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Table 3.27 Column chromatography fractionation of Fr. D5-3-2-1 of G. divaricata 
Fraction Weight (mg) 
Fr. D5-3-2-1-1 66 
Fr. D5-3-2-1-2 102 
Fr. D5-3-2-1-3 186 
 
Fr. D5-3-2-1-2 (102 mg) was analyzed by HPLC before its further purification. Five mg of 
Fr. D5-3-2-1-2 was dissolved in 1 mL MeOH and filtered with 0.45 m filter prior to 
injection. The analytical HPLC conditions were the following: column, inertsil ODS-SP, 5 
m 4.6  250 mm, Shimadzu; solvents for the mobile phase, water-0.1% formic acid (A) 
and MeCN (B); elution, linear gradient mode 10-30% B in 0-30 min, 30-100% B in 30-45 
min, 100-10% in 45-50 min; flow rate, 0.8 mL/min; detection, UV 325 nm; running time, 
50 min. In the HPLC spectrum (Figure 3.3), two major peaks (Rt 22.27 and Rt 25.30) were 
observed and these two compounds were targeted in the subsequent separation. 
 
Figure 3.3 HPLC chromatogram of the constituents in Fr. D5-3-2-1-2 of G. divaricata 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To isolate the target compounds, a preparative-HPLC method was developed. The 
prep-HPLC conditions were: C18 column with guard cartridge, 21.2 mm ID  150 mm (5 
m); solvents for the mobile phase, water-0.1% formic acid (A) and MeCN (B); elution, 
linear gradient mode 15-20% B in 0-25 min, 20-50% B in 25-28 min, 50-15% in 28-30 min; 
flow rate, 6 mL/min; detection, UV 325 nm; room temperature; injection volume, 120 L 
per time; running time, 30 mins per injection; automatic fraction collector mode 
peak-based. About 50 mg of sample was dissolved in 1 mL MeOH and filtered with 0.45 
m filter prior to injection. Four eluates named Fr. D5-3-2-1-2-1~4 were collected (Table 
3.28). Fr. D5-3-2-1-2-1 and Fr. D5-3-2-1-2-4 were dried under high vacuum to afford 
compounds 171 (1.2 mg) and 172 (8.7 mg), respectively. 
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Table 3.28 Column chromatography fractionation of Fr. D5-3-2-1-2 of G. divaricata 
Fraction Weight (mg) 
Fr. D5-3-2-1-2-1 1.2 
Fr. D5-3-2-1-2-2 0.3 
Fr. D5-3-2-1-2-3 0.6 
Fr. D5-3-2-1-2-4 8.7 
 
Analysis of their spectral data, together with comparison with data available in the 
literatures,188,189 allowed to elucidate the structure of compounds 171-172 as 
5-O-p-coumaroylquinic acid and methyl 5-O-caffeoylquinate, respectively. 
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5-O-p-Coumaroylquinic acid 171: white powder; m.p. 207-208 C; ESI-MS m/z: 337 
[M-H]-; 1H NMR δ ppm (MeOH-d4, 300 MHz): 7.63 (1H, d, J = 16.0 Hz, H-7’), 7.47 (2H, d, J 
= 8.8 Hz, H-2’ and H-6’), 6.81 (2H, d, J = 8.8 Hz, H-3’ and C-5’), 6.33 (1H, d, J = 16.0 Hz, 
H-8’), 5.28-5.38 (m, H-5), 4.12-4.20 (1H, m, H-3), 3.73 (1H, dd, J = 8.3, 2.8 Hz, H-4), 
2.01-2.25 (4H, m, H-2 and H-6); 13C NMR δ ppm (MeOH-d4, 75 MHz): 177.1 (COOH), 
168.5 (C-9’), 160.8 (C-4’), 146.5 (C-7’), 130.9 (C-2’ and C-6’), 127.0 (C-1’), 116.5 (C-3’ and 
C-5’), 115.0 (C-8’), 76.0 (C-1), 73.1 (C-5), 71.7 (C-3), 71.0 (C-4), 38.5 (C-6), 37.9 (C-2). 
 
Methyl 5-O-caffeoylquinate 172: white powder; m.p. 162-163 C; ESI-MS m/z: 367 
[M-H]-; 1H NMR δ ppm (MeOH-d4, 300 MHz): 7.52 (1H, d, J = 16.0 Hz, H-7’), 7.04 (1H, d, J 
= 2.2 Hz, H-2’), 6.95 (1H, dd, J = 8.0, 2.2 Hz, H-6’), 6.78 (1H, d, J = 8.0 Hz, H-5’), 6.22 (1H, 
d, J = 16.0 Hz, H-8’), 5.24-5.30 (1H, m, H-5), 4.12-4.15 (1H, m, H-3), 3.72-3.75 (1H, m, 
H-4), 3.69 (3H, s, COOCH3), 1.97-2.25 (4H, m, H-2 and H-6);
 13C NMR δ ppm (MeOH-d4, 75 
MHz): 175.4 (COOCH3), 168.3 (C-9’), 149.7 (C-4’), 147.2 (C-3’), 146.9 (C-7’), 127.6 (C-1’), 
123.0 (C-6’), 116.5 (C-5’), 115.1 (C-2’), 115.0 (C-8’), 75.8 (C-1), 72.5 (C-5), 72.1 (C-4), 70.3 
(C-3), 53.0 (COOCH3), 38.0 (C-6), 37.7 (C-2). 
 
Fr. D5-3-2-1-2-2 and Fr. D5-3-2-1-2-3 were combined for further purification, by a 
preparative-HPLC method. The preparative-HPLC conditions were: C18 column with 
guard cartridge, 21.2 mm ID  150 mm (5 m); solvents for the mobile phase, water-0.1% 
formic acid (A) and MeCN (B); elution, isocratic mode 21% B; flow rate, 6 mL/min; 
detection, UV 325 nm; room temperature; injection volume, 60 L per time; running 
time, 30 mins per injection; automatic fraction collector mode peak-based. The eluate 
was collected and dried under high vacuum to afford compound 173 (0.5 mg). 
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Analysis of its spectral data, together with comparison of data available in the 
literature,190 allowed to elucidate the structure of compound 173 as 5-O-feruloylquinic 
acid. 
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5-O-Feruloylquinic acid 173: white powder; m.p. 196-197 C; ESI-MS m/z: 367 [M-H]-; 1H 
NMR δ ppm (MeOH-d4, 300 MHz): 7.62 (1H, d, J = 16.0 Hz, H-7’), 7.19 (1H, s, H-2’), 7.08 
(1H, d, J = 7.4 Hz, H-6’), 6.81 (1H, d, J = 7.4 Hz,H-5’), 6.36 (1H, d, J = 16.0 Hz, H-8’), 
5.30-5.40 (1H, m, H-5), 4.16-4.22 (1H, m, H-3), 3.89 (3H, s, OCH3), 3.69-3.77 (1H, m, H-4), 
1.87-2.21 (4H, m, H-2 and H-6). 
 
3.2.3.2.12 Isolation of 5-O-caffeoylquinic acid 74 
Fr. D5-3-2-1-3 (186 mg) was analyzed by HPLC before further purification. Five mg of Fr. 
D5-3-2-1-3 was dissolved in 1 mL MeOH and filtered with a 0.45 m filter prior to 
injection. The analytical HPLC conditions were the following: column, inertsil ODS-SP, 5 
m 4.6  250 mm, Shimadzu; solvents for the mobile phase, water-0.1% formic acid (A) 
and MeCN (B); elution, linear gradient mode 10-30% B in 0-30 min, 30-100% B in 30-45 
min, 100-10% in 45-50 min; flow rate, 0.8 mL/min; detection, UV 325 nm; running time, 
50 min. In the HPLC spectrum (Figure 3.4), three major peaks (Rt 17.52, 22.48 and 25.43 
min) were observed with good resolution. The peak with retention time 17.52 min was 
targeted in a subsequent separation. 
 
Figure 3.4 HPLC chromatogram of the constituents in Fr. D5-3-2-1-3 of G. divaricata 
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A preparative-HPLC method was developed to isolate the target compound. The 
preparative-HPLC conditions were: C18 column with guard cartridge, 21.2 mm ID  150 
mm (5 m); solvents for the mobile phase, water-0.1% formic acid (A) and MeCN (B); 
elution, linear gradient mode 16-20% B in 0-25 min, 20-50% B in 25-27 min, 50-16% in 
27-28 min; flow rate, 6 mL/min; detection, UV 325 nm; room temperature; injection 
volume, 150 L per time; running time, 28 mins per injection; automatic fraction 
collector mode peak-based. About 50 mg of sample was dissolved in 1 mL MeOH and 
filtered with a 0.45 m filter prior to injection. The eluate was collected and dried under 
high vacuum to afford compound 74 (5.0 mg). 
 
Analysis of the spectral data, together with comparison with data available in the 
literature,189 allowed to elucidate the structure of the compound 74 as 
5-O-caffeoylquinic acid. 
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5-O-Caffeoylquinic acid 74: white powder; m.p. 207-208 C; ESI-MS m/z: 353 [M-H]-; 1H 
NMR δ ppm (MeOH-d4, 300 MHz): 7.56 (1H, d, J = 16.0 Hz, H-7’), 7.04 (1H, d, J = 1.7 Hz, 
H-2’), 6.95 (1H, d, J = 8.3, H-6’), 6.77 (1H, d, J = 8.3 Hz, H-5’), 6.27 (1H, d, J = 16.0 Hz, 
H-8’), 5.29-5.36 (1H, m, H-5), 4.12-4.20 (1H, m, H-3), 3.70-3.75 (1H, m, H-4), 2.01-2.08 
(2H, m, H-2), 2.16-2.21 (2H, m, H-6); 13C NMR δ ppm (MeOH-d4, 75 MHz): 177.0 (COOH), 
168.7 (C-9’), 149.6 (C-4’), 147.1 (C-3’), 146.8 (C-7’), 127.8 (C-1’), 123.0 (C-6’), 116.5 (C-5’), 
115.3 (C-2’), 115.2 (C-8’), 76.1 (C-1), 73.5 (C-5), 72.0 (C-4), 71.3 (C-3), 38.8 (C-6), 38.2 
(C-2). 
 
3.2.3.2.13 Isolation of ethyl 4,5-dicaffeoylquinate 174 
Fr. D5-3-2-3 (320 mg) was subjected to column chromatography over silica gel eluted by 
a solvent gradient system consisting of CHCl3-MeOH (Table 3.29) to yield four fractions 
(Fr. D5-3-2-3-1~4, Table 3.30). 
 
Table 3.29 Programme for fractionation of Fr. D5-3-2-3 of G. divaricata by column 
chromatography 
Mobile phase Gradient elution Solvent volume (mL) 
CHCl3/MeOH 20:1 1050 
CHCl3/MeOH 10:1 1100 
CHCl3/MeOH 9:1 1000 
CHCl3/MeOH 6:1 700 
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Table 3.30 Column chromatography fractionation of Fr. D5-3-2-3 of G. divaricata 
Fraction Weight (mg) 
Fr. D5-3-2-3-1 25 
Fr. D5-3-2-3-2 26 
Fr. D5-3-2-3-3 33 
Fr. D5-3-2-3-4 46 
 
Fr. D5-3-2-3-3 (33 mg) was additionally purified by prep-HPLC. Fr. D5-3-2-3-3 was 
dissolved in 1 mL MeOH and filtered with a 0.45 m filter prior to injection. The 
preparative-HPLC conditions were: C18 column with guard cartridge, 21.2 mm ID  150 
mm (5 m); solvents for the mobile phase, water-0.1% formic acid (A) and MeCN (B); 
elution, isocratic 35% B in 15 min; flow rate, 6 mL/min; detection, UV 325 nm; room 
temperature; injection volume, 80 L per time; running time, 15 mins per injection; 
automatic fraction collector mode peak-based. The eluate from 12.4 to 12.7 min was 
collected and dried under high vacuum to afford compound 174 (1.0 mg). 
 
Analysis of the spectral data, together with comparison with data available in the 
literature,191 allowed to elucidate the structure of compound 174 as ethyl 
4,5-dicaffeoylquinate. 
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Ethyl 4,5-dicaffeoylquinate 174: white powder; m.p. 118-119 C; ESI-MS m/z: 543 [M-H]-; 
1H NMR δ ppm (MeOH-d4, 300 MHz): 7.61, 7.51 (2H, d, J = 16.0 Hz, H-7’, 7”), 7.04, 7.01 
(2H, d, J = 1.7 Hz, H-2’, 2”), 6.90-6.95 (2H, m, H-6’, 6”), 6.76 (2H, d, J = 8.3 Hz, H-5’, 5”), 
6.30, 6.18 (2H, d, J = 16.0 Hz, H-8’, 8”), 5.50-5.57 (1H, m, H-5), 5.09-5.13 (1H, m, H-4), 
4.34-4.36 (1H, m, H-3), 4.13-4.21 (2H, m, COOCH2CH3), 2.03-2.36 (4H, m, H-2 and H-6), 
1.26 (3H, t, J = 7.2 Hz, COOCH2CH3);
 13C NMR δ ppm (MeOH-d4, 75 MHz): 174.7 (COOEt), 
168.5, 167.9 (C-9’, 9”), 149.8, 149.7 (C-4’, 4”), 147.7, 147.6 (C-7’, 7”), 146.8 (C-3’, 3”), 
127.6, 127.5 (C-1’, 1”), 123.1 (C-6’, 6”), 116.5 (C-2’, 2”), 115.1 (C-5’, 5”), 114.6, 114.5 (C-8’, 
8”), 75.6 (C-1), 74.8 (C-5), 69.1 (C-4), 68.5 (C-3), 62.7 (COOCH2CH3), 38.4 (C-6), 38.3 (C-2), 
14.3 (COOCH2CH3). 
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3.3 Results and Discussion 
Gynura divaricata is a traditional Chinese medicine which is called “Bai Bei San Qi” in 
Chinese. The chemical constituents of G. divaricata include alkaloids,22 
cerebrosides,41,42,43 phenolics,31 polysaccharides and oligosaccharides.192 
 
In the present study, one organic acid (94) and three of its derivatives (161-163), four 
phenolic acids (79, 160, 164-165), one coumarin (166), five flavonoids (35-36, 38, 40-41), 
and eleven quinic acid derivatives (72-74, 167-174) were isolated from the aerial parts of 
G. divaricata. All the compounds were characterized by spectrometric methods (NMR, 
MS). It should be noted that regarding these constituents, compounds 36, 73-74, 79, 94 
and 160-174 were isolated for the first time from this plant. 
 
3.3.1 Organic acid and its derivatives from aerial parts of G. divaricata 
3.3.1.1 Organic acid compound: succinic acid 94 
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Compound 94 was obtained as needle crystals. The ESI mass spectrum of compound 94 
displayed a pseudomolecular ion peak at m/z 117 which may correspond to the 
fragment [M-H]-. The molecular formula of C4H6O4 was deduced. The 
1H NMR spectrum 
of 94 disclosed the presence of a single resonance signal at δ 2.57. On the other hand, 
the 13C NMR spectrum of 94 exhibited two signals at δ 174.1, which was deduced to 
result from a carboxylic acid, and 29.3, which could be attributed to a carbon connected 
with the carboxylic acid. According to its molecular formula, compound 94 was 
elucidated as succinic acid. The assigned structure was in full agreement with data found 
in the Spectral Database for Organic Compounds (SDBS).175 
 
3.3.1.2 Organic acid derivatives: ethyl methyl succinate 161, methyl succinate 162 and 
ethyl succinate 163 
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161: R1 = Me, R2 = Et 
162: R1 = H, R2 = Me 
163: R1 = H, R2 = Et 
 
Compound 161 was obtained as a colorless liquid. The 1H NMR spectrum of 161 
contained one methyl proton signal at δ 1.27 (3H, t), one singlet of a methyl substituent 
at δ 3.71 (3H, s) which was coupled to an oxygen. Besides, a methylene was observed at 
δ 4.16 as quartet suggesting the presence of the –OCH2CH3 moiety. Additionally, one 
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multiplet (4H) at δ 2.60-2.73 could be assigned to two nonequivalent methylenes 
adjacent to the carbonyl. In the 13C NMR spectrum of 161, two carbonyl signals at δ 
172.8 (C-4) and 172.3 (C-1), and a carbon signal (2C) at δ 28.9 were visible. These 
spectral data resulted in the assignment of the structure of compound 161 as ethyl 
methyl succinate. 
 
Compound 162 was obtained as a white powder. The ESI mass spectrum of compound 
162 displayed an ion peak at m/z 150 which could correspond to the fragment [M+NH4]
+, 
suggesting a molecular formula of C5H8O4. The 
1H NMR spectrum of 162 contained a 
methoxy signal at δ 3.57 (3H, s), one multiplet (4H) at δ 2.49-2.51. In the 13C NMR 
spectrum of 162, four carbon signals were assigned to two carbonyls at δ 174.8 and 
173.5, one methoxy at δ 50.9 and two methylenes at δ 28.5. These spectral data led to 
the structure assignment of compound 162 as methyl succinate. 
 
Compound 163 was obtained as a white powder. The ESI mass spectrum of compound 
163 showed an ion peak at m/z 145 corresponding to the fragment [M-H]-, suggesting a 
molecular formula of C6H10O4. The 
1H NMR spectrum of 163 was similar as that of ethyl 
methyl succinate 161 except the absence of a methoxy signal around δ 3.71. Compared 
with the 13C NMR spectrum of 161, the oxygenated methyl at δ 52.1 was missing. Based 
on these observations, compound 163 could be elucidated as ethyl succinate. 
 
The comparison of characteristic NMR data of compounds 94 and 161-163 with 
literature data is listed in Table 3.31.175 
 
Table 3.31 Comparison of characteristic NMR data of succinic acid 94 (300/75 MHz, D2O), ethyl 
methyl succinate 161 (300/75 MHz, CDCl3), methyl succinate 162 (300/75 MHz, CDCl3) and ethyl 
succinate 163 (300/75 MHz, MeOH-d4) with literature data (400/100 MHz, DMSO-d6)
175 
Position 
Compounds isolated in this work Literature data 
94 161 162 163 succinic acid 
1H NMR      
COOCH2CH3  4.16 (2H, q)  4.16 (2H, q)  
COOCH2CH3  1.27 (3H, t)  1.25 (3H, t)  
COOCH3  3.71 (3H, s) 3.57 (3H, s)   
H-2 2.57 2.60-2.73 
(4H, m) 
2.49-2.51 
(4H, m) 
2.38-2.69 
(4H, m) 
2.43 (s) 
H-3 (4H, s) 
13C NMR      
C-1 174.1 172.3 173.5 176.4 173.5 
C-2 29.3 28.9 28.5 28.5 28.8 
C-3 29.3 28.9 28.5 28.5 28.8 
C-4 174.1 172.8 174.8 176.4 173.5 
COOCH2CH3  61.0  60.9  
COOCH2CH3  14.2  14.1  
COOCH3  52.1 50.9   
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                                       Extraction with 
                                       80% aqueous ethanol 
 
 
 
 
                                       Liquid-liquid partitioned with 
n-hexane, EtOAc and n-BuOH, respectively 
                                         
 
    n-Hexane extract   EtOAc extract (47.5 g)   n-BuOH extract         residue 
                                   CC-Si:                                                                                                                    
n-hexane/EtOAc/acetone, gradient 
                           
 
Fr. D1  Fr. D2  Fr. D3  Fr. D4  Fr. D5  Fr. D6  Fr. D7 
(0.8 g)   (2.1 g)   (7.0 g)   (7.6 g)  (11.3 g)  (8.1 g) 
  CC-Si: 
PE/EtOAc/acetone, gradient 
 
 
Fr. D3-1    Fr. D3-2   Fr. D3-3    Fr. D3-4   Fr. D3-5 
(220 mg)    (540 mg)    (1600 mg)   (3500 mg)    (800 mg) 
Recrystallization                            
(EtOAc)                           CC-Si: 
                                             n-hexane/EtOAc/acetone, gradient 
 
 
Fr. D3-4-1  Fr. D3-4-2  Fr. D3-4-3  Fr. D3-4-4 
                                (150 mg)  (1300 mg)  (800 mg)   (500 mg) 
                                         Auto. flash-Si: 
    94 (1.1 g)                 CH2Cl2/MeOH, 
                                         100%-91% 
         
                         
Fr. D3-4-2-1 Fr. D3-4-2-2 Fr. D3-4-2-3 Fr. D3-4-2-4 
(103 mg)    (52 mg)   (89 mg)   (170 mg) 
                                       CC-Sephadex-LH20: 
             160 (3.0 mg)                  (MeOH) 
              
                                          prep-HPLC: 
161 (6.7 mg)                                MeCN/H2O 
                                                     28:72 
 
 
 
 
 
 
                  
 
                                            162 (4.3 mg)             163 (3.2 mg) 
Scheme 3.1 describes the complete isolation of compounds 94 and 161-163 from the 
aerial parts of G. divaricata. 
 
Scheme 3.1 The complete isolation of compounds 94 and 161-163 from G. divaricata 
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3.3.2 Phenolic acids from aerial parts of G. divaricata 
3.3.2.1 Phenolic acid compound: salicylic acid 160 
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160 
 
Compound 160 was obtained as a white powder. The ESI mass spectrum of compound 
160 showed an ion peak at m/z 137 corresponding to the fragment [M-H]-, suggesting a 
molecular formula of C7H6O3. The 
1H NMR spectrum of compound 160 displayed four 
aromatic protons at δ 7.85 (1H, dd, J = 8.2, 1.7 Hz, H-6), 7.46 (1H, ddd, J = 8.3, 7.2, 1.7 Hz, 
H-4), 6.91 (1H, ddd, J = 8.2, 7.2, 1.1 Hz, H-5) and 6.87 (1H, dd, J = 8.3, 1.1 Hz, H-3). In its 
13C NMR spectrum, compound 160 exhibited a signal at δ 173.5 for a carbonyl carbon 
and 163.2 for an oxygenated quaternary carbon (C-2). Additionally, five aromatic carbon 
signals were seen at δ 136.6 (C-4), 131.5 (C-6), 120.1 (C-5), 118.1 (C-3) and 113.9 (C-1), 
respectively. The above spectral data revealed the structure of compound 160 as salicylic 
acid. The spectral data of the compound isolated in the present study match well with 
those reported earlier.176 The comparison of characteristic NMR data of compound 160 
with literature data is listed in Table 3.32.176 
 
Table 3.32 Comparison of characteristic 1H NMR (300 MHz, MeOH-d4) and 
13C NMR (75 MHz, 
MeOH-d4) data of salicylic acid 160 with literature data (500/125 MHz, MeOH-d4)
176 
Position 
This work Literature data 
1H 13C 1H 13C 
1  113.9  113.2 
2  163.2  163.1 
3 6.87 (1H, dd, J = 8.3, 1.1 Hz) 118.1 6.95 (1H, d, J = 8.2 Hz) 118.1 
4 7.46 (1H, ddd, J = 8.3, 7.2, 1.7 Hz) 136.6 7.54 (1H, dt, J = 8.2, 1.6 Hz, H-4) 136.8 
5 6.91 (1H, ddd, J = 8.2, 7.2, 1.1 Hz) 120.1 6.96 (1H, d, J = 8.2 Hz, H-5) 119.9 
6 7.85 (1H, dd, J = 8.2, 1.7 Hz) 131.5 7.90 (1H, dd, J = 8.2, 1.6 Hz, H-6) 131.2 
COOH  173.5  172.7 
 
3.3.2.2 Phenolic acid compound: isovanillic acid 164 
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Compound 164 was obtained as a white powder. The ESI mass spectrum of compound 
164 showed an ion peak at m/z 167 corresponding to the fragment [M-H]-, suggesting a 
molecular formula of C8H8O4. The 
1H NMR spectrum of compound 165 displayed three 
aromatic proton signals at 7.47 (1H, dd, J = 8.3, 1.7 Hz), 7.47 (1H, d, J = 1.7 Hz) and 6.75 
(1H, d, J = 8.7 Hz) assignable to an ABX coupling system. Furthermore, its 13C NMR 
spectral data were corresponding with those of isovanillic acid reported.178 
 
The comparison of characteristic NMR data of compound 164 with literature data178 is 
listed in Table 3.33. 
 
Table 3.33 Comparison of characteristic 1H NMR (300 MHz, MeOH-d4) and 
13C NMR (75 MHz, 
MeOH-d4) data of isovanillic acid 164 with literature data (500/125 MHz, MeOH-d4)
178 
Position 
This work Literature data 
1H 13C 1H 13C 
1  121.8  122.2 
2 7.47 (1H, d, J = 1.7 Hz) 114.5 7.56 (1H, d, J = 1.9 Hz) 114.5 
3  147.3  146.8 
4  151.3  150.7 
5 6.75 (1H, d, J = 8.7 Hz) 112.4 6.90 (1H, d, J = 8.0 Hz) 112.6 
6 7.48 (1H, dd, J = 8.7, 1.7 Hz) 123.9 7.63 (1H, dd, J = 8.0, 1.9 Hz) 124.7 
COOH  168.8  168.9 
OCH3 3.81 (3H, s) 55.0 3.94 (3H, s, H-8) 56.1 
 
3.3.2.3 Phenolic acid compound: 4-hydroxybenzoic acid 79 
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Compound 79 was isolated as a white powder. The ESI Mass spectrum of compound 79 
displayed an ion peak at m/z 137 [M-H]-, suggesting a molecular formula of C7H6O3. In 
the 1H NMR spectrum of compound 79, two doublets in the aromatic region at δ 7.77 
(2H, J = 8.3 Hz, H-2, 6) and δ 6.71 (2H, J = 8.3 Hz, H-3, 5) were assigned to the presence 
of a 1,4-disubstituted aromatic ring. By comparison of characteristic NMR data of 
compound 79 with data of compound 79 previously discussed in Chapter 2 (Table 3.34), 
the structure of compound 79 present isolated was elucidated as 4-hydroxybenzoic acid. 
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Table 3.34 Comparison of characteristic NMR (300/75 MHz, MeOH-d4) data of 4-hydroxybenzoic 
acid 79 with identified one from G. bicolor (300/75 MHz, DMSO-d6). 
Position 
Compound 79 from Gynura divaricata 4-Hydroxybenzoic acid from Gynura bicolor 
1H 13C 1H 13C 
1  121.7  122.0 
2 7.77 (1H, d, J = 8.3 Hz) 131.7 7.77 (1H, dd, J = 8.8, 3.9 Hz) 132.1 
3 6.71 (1H, d, J = 8.3 Hz) 114.7 6.80 (2H, dd, J = 8.8, 3.9 Hz) 115.7 
4  161.9  162.1 
5 6.71 (1H, d, J = 8.3 Hz) 114.7 6.80 (2H, dd, J = 8.8, 3.9 Hz) 115.7 
6 7.77 (1H, d, J = 8.3 Hz) 131.7 7.77 (1H, dd, J = 8.8, 3.9 Hz) 132.1 
COOH  169.0  167.7 
 
3.3.2.4 Phenolic acid compound: p-coumaric acid 165 
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Compound 165 was obtained as a white powder. The ESI mass spectrum of compound 
165 displayed an ion peak at m/z 163 [M-H]-, suggesting its molecular formula as C9H8O3. 
The 1H NMR spectrum of compound 165 showed two doublets at δ 7.52 (1H, J = 15.9 Hz) 
and δ 6.20 (1H, J = 15.9 Hz) revealing the presence of a pair of olefinic protons and their 
coupling constants suggested a trans configuration. Two doublets centered at δ 7.37 (J = 
8.8 Hz) and 6.73 (J = 8.8 Hz), each integrating for two protons, indicated a 
1,4-disubstituted aromatic ring. On the other hand, the 13C NMR of 165 displayed seven 
carbon signals, of which, the signals at δ 169.7 and 159.9 were assignable to a carbonyl 
and oxygenated aromatic carbon, respectively. The above spectral features were in close 
agreement to those observed for trans-p-coumaric acid. The comparison of characteristic 
NMR data of compound 165 with literature data is listed in Table 3.35.177 
 
Table 3.35 Comparison of characteristic 1H NMR (300 MHz, MeOH-d4) and 
13C NMR (75 MHz, 
MeOH-d4) data of p-coumaric acid 165 with literature data (400/100 MHz, DMSO-d6)
177 
Position 
This work literature data 
1H 13C 1H 13C 
1  125.9  124.4 
2,6 7.37 (2H, d, J = 8.8 Hz) 129.8 7.38 (2H, d, J = 8 Hz) 128.6 
3,5 6.73 (2H, d, J = 8.8 Hz) 115.5 6.82 (2H, d, J = 8 Hz) 114.8 
4  159.9  158.6 
7 6.20 (1H, d, J = 15.9) 114.3 6.21 (1H, d, J =16 Hz) 114.0 
8 7.52 (1H, d, J = 15.9 Hz) 145.3 7.54 (1H, d, J =16 Hz) 143.4 
COOH  169.7  167.7 
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                                       Extraction with 
                                       80% aqueous ethanol 
 
 
 
                                        
Liquid-liquid partitioned with 
n-hexane, EtOAc and n-BuOH, respectively 
                                         
 
    n-Hexane extract   EtOAc extract (47.5 g)   n-BuOH extract         residue 
                                   CC-Si:                                                                                                                    
n-hexane/EtOAc/acetone, gradient 
                           
 
Fr. D1  Fr. D2  Fr. D3  Fr. D4  Fr. D5  Fr. D6  Fr. D7 
(0.8 g)   (2.1 g)   (7.0 g)   (7.6 g)  (11.3 g)  (8.1 g) 
  CC-Si: 
PE/EtOAc/acetone, gradient 
 
 
Fr. D3-1    Fr. D3-2   Fr. D3-3    Fr. D3-4   Fr. D3-5 
(220 mg)    (540 mg)    (1600 mg)   (3500 mg)    (800 mg) 
                     CC-Si: 
                                  n-hexane/EtOAc/acetone, gradient 
 
 
Fr. D3-4-1      Fr. D3-4-2     Fr. D3-4-3    Fr. D3-4-4 
                 (150 mg)      (1300 mg)     (800 mg)     (500 mg) 
                                               CC-Si:  
Auto. flash-Si:                          CH2Cl2/MeOH (10:1) 
CH2Cl2/MeOH, 
                        100%-91% 
                                Fr. D3-4-4-1  Fr. D3-4-4-2   Fr. D3-4-4-3 
(62 mg)      (182 mg)      (55 mg) 
                                    recrystallization:             
                             CH2Cl2/acetone               
 
 
prep-HPLC 
                                                          MeCN/H2O 
                                                               28:72 
 
 
 
 
                                                
 
                  
 
                                                          
 
 
 
 
                                                                           165 (4.8 mg) 
                                               79 (5.6 mg)                
Scheme 3.2 describes the complete isolation of compounds 79, 160 and 164-165 from 
the aerial parts of G. divaricata. 
 
Scheme 3.2 The complete isolation of compounds 79, 160 and 164-165 from G. divaricata 
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3.3.3 Coumarin compound from the aerial part of G. divaricata 
3.3.3.1 Coumarin compound: esculetin 166 
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Compound 166 was obtained as yellowish crystals. The ESI Mass spectrum of compound 
166 displayed an ion peak at m/z 177 [M-H]-. The 1H NMR spectrum of compound 166 
displayed two characteristic doublets at 7.70 (1H, d, J = 9.9 Hz, H-4) and 6.09 (1H, d, J = 
9.9 Hz, H-3). Combined with the carbon signal at 144.7 (C-4) and 111.5 (C-3) in its 13C 
NMR spectrum, the presence of a coumarin skeleton was deduced. Besides, the two 
singlet proton signals at 6.85 and 6.67, indicated a 6,7-disubstituted B-ring. Additionally, 
the chemical shifts in the NMR spectra were in close agreement to those observed for 
esculetin in literature data.180 
 
The comparison of characteristic NMR data of compound 166 with literature data is 
listed in Table 3.36.180 
 
Table 3.36 Comparison of characteristic 1H NMR (300 MHz, MeOH-d4) and 
13C NMR (75 MHz, 
MeOH-d4) data of esculetin 166 with literature data (400/100 MHz, DMSO-d6)
180 
Position 
This work literature data 
1H 13C 1H 13C 
1     
2  163.0  160.9 
3 6.09 (1H, d, J = 9.9 Hz) 111.5 6.15 (1H, d, J = 9.6 Hz) 111.7 
4 7.70 (1H, d, J = 9.9 Hz) 144.7 7.85 (1H, d, J = 9.6 Hz) 144.5 
5 6.85 (1H, s) 111.7 6.97 (1H, s) 112.5 
6  143.2  142.9 
7  150.7  150.5 
8 6.67 (1H, s) 102.3 6.74 (1H, s) 102.8 
9  149.1  148.7 
10  111.2  110.9 
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 Extraction with 
                                       80% aqueous ethanol 
 
 
 
 
                                       Liquid-liquid partitioned with 
n-hexane, EtOAc and n-BuOH, respectively 
                                         
 
    n-Hexane extract   EtOAc extract (47.5 g)   n-BuOH extract         residue 
                                   CC-Si:                                                                                                                    
n-hexane/EtOAc/acetone, gradient 
                           
 
Fr. D1  Fr. D2  Fr. D3  Fr. D4  Fr. D5  Fr. D6  Fr. D7 
(0.8 g)   (2.1 g)   (7.0 g)   (7.6 g)  (11.3 g)  (8.1 g) 
  CC-Si: 
PE/EtOAc/acetone, gradient 
 
 
Fr. D3-1    Fr. D3-2   Fr. D3-3    Fr. D3-4   Fr. D3-5 
(220 mg)    (540 mg)    (1600 mg)   (3500 mg)    (800 mg) 
                         CC-Si: 
                         CH2Cl2/MeOH, gradient 
 
 
Fr. D3-5-1     Fr. D3-5-2     Fr. D3-5-3  
                            (153 mg)     (177 mg)       (86 mg) 
                                         
 
acetone 
                               
 
 
 
 
 
                          
                        166 (12.7 mg) 
Scheme 3.3 describes the complete isolation of compound 166 from the aerial parts of G. 
divaricata. 
 
Scheme 3.3 The complete isolation of compound 166 from G. divaricata 
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3.3.4 Flavonoids from the aerial part of G. divaricata 
3.3.4.1 Flavonol compounds: quercetin 35 and kaempferol 40 
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Compound 35 and 40 were both obtained as a yellow amorphous powder. Their ESI mass 
spectra displayed quasi-molecular ion peaks [M-H]- at m/z 301 and [M+H]+ at m/z 287, 
compatible with their molecular formula C15H10O7 and C15H10O6, respectively. In their 
1H 
NMR spectra, both compounds displayed two doublets around δ 6.08 and 6.30 with a 
coupling constant of about 2 Hz, which could be assigned to the meta-coupled protons 
on the A-ring of a flavonoid. In the 1H NMR spectrum of compound 35, the aromatic 
region also exhibited an ABX system at δ 7.63 (1H, d, J = 2.1 Hz, H-2), 7.53 (1H, dd, J = 
8.1, 2.1 Hz, H-6) and 6.78 (1H, d, J = 8.1 Hz, H-5) due to a 3’,4’-disubstituted B-ring. On 
the other hand, a typical A2B2 system was observed in the 
1H NMR spectrum of 
compound 40 at δ 7.99 (2H, d, J = 9.1 Hz, H-2, 6) and 6.81 (2H, d, J = 9.1 Hz, H-3, 5), 
which were assignable to the protons on a para-substituted B-ring. The 13C NMR spectra 
of 35 and 40 both showed the presence of fifteen aromatic carbon signals. Based on the 
NMR data and comparison of the data given in the literatures,182,183 the structures of 
compound 35 and 40 were identified as quercetin and kaempferol, respectively. 
 
3.3.4.2 Flavonol glycoside compounds: rutin 38, quercetin 3-O-β-D-glucoside 36 and 
kaempferol 3-O-β-D-glucoside 41 
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38                              41: R = H 
 
Compounds 38 and 36 were isolated as a yellow amorphous powder. Their negative ESI 
mass spectra gave quasi-molecular ion peaks [M-H]- at m/z 609 and 463, suggesting their 
molecular formula C27H30O16 and C21H20O12, respectively. Their 
1H NMR spectra looked 
very similar in the aromatic region, indicating the presence of a quercetin moiety in their 
structures. Sugar residues were also observed in 1H NMR spectra and their integration 
indicated that compound 36 contained one simple sugar while compound 38 contained 
two. By comparison of 13C NMR data with literature data, the sugar moiety of compound 
36 was identified as glucose, while compound 38 had glucose and rhamnose parts. The 
anomeric proton signals appeared as doublets at δ 5.01 and 5.13 with a coupling 
constant for both of 7.2 Hz suggesting the presence of -glucopyranose units in 
compound 38 and 36 respectively. In the HMBC spectrum of compound 36, a crosspeak 
between C-3 at δ 135.6 and H-1 at δ 5.13 established the linkage point of quercetin and 
-glucopyranose. Based on these facts, the structure of compound 36 was identified as 
quercetin 3-O--D-glucopyranoside (isoquercitrin). Finally, by comparison of the 13C NMR 
data of the sugar moiety with literature data,181 compound 38 was characterized as 
quercetin 3-O-rutinoside (rutin).  
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Compound 41 was obtained as a yellow amorphous powder. The ESI Mass spectrum 
displayed an ion peak at m/z 447 [M-H]-, suggesting its molecular formula as C21H20O11. 
The aromatic protons were present at δ 6.25 and 6.07 as meta-related doublets (J = 1.8 
Hz) for H-8 and H-6, and at δ 7.96 (d) and 6.79 (d) integrating for two protons each with a 
coupling constant of 8.8 Hz for H-2, 6 and H-3, 5, respectively. The signals in the 
aromatic region indicated the presence of a kaempferol aglycone. The sugar part was 
confirmed by a comparison of the TLC Rf value and the HPLC retention time with those 
of standards. Thus, compound 41 was characterized as kaempferol 3-O-β-D-glucoside 
(astragalin). 
 
The spectral data of the compounds isolated in the present study match well with those 
reported earlier. The comparison of characteristic NMR data of compounds 35-36, 38 
and 40-41 with literature data is listed in the Table 3.37 and 3.38.181,182,183 
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Table 3.37 Comparison of characteristic 1H NMR (300 MHz, MeOH-d4) data of compounds 35-36, 38 and 40-41 with literature data (400 MHz, MeOH-d4) 
Position 
This work 
38 36 41 35 40 
H-6 6.12 (1H, s) 6.08 (1H, d, J = 1.9 Hz) 6.07 (1H, d, J = 1.8 Hz) 6.08 (1H, d, J = 1.8 Hz) 6.08 (1H, d, J = 2.1 Hz) 
H-8 6.31 (1H, s) 6.27 (1H, d, J = 1.9 Hz) 6.25 (1H, d, J = 1.8 Hz) 6.29 (1H, d, J = 1.8 Hz) 6.30 (1H, d, J = 2.1 Hz) 
H-2 7.57 (1H, d, J = 2.2 Hz) 7.60 (1H, d, J = 2.2 Hz) 7.96 (1H, d, J = 8.8 Hz) 7.63 (1H, d, J = 2.1 Hz) 7.99 (1H, d, J = 9.1 Hz) 
H-3   6.79 (1H, d, J = 8.8 Hz)  6.81 (1H, d, J = 9.1 Hz) 
H-5 6.78 (1H, d, J = 8.7 Hz) 6.77 (1H, d, J = 8.8 Hz) 6.79 (1H, d, J = 8.8 Hz) 6.78 (1H, d, J = 8.1 Hz) 6.81 (1H, d, J = 9.1 Hz) 
H-6 7.54 (1H, d, J = 8.7, 2.2 Hz) 7.49 (1H, dd, J = 8.8, 2.2 Hz) 7.96 (1H, d, J = 8.8 Hz) 7.53 (1H, dd, J = 8.1, 2.1 Hz) 7.99 (1H, d, J = 9.1 Hz) 
H-1 5.01 (1H, d, J = 7.2 Hz) 5.13 (1H, d, J = 7.2 Hz) 5.12 (1H, d, J = 6.9 Hz)   
H-1’ 4.42 (1H, brs)     
H-sugar 3.26-3.73 (11H, m) 3.30-3.64 (6H, m) 3.30-3.62 (6H, m)   
CH3-6’ 1.02 (3H, d, J = 5.4 Hz)     
Position 
Literature data 
rutin181 isoquercitrin182 astragalin183 quercetin183 kaempferol182 
H-6 6.20 (1H, d, J = 1.8 Hz) 6.16 (1H, d, J = 2.0 Hz) 6.19 (1H, brs) 6.17 (1H, d, J = 2.0 Hz) 6.16 (1H, d, J = 2.0 Hz) 
H-8 6.39 (1H, d, J = 2.2 Hz) 6.34 (1H, d, J = 2.0 Hz 6.38 (1H, brs) 6.37 (1H, d, J = 2.0 Hz) 6.36 (1H, d, J = 2.0 Hz) 
H-2 7.66 (1H, d, J = 1.8 Hz) 7.70 (1H, d, J = 2.4 Hz) 8.04 (1H, d, J = 8.4 Hz) 7.73 (1H, d, J = 2.0 Hz) 8.06 (1H, d, J = 9.2 Hz) 
H-3   6.87 (1H, d, J = 8.4 Hz)  6.89 (1H, d, J = 9.2 Hz) 
H-5 6.86 (1H, d, J = 8.0 Hz) 6.85 (1H, d, J = 8.6 Hz) 6.87 (1H, d, J = 8.4 Hz) 6.87 (1H, d, J = 8.0 Hz) 6.89 (1H, d, J = 9.2 Hz) 
H-6 7.60 (1H, dd, J = 8.0, 1.8 Hz) 7.55 (1H, dd, J = 8.6, 2.4 Hz) 8.04 (1H, d, J = 8.4 Hz) 7.62 (1H, dd, J = 7.5, 2.0 Hz) 8.06 (1H, d, J = 9.2 Hz) 
H-1 5.09 (1H, d, J = 7.8 Hz) 5.22 (1H, d, J = 7.2 Hz) 5.23 (1H, d, J = 7.2 Hz)   
H-1’ 4.51 (1H, d, J = 1.8 Hz)     
H-sugar 3.25-3.80 (11H, m) 3.22-3.71 (6H, m) 3.18-3.71 (6H, m)   
CH3-6’ 1.11 (3H, d, J = 6.0 Hz)     
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Table 3.38 Comparison of characteristic 13C NMR (75 MHz, MeOH-d4) data of compounds 35-36, 
38 and 40-41 with literature data (100 MHz, MeOH-d4) 
Position 38 rutin181 36 isoquercitrin182 35 quercetin183 40 kaempferol182 
2 158.0  158.5 158.5 158.1 146.7 147.9 146.6 147.8 
3 134.3 135.6 135.6 135.4 135.9 137.2 135.9 137.1 
4 178.1 179.4 179.5 179.1 176.0 177.3 175.8 177.1 
5 161.7 162.5 163.1 162.7 156.9 162.5 156.9 162.3 
6 98.6 99.9 100.0 99.7 97.9 99.3 97.9 99.2 
7 164.7 166.0 166.5 165.7 164.2 165.7 164.3 165.3 
8 93.5 94.8 94.8 94.6 93.1 94.4 93.1 94.4 
9 157.2 159.3 159.0 158.2 161.2 158.2 161.2 158.1 
10 104.3 105.6 105.6 105.4 103.2 104.4 103.2 104.4 
1’ 121.8 123.1 123.2 122.6 122.8 124.1 122.2 123.6 
2’ 114.7 117.6 116.0 115.8 114.7 116.0 129.4 130.5 
3’ 144.5 145.8 147.0 145.5 144.9 146.2 115.0 116.2 
4’ 148.5 149.7 149.9 149.6 147.4 148.7 159.1 160.3 
5’ 116.4 116.1 117.5 117.4 114.9 116.2 115.0 116.2 
6’ 122.2 123.5 123.1 123.0 120.3 121.6 129.4 130.5 
1” 103.4 104.7 104.3 104.3     
2” 74.4 75.7 75.7 75.6     
3” 75.9 77.2 78.1 78.2     
4” 70.9 71.4 71.2 71.1     
5” 76.9 78.1 78.4 78.0     
6” 67.2 68.6 62.6 62.5     
1”’ 101.1 102.4       
2”’ 70.8 72.0       
3”’ 70.1 72.2       
4”’ 72.6 73.9       
5”’ 68.4 69.7       
6”’ 16.6 17.9       
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 Extraction with 
                                       80% aqueous ethanol 
 
 
 
 
                                       Liquid-liquid partitioned with 
n-hexane, EtOAc and n-BuOH, respectively 
                                         
 
    n-Hexane extract   EtOAc extract (47.5 g)  n-BuOH extract          residue 
                                   CC-Si:                                                                                                                    
n-hexane/EtOAc/acetone, gradient 
                           
 
Fr. D1  Fr. D2  Fr. D3  Fr. D4  Fr. D5  Fr. D6  Fr. D7 
(0.8 g)   (2.1 g)   (7.0 g)   (7.6 g)  (11.3 g)  (8.1 g) 
         CC-MCI CHP20P: 
MeOH/H2O, gradient 
 
 
Fr. D4-1    Fr. D4-2   Fr. D4-3    Fr. D4-4   Fr. D4-5 
(3.2 g)       (1.3 g)      (0.9 g)      (0.8 g)      (1.1 g) 
                CC-Si: 
                              CH2Cl2/methanol (100:5-8:1) 
 
 
Fr. D4-3-1   Fr. D4-3-2    Fr. D4-3-3    Fr. D4-3-4   Fr. D4-3-5 
     (164 mg)     (76 mg)     (65 mg)      (51 mg)     (29 mg) 
                
                             
Sephadex LH-20 
CHCl3/MeOH (1:1) 
                                     
 
                                    
 
 
 
 
                      + 
 
 
 
 
35 (10.2 mg)                                 40 (8.8 mg) 
Scheme 3.4 describes the complete isolation of compounds 35 and 40 from the aerial 
parts of G. divaricata. 
 
Scheme 3.4 The complete isolation of compounds 35 and 40 from G. divaricata 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.5 describes the complete isolation of compounds 36, 38 and 41 from the aerial 
parts of G. divaricata. 
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 Extraction with 
                                       80% aqueous ethanol 
 
 
 
 
                                       Liquid-liquid partitioned with 
n-hexane, EtOAc and n-BuOH, respectively 
                                         
 
    n-Hexane extract   EtOAc extract (47.5 g)  n-BuOH extract          residue 
                                   CC-Si:                                                                                                                    
n-hexane/EtOAc/acetone, gradient 
                           
 
Fr. D1  Fr. D2  Fr. D3  Fr. D4  Fr. D5  Fr. D6  Fr. D7 
(0.8 g)   (2.1 g)   (7.0 g)   (7.6 g)  (11.3 g)  (8.1 g) 
         CC-MCI CHP20P: 
MeOH/H2O, gradient 
 
 
Fr. D4-1    Fr. D4-2   Fr. D4-3    Fr. D4-4   Fr. D4-5 
(3.2 g)       (1.3 g)      (0.9 g)      (0.8 g)      (1.1 g) 
    Auto. flash-C18: 
                    MeOH/H2O, gradient 
 
 
Fr. D4-2-1     Fr. D4-2-2   Fr. D4-2-3    Fr. D4-2-4 
     (315 mg)      (208 mg)    (136 mg)     (46 mg) 
               CC-Si: 
       CHCl3/MeOH (4:1)                                      CC-Si: 
                                   CHCl3/MeOH (6:1) 
CC- Sephadex LH-20:                                    
Methanol                                   (37 mg) 
                               
                                         Prep-LC 
MeOH/H2O (55:45) 
 
 
 
 
                          
                        
 
 
 
 
 38 (8.9 mg)                          36 (2.5 mg) 
 
                                        + 
 
 
 
 
 
 
 
 
                                    41 (2.8 mg) 
Scheme 3.5 The complete isolation of compounds 36, 38 and 41 from G. divaricata 
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3.3.5 Hydroxycinnamic acid conjugates from the aerial part of G. divaricata 
3.3.5.1 Caffeoylquinic acid derivatives: 5-O-caffeoylquinic acid 74, methyl 
5-O-caffeoylquinate 172, 5-O-feruloylquinic acid 173 and 5-O-p-coumaroylquinic acid 
171 
 
5
4
3
1HO
6
OH
HO
COOR1
O
8'
O
7'
1'
6'
5'
4'
3'
2'
OH
R2
2
9'
 
74: R1 = H, R2 = OH 
172: R1 = Me, R2 = OH 
173: R1 = H, R2 = OMe 
171: R1 = H, R2 = H 
 
Compound 74 was isolated as a white powder. The negative ESI mass spectrum of 74 
displayed a pseudomolecular ion peak at 353 [M-H]-, suggesting a molecular formula 
C16H18O9. The 
1H NMR spectrum showed one ABX spin system at δ 7.04 (1H, d, J = 1.7 Hz), 
6.95 (1H, d, J = 8.3 Hz) and 6.77 (1H, d, J = 8.3 Hz) in the aromatic region originating from 
a 1,3,4-trisubstituted benzene ring. A pair of doublets appeared at δ 7.56 and 6.27 with 
coupling constant 16.0 Hz assigned to a trans-configurated olefinic moiety conjugated to 
a carbonyl group. In the 13C NMR spectrum, two methylenes at δ 38.8 and 38.2, three 
oxygen-bearing methines at δ 73.5, 72.0 and 71.3, one oxygen-bearing quaternary 
carbon at δ 76.1 and one carboxyl group at δ 177.0, revealed the presence of a quinic 
acid moiety. Besides, a caffeoyl moiety was observed as well. In the 1H NMR spectrum, 
the downfield shift of the resonance signal of H-5 around at δ 5.29-5.36 indicated that 
the hydroxyl group on C-5 was acylated with a caffeic acid moiety.193 Thus, compound 74 
was identified as 5-O-caffeoylquinic acid. The spectral data of the isolated compound 74 
in the present study match well with those reported earlier.189 
 
Compound 172 was isolated as a white powder. The negative ESI mass spectrum of 172 
displayed a pseudomolecular ion peak at 367 [M-H]-, suggesting a molecular formula 
C17H20O9. All of the present signals in the NMR spectra of compound 172 were similar as 
those of compound 74. The difference was that the 1H NMR spectrum of compound 172 
showed a extra singlet at δ 3.69 integrating for three protons, along with the 
corresponding oxygen-bearing methyl observed at δ 53.0 in its 13C NMR spectrum. By 
comparison of the chemical shift of this MeO group with data in the literature 
reported,194 it was concluded that the methoxy group was part of the carboxylic unit. 
Based on this, compound 172 was identified as methyl 5-O-caffeoylquinate. The spectral 
data of the isolated compound 172 in the present study match well with those reported 
earlier.189 
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Compound 173 was isolated as a white powder. The negative ESI mass spectrum of 173 
displayed a pseudomolecular ion peak at 367 [M-H]-, suggesting a molecular formula 
C17H20O9. All of the spectral data indicated that 173 was a methoxy-caffeoylquinic acid 
derivative with similar molecular structure as compound 172 (methyl 
5-O-caffeoylquinate). In the 1H NMR spectra of compound 173, the downfield shift of 
OCH3 (singlet, δ 3.89) in comparison to that of methyl 5-O-caffeoylquinate (singlet, δ 
3.69), suggested that the methoxy was attached to the benzene ring.193,194 By 
comparison of the chemical shift of compound 173 with literature reported,190 the 
structure of compound 173 was assigned as 5-O-feruloylquinic acid. 
 
Compound 171 was isolated as a white powder. The negative ESI mass spectrum of 171 
displayed a pseudomolecular ion peak at 337 [M-H]-, suggesting a molecular formula 
C16H18O8. The appearance of its proton chemical shifts and proton-proton coupling 
patterns in the 1H NMR spectrum were consistent with a p-coumaroyl chemical structure 
and a quinic acid ring system. The 1H and 13C NMR data of the quinic acid moiety were 
analogous to those of the above three compounds, and, therefore, compound 171 was 
assigned as 5-O-p-coumaroylquinic acid. The spectral data of the isolated compound 171 
in the present study match well with those reported earlier.188 
 
The comparison of characteristic NMR data of compounds 74 and 171-173 with 
literature data is listed in Table 3.39, 3.40, 3.41 and 3.42.188,189,190 
 
Table 3.39 Comparison of characteristic 1H NMR (300 MHz, MeOH-d4) and 
13C NMR (75 MHz, 
MeOH-d4) data of 5-O-caffeoylquinic acid 74 with literature data (300/75 MHz, MeOH-d4)
189 
Position 
Compound 74 literature data 
1H 13C 1H 13C 
1  76.1  76.1 
2 2.01-2.08 (2H, m) 38.2 1.92-1.98 (2H, m) 38.2 
3 4.12-4.20 (1H, m) 71.3 4.10 (1H, m) 71.3 
4 3.70-3.75 (1H, m) 72.0 3.67 (1H, m) 72.0 
5 5.29-5.36 (1H, m) 73.5 5.36 (1H, m) 73.5 
6 2.16-2.21 (2H, m) 38.8 2.11 (2H, m) 38.8 
1’  127.8  127.8 
2’ 7.04 (1H, d, J = 1.7 Hz) 115.3 7.04 (1H, d, J = 1.8 Hz) 115.2 
3’  147.1  147.1 
4’  149.6  149.6 
5’ 6.77 (1H, d, J = 8.3 Hz) 116.5 6.76 (1H, d, J = 8.2 Hz) 116.5 
6’ 6.95 (1H, d, J = 8.3 Hz) 123.0 6.94 (1H, d, J = 8.1, 1.8 Hz) 123.0 
7’ 7.56 (1H, d, J = 16.0 Hz) 146.8 7.56 (1H, d, J = 15.9 Hz) 146.8 
8’ 6.27 (1H, d, J = 16.0 Hz) 115.2 6.28 (1H, d, J = 15.9 Hz) 115.1 
9’  168.7  168.7 
COO  177.0  177.0 
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Table 3.40 Comparison of characteristic 1H NMR (300 MHz, MeOH-d4) and 
13C NMR (75 MHz, 
MeOH-d4) data of methyl 5-O-caffeoylquinate 172 with literature data (300/75 MHz, MeOH-d4)
189 
Position 
Compound 172 literature data 
1H 13C 1H 13C 
1  75.8  75.8 
2 1.97-2.06 (2H, m) 37.7 1.96-2.02 (2H, m) 37.8 
3 4.12-4.15 (1H, m) 70.3 4.12 (1H, m, H-3) 70.3 
4 3.72-3.75 (1H, m) 72.1 3.72 (1H, m, H-4) 72.1 
5 5.24-5.30 (1H, m) 72.5 5.26 (1H, m, H-5) 72.5 
6 2.18-2.25 (2H, m) 38.0 2.17 (2H, m) 38.0 
1’  127.6  127.6 
2’ 7.04 (1H, d, J = 2.2 Hz)  115.1 7.03 (1H, d, J = 1.8 Hz)  115.1 
3’  147.2  147.2 
4’  149.7  149.7 
5’ 6.78 (1H, d, J = 8.0 Hz) 116.5 6.77 (1H, d, J = 8.1 Hz) 116.5 
6’ 6.95 (1H, dd, J = 8.0, 2.2 Hz) 123.0 6.94 (1H, dd, J = 8.2, 1.8 Hz) 123.0 
7’ 7.52 (1H, d, J = 16.0 Hz) 146.9 7.51 (1H, d, J = 15.9 Hz) 146.9 
8’ 6.22 (1H, d, J = 16.0 Hz) 115.0 6.21 (1H, d, J = 15.9 Hz) 115.0 
9’  168.3  168.3 
COO  175.4  175.4 
OCH3 3.69 (3H, s) 53.0 3.68 (3H, s) 53.0 
 
Table 3.41 Comparison of characteristic 1H NMR (300 MHz, MeOH-d4) data of 5-O-feruloylquinic 
acid 173 with literature data (360 MHz, MeOH-d4)
190 
Position 
Compound 173 literature data 
1H 1H 
1   
2 1.87-2.21 (2H, m) 2.19-1.92 (2H, m) 
3 4.16-4.22 (1H, m) 4.15 (1H, q, J = 2.8 Hz) 
4 3.69-3.77 (1H, m) 3.69 (1H, dd, J = 9.9, 3.1 Hz) 
5 5.30-5.40 (1H, m) 5.38 (1H, ddd, J = 11.3, 10.1, 5.0 Hz) 
6 1.87-2.21 (2H, m) 1.92-2.19 (2H, m) 
1’   
2’ 7.19 (1H, s) 7.15 (1H, d, J = 1.9 Hz) 
3’   
4’   
5’ 6.81 (1H, d, J = 7.4 Hz) 6.77 (1H, d, J = 8.2 Hz) 
6’ 7.08 (1H, d, J = 7.4 Hz) 7.04 (1H, dd, J = 8.3, 1.8 Hz) 
7’ 7.62 (1H, d, J = 16.0 Hz) 7.63 (1H, d, J = 15.9 Hz) 
8’ 6.36 (1H, d, J = 16.0 Hz) 6.35 (1H, d, J = 15.9 Hz) 
9’   
OCH3 3.89 (3H, s) 3.87 (3H, s) 
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Table 3.42 Comparison of characteristic 1H NMR (300 MHz, MeOH-d4) and 
13C NMR (75 MHz, 
MeOH-d4) data of 5-O-p-coumaroylquinic acid 171 with literature data (300/75 MHz, 
MeOH-d4)
188 
Position 
Compound 171 literature data 
1H 13C 1H 13C 
1  76.0  76.60 
2 2.01-2.25 (2H, m) 37.9 2.01-2.29 (2H, m) 38.56 
3 4.12-4.20 (1H, m) 71.7 3.90 (1H, d, J = 3.1 Hz) 72.43 
4 3.73 (1H, dd, J = 8.3, 2.8 Hz) 71.0 3.77 (1H, dd, J = 8.6, 3.0 Hz) 71.66 
5 5.28-5.38 (m) 73.1 5.33 (1H, m) 73.82 
6 2.01-2.25 (2H, m) 38.5 2.01-2.29 (2H, m) 39.14 
1’  127.0  127.70 
2’ 7.47 (1H, d, J = 8.8 Hz) 130.9 7.48 (1H, d, J = 8.6Hz) 131.69 
3’ 6.81 (1H, d, J = 8.8 Hz) 116.5 6.84 (1H, d, J = 8.6 Hz) 117.31 
4’  160.8  161.48 
5’ 6.81 (1H, d, J = 8.8 Hz) 116.5 6.84 (1H, d, J = 8.6 Hz) 117.31 
6’ 7.47 (1H, d, J = 8.8 Hz) 130.9 7.48 (1H, d, J = 8.6Hz) 131.69 
7’ 7.63 (1H, d, J = 16.0 Hz) 146.5 7.65 (1H, d, J = 16.0 Hz) 147.34 
8’ 6.33 (1H, d, J = 16.0 Hz) 115.0 6.34 (1H, d, J = 16.0Hz) 115.68 
9’  168.5  169.38 
COO  177.1  177.64 
 
Scheme 3.6 describes the complete isolation of compounds 74 and 171-173 from the 
aerial parts of G. divaricata. 
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 Extraction with 
                                       80% aqueous ethanol 
 
 
 
 
                                       Liquid-liquid partitioned with 
n-hexane, EtOAc and n-BuOH, respectively 
                                         
 
    n-Hexane extract   EtOAc extract (47.5 g)   n-BuOH extract         residue 
                                   CC-Si:                                                                                                                    
n-hexane/EtOAc/acetone, gradient 
                           
 
Fr. D1  Fr. D2  Fr. D3  Fr. D4  Fr. D5  Fr. D6  Fr. D7 
(0.8 g)   (2.1 g)   (7.0 g)   (7.6 g)  (11.3 g)  (8.1 g) 
                CC-MCI CHP20P: 
MeOH/H2O, gradient 
 
 
Fr. D5-1    Fr. D5-2   Fr. D5-3    Fr. D5-4 
(2.4 g)       (1.3 g)      (6.2 g)      (0.8 g) 
                       Auto. flash-C18: 
                                    H2O/methanol, gradient 
 
 
Fr. D5-3-1    Fr. D5-3-2    Fr. D5-3-3    Fr. D5-3-4   Fr. D5-3-5 
           (1200 mg)    (1530 mg)    (610 mg)    (380 mg)    (750 mg) 
                            CC-Sephadex LH-20: 
H2O/MeOH, gradient 
                                     
            
Fr. D5-3-2-1   Fr. D5-3-2-2  Fr. D5-3-2-3 
(450 mg)      (680 mg)    (320 mg) 
               CC-Si: 
    CHCl3/MeOH, gradient 
 
 
Fr. D5-3-2-1-1     Fr. D5-3-2-1-2    Fr. D5-3-2-1-3 
(66 mg)         (102 mg)        (186 mg) 
Prep-LC-C18:                        Prep-LC-C18: 
H2O-0.1% formic acid/MeCN,          H2O-0.1% formic acid/MeCN, 
      gradient                           gradient 
                                           compound 74 
                                              (5.0 mg) 
compound 171  Fr. D5-3-2-1-2-2   Fr. D5-3-2-1-2-3   compound 172 
(1.2 mg)         (0.3 mg)         (0.6 mg)        (8.7 mg) 
 
                   Prep-LC-C18: 
                   H2O-0.1% formic acid/MeCN, 
                   79:21 
compound 173 (0.5 mg) 
 
 
 
 
 
 
 
            171: R
1
 = p-coumaroyl, R
2
 = H;  172: R
1
 = caffeoyl, R
2
 = Me; 
            173: R
1
 = feruloyl, R
2 
= H;       74: R
1
 = caffeoyl, R
2 
= H;  
Scheme 3.6 The complete isolation of compounds 74 and 171-173 from G. divaricata 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gynura divaricata 
(aerial part, 7.5 kg) 
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3.3.5.2 Dicaffeoylquinic acid derivatives: 3,4-dicaffeoylquinic acid 167, 
3,5-dicaffeoylquinic acid 72, 4,5-dicaffeoylquinic acid 73, methyl 3,4-dicaffeoylquinate 
168, methyl 3,5-dicaffeoylquinate 169,methyl 4,5-dicaffeoylquinate 170 and ethyl 
4,5-dicaffeoylquinate 174 
 
1'
2'
3'
5'
6' 7'
8'
OH
4'HO
9'
O
OR2
R1O OH
COOHHO
12
3
4
5
6
caffeoyl =
 
167: R1 = R2 = caffeoyl 
 
Compound 167 was isolated as a pale green powder. The negative ESI mass spectrum of 
167 displayed a pseudomolecular ion peak at 515 [M-H]-, suggesting a molecular formula 
C25H24O12. The 
1H NMR spectrum of 167 displayed two sets of proton signals with two 
pairs of doublets with a coupling constant of 16 Hz at δ 7.57, 7.55, and 6.29, 6.26, due to 
two (E)-olefinic moieties each attached to a carbonyl group, and a pair of ABX spin-spin 
coupling systems at δ (7.04, 7.02, d, 2 Hz), (6.93, 6.88, dd, 8, 2 Hz) and (6.77, 6.73, d, 8 
Hz), respectively, due to two trisubstituted aromatic moieties. Thus, the presence of two 
caffeoyl moieties was deduced to be part of the chemical structure of 167. In addition, 
one quinic acid moiety was observed due to three O-bearing methines at δ ca. 5.63 (m), 
5.00 (dd) and 4.37 (m), along with a system integrating for four protons appearing at δ 
1.99-2.38. The presence of one quinic acid moiety was further supported by the 13C NMR 
spectrum of compound 167. The position on which the two caffeoyl residues were 
present on the quinic acid moiety were deduced from the comparative analysis of 1H 
NMR chemical shifts of the protons in 3-O-caffeoylquinic acid.189 In compound 167, the 
signals of H-3, H-4 and H-5 were shifted downfield by ca. 0.21, 1.28 and 0.35 ppm, 
respectively, compared to that of 3-O-caffeoylquinic acid. On the basis of paramagnetic 
chemical shifts due to acylation,195 it was concluded that the hydroxyl group at C-4 of 
compound 167 was esterified by caffeic acid and it was identified as 3,4-dicaffeoylquinic 
acid. The spectral data of the isolated compound 167 in the present study match well 
with those reported earlier.184,185 
 
The comparison of characteristic NMR data of compound 167 with literature data is 
listed in Table 3.43.184,185 
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Table 3.43 Comparison of characteristic 1H NMR (300 MHz, CD3OD) and 
13C NMR (75 MHz, CD3OD) 
data of 3,4-dicaffeoylquinic acid 167 with literature data (400/125 MHz, CD3OD) 
Position 
This work Literature data 
1H 13C 1H 13C 
1  75.6  73.79 
2 1.99-2.38 (2H, m) 42.0 2.11-2.28 (2H, m) 40.57 
3 5.60-5.67 (1H, m) 70.4 5.63 (1H, m) 68.72 
4 5.00 (1H, dd, J = 3.3, 9 Hz) 76.6 5.12 (1H, br. d, J = 6.5 Hz) 75.29 
5 4.31-4.41 (1H, m) 66.1 4.38 (1H, m) 64.37 
6 1.99-2.38 (2H, m) 37.2 2.11-2.28 (2H, m) 35.63 
COOH  178.5  176.62 
1’/1”  128.0  126.36 
2’/2” 7.04/7.02 (2H, d, J = 2 Hz) 115.4 7.02/7.01 (1H, d, J = 2.0 Hz) 113.82 
3’/3”  146.9  145.41 
4’/4”  149.7  148.22 
5’/5” 6.77/6.73 (2H, d, J = 8 Hz) 116.7 6.76/6.75 (1H, d, J = 8.5 Hz) 115.06 
6’/6” 6.93/6.88 (2H, dd, J = 8, 2 Hz) 123.5 6.92/6.91 (1H, dd, J = 8.5, 2.0 Hz) 121.82 
7’/7” 7.57/7.55 (2H, d, J = 16 Hz) 147.6 7.60/7.52 (1H, d, J = 15.8 Hz) 145.97 
8’/8” 6.29/6.26 (2H, d, J = 16 Hz) 115.2 6.29/6.19 (1H, d, J = 15.8 Hz) 113.49 
9’/9”  168.9  167.20 
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72: R1 = R3 = caffeoyl, R2 = H 
73: R1 = R2 = caffeoyl, R3 = H 
 
Compound 72 and 73 were both isolated as a pale green powder. Their ESI and NMR 
spectral data indicated that compound 72 and 73 were isomers of compound 167 with 
the same molecular formula C25H24O12. The observed chemical shifts of H-3, H-4 and H-5 
were used to distinguish these three compounds from one to another. By comparison 
the spectral data of compound 72 with that of 5-O-caffeoylquinic acid,189 a downfield 
shift by ca. 1.31 ppm was observed for H-3 in the quinic acid moiety, whereas H-4 and 
H-5 were only slightly affected. On the basis of paramagnetic chemical shifts due to 
acylation,195 the structure of compound 72 as 3,5-dicaffeoylquinic acid was concluded. In 
the same manner, compound 73 was identified as 4,5-dicaffeoylquinic acid. The NMR 
spectral data of the isolated compounds in the present study match well with those 
reported earlier.184,185,186 
 
The comparison of characteristic NMR data of compounds 72 and 73 with literature data 
is listed in Table 3.44 and 3.45, respectively.184,185,186 
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Table 3.44 Comparison of characteristic 1H NMR (300 MHz, CD3OD) and 
13C NMR (75 MHz, CD3OD) 
data of 3,5-dicaffeoylquinic acid 72 with literature data (400/125 MHz, CD3OD) 
Position 
This work Literature data 
1H 13C 1H 13C 
1  74.8  73.34 
2 2.04-2.34 (2H, m) 36.1 2.16-2.32 (2H, m) 34.62 
3 5.34-5.46 (1H, m) 72.6 5.43 (1H, m) 70.68 
4 3.97 (1H, dd, J = 7.5, 2.7 Hz) 70.7 3.97 (1H, dd, J = 7.5, 3.0 Hz) 69.27 
5 5.34-5.46 (1H, m) 72.1 5.38 (1H, m, H-5) 71.15 
6 2.04-2.34 (2H, m) 37.7 2.21-2.24 (2H, m) 36.29 
COOH  177.6  176.09 
1’/1”  127.9/127.8  126.50 
2’/2” 7.07 (2H, s) 115.6/115.2 7.06 (2H, s) 113.80 
3’/3”  146.8  145.38 
4’/4”  149.6/149.5  148.20 
5’/5” 6.79/6.77 (2H, d, J = 8.3 Hz) 116.4 6.78 (2H, d, J = 8.0 Hz) 115.05 
6’/6” 6.97/6.96 (2H, dd, J = 8.3, 
2.2 Hz) 
123.1/123.0 6.96/6.97 (1H, dd, J = 8.0, 2.0 Hz) 121.66 
7’/7” 7.62/7.59 (2H, d, J = 16 Hz) 147.3/147.0 7.62/7.58 (1H, d, J = 16.0 Hz) 145.86/145.63 
8’/8” 6.36/6.27 (2H, d, J = 16 Hz) 115.1 6.35/6.26 (1H, d, J = 16.0 Hz) 114.17/113.68 
9’/9”  168.9/168.4  167.47/166.95 
 
Table 3.45 Comparison of characteristic 1H NMR (300 MHz, CD3OD) and 
13C NMR (75 MHz, CD3OD) 
data of 4,5-dicaffeoylquinic acid 73 with literature data (400/125 MHz, CD3OD) 
Position 
This work Literature data 
1H 13C 1H 13C 
1  75.8  74.31 
2 1.93-2.38 (2H, m) 38.3 2.09 (2H, m) 37.02 
3 4.27-4.42 (1H, m) 69.4 4.35 (1H, br s) 67.94 
4 5.00-5.20 (1H, m) 76.2 5.10 (1H, dd, J = 2.8, 8.8 Hz) 74.36 
5 5.50-5.68 (1H, m) 69.0 5.59 (1H, m) 67.59 
6 1.93-2.38 (2H, m) 39.4 2.20 (2H, m) 37.94 
COOH  177.1  175.45 
1’/1”  127.6  126.28 
2’/2” 6.96 (2H, s) 115.2 7.01/6.99 (2H, d, J = 2.0 Hz) 113.74 
3’/3”  146.6  145.36 
4’/4”  149.6  148.27 
5’/5” 6.72/6.69 (2H, d, J = 7.2 Hz) 116.4 6.75/6.73 (2H, d, J = 8 Hz) 115.05 
6’/6” 6.86/6.84 (2H, d, J = 7.2 Hz) 123.1 6.91/6.88 (2H, dd, J = 1.6, 6.8 Hz) 121.74 
7’/7” 7.56/7.47 (2H, d, J = 16 Hz) 147.7/147.5 7.57/7.49 (2H, d, J = 16.0 Hz) 146.92/146.17 
8’/8” 6.25/6.15 (2H, d, J = 16 Hz) 114.7 6.26/6.16 (2H, d, J = 16 Hz) 113.32/113.26 
9’/9”  168.5/168.3  167.13/166.80 
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168: R1 = H, R2 = R3 = caffeoyl 
169: R1 = R3 = caffeoyl, R2 = H 
170: R1 = R2 = caffeoyl, R3 = H 
 
Compounds 168-170 were isolated as pale yellow powders. All their negative ESI mass 
spectra displayed the same pseudomolecular ion peaks at 529 [M-H]-, suggesting their 
molecular formula C26H26O12. All of the NMR spectral data indicated that compound 
168-170 were methyl ester isomers of the above three dicaffeoylquinic acids. By 
comparison of the chemical shifts of the MeO group with literature reported,194 it was 
concluded that the methoxy was attached to the carboxylic acid group. Thus, compounds 
168-170 were identified as methyl 3,4-dicaffeoylquinate, methyl 3,5-dicaffeoylquinate 
and methyl 4,5-dicaffeoylquinate, respectively. The NMR spectral data of the isolated 
compounds in the present study match well with those reported earlier.185,187 
 
The comparison of characteristic NMR data of compounds 168-170 with literature data is 
listed in Table 3.46, 3.47 and 3.48, respectively.185,187 
 
Table 3.46 Comparison of characteristic 1H NMR (300 MHz, CD3OD) and 
13C NMR (75 MHz, CD3OD) 
data of methyl 3,4-dicaffeoylquinate 168 with literature data (400/125 MHz, CD3OD) 
Position 
This work Literature data 
1H 13C 1H 13C 
1  75.2  74.9 
2 1.96-2.35 (2H, m) 41.3 2.03-2.27 (2H, dd) 38.5 
3 5.52-5.66 (1H, m) 69.8 5.48 (1H, m) 69.1 
4 4.95-5.15 (1H, m) 75.6 5.05 (1H, dd, J = 8.0, 3.2 Hz) 75.8 
5 4.20-4.35 (1H, m) 69.8 4.29 (1H, dd, J = 3.2, 2.8 Hz) 68.6 
6 1.96-2.35 (2H, m) 36.8 2.20 (2H, m) 38.4 
COOCH3 3.73 (3H, s) 52.9 3.66 (3H, s) 53.1 
COO  176.1  175.2 
1’/1”  127.7  127.7/127.5 
2’/2” 7.01 (2H, s) 115.1 6.97/6.95 (2H, s) 116.5 
3’/3”  146.8  146.8 
4’/4”  149.6  149.8/149.7 
5’/5” 6.74 (2H, d, J = 7.7 Hz) 116.4 6.70 (2H, d, J = 8 Hz) 115.2/115.1 
6’/6” 6.87 (2H, d, J = 7.7 Hz) 123.2/123.1 6.87 (2H, d, J = 6.4 Hz) 123.1 
7’/7” 7.55/7.50 (2H, d, J = 16 Hz) 147.3 7.54/7.45 (2H, d, J = 16 Hz) 147.3 
8’/8” 6.27/6.22 (2H, d, J = 16 Hz) 115.0/114.8 6.24/6.11 (2H, d, J = 16 Hz) 114.7/114.5 
9’/9”  168.5  168.5/167.9 
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Table 3.47 Comparison of characteristic 1H NMR (300 MHz, CD3OD) and 
13C NMR (75 MHz, CD3OD) 
data of methyl 3,5-dicaffeoylquinate 169 with literature data (400/125 MHz, CD3OD) 
Position 
This work Literature data 
1H 13C 1H 13C 
1  74.6  73.20 
2 2.11-2.36 (2H, m) 35.6 2.21-2.36 (2H, m) 35.35 
3 5.27-5.35 (1H, m), 72.2 5.38 (1H, m) 70.79 
4 3.98 (1H, dd, J = 7.5, 2.7 Hz) 69.7 3.99 (1H) 68.35 
5 5.36-5.43 (1H, m) 72.0 5.40 (1H) 70.53 
6 2.11-2.36 (2H, m) 37.0 2.21-2.36 (2H, m) 34.22 
COOCH3 3.69 (3H, s) 53.0 3.70 (3H, s) 51.61 
COO  175.6  174.20 
1’/1”  127.9/127.6  126.44 
2’/2” 7.07 (2H, d, J = 2 Hz) 115.5/115.1 7.07 (2H, d, J = 2.3 Hz) 113.69 
3’/3”  146.9/146.8  145.48 
4’/4”  149.8/149.6  148.37 
5’/5” 6.80/6.77 (2H, d, J = 8 Hz) 116.6/116.5 6.80 (2H, d, J = 8.3 Hz) 115.13 
6’/6” 6.99/6.96 (2H, d, J = 8 Hz) 123.1/123.0 6.99 (2H, d, J = 2.3, 8.3 Hz) 121.67 
7’/7” 7.62/7.55 (2H, d, J = 16 Hz) 147.4/147.1 7.64/7.57 (2H, d, J = 16 Hz) 146.06/145.74 
8’/8” 6.35/6.22 (2H, d, J = 16 Hz) 115.1/114.8 6.36/6.24 (2H, d, J = 16 Hz) 114.00/113.40 
9’/9”  168.7/167.9  167.32/166.51 
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Table 3.48 Comparison of characteristic 1H NMR (300 MHz, CD3OD) and 
13C NMR (75 MHz, CD3OD) 
NMR data of methyl 4,5-dicaffeoylquinate 170 with literature data (400/125 MHz, CD3OD) 
Position 
This work Literature data 
1H 13C 1H 13C 
1  74.8  74.04 
2 1.99-2.36 (2H, m) 38.4 2.24-2.35 (2H, m) 36.96 
3 4.30-4.39 (1H, m) 69.1 4.36 (1H, m) 67.13 
4 5.08-5.15 (1H, m) 75.8 5.13 (1H, m) 74.32 
5 5.48-5.59 (1H, m) 68.6 5.54 (1H, m) 67.66 
6 1.99-2.36 (2H, m) 38.5 2.24-2.35 (2H, m) 36.96 
COOCH3 3.72 (3H, s) 53.1 3.72 (3H, s) 51.68 
COO  175.2  173.76 
1’/1”  127.7/127.5  126.26/126.10 
2’/2” 7.03 (2H, s) 115.1 7.04 (2H, d, J = 2.4 Hz) 113.73 
3’/3”  146.8  145.42 
4’/4”  149.8/149.7  148.38 
5’/5” 6.78/6.75 (2H, d, J = 8 Hz) 116.5 6.77 (2H, d, J = 8.3 Hz) 115.09 
6’/6” 6.91-6.93 (2H, m) 123.2 6.95 (2H, d, J = 2.3, 8.2 Hz) 121.75 
7’/7” 7.61/7.51 (2H, d, J = 16 Hz) 147.7 7.62/7.52 (2H, d, J = 16 Hz) 146.31 
8’/8” 6.30/6.18 (2H, d, J = 16 Hz) 114.7/114.5 6.32/6.19 (2H, d, J = 16 Hz) 113.28/113.10 
9’/9”  168.5/167.9  167.05/166.46 
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 Extraction with 
                                       80% aqueous ethanol 
 
 
 
 
                                       Liquid-liquid partitioned with 
n-hexane, EtOAc and n-BuOH, respectively 
                                         
 
    n-Hexane extract   EtOAc extract (47.5 g)  n-BuOH extract          residue 
                                   CC-Si:                                                                                                                    
n-hexane/EtOAc/acetone, gradient 
                           
 
Fr. D1  Fr. D2  Fr. D3  Fr. D4  Fr. D5  Fr. D6  Fr. D7 
(0.8 g)   (2.1 g)   (7.0 g)   (7.6 g)  (11.3 g)  (8.1 g) 
                CC-MCI CHP20P: 
MeOH/H2O, gradient 
 
 
Fr. D5-1    Fr. D5-2   Fr. D5-3    Fr. D5-4 
(2.4 g)       (1.3 g)      (6.2 g)      (0.8 g) 
                       Auto. flash-C18: 
                                    H2O/methanol, gradient 
 
 
Fr. D5-3-1    Fr. D5-3-2    Fr. D5-3-3    Fr. D5-3-4   Fr. D5-3-5 
           (1200 mg)    (1530 mg)    (610 mg)    (380 mg)    (750 mg) 
                            CC-Sephadex LH-20: 
H2O/MeOH, gradient 
                                     
            
Fr. D5-3-2-1   Fr. D5-3-2-2  Fr. D5-3-2-3 
(450 mg)      (680 mg)    (320 mg) 
            
Prep-LC-C18                         
           H2O/MeCN, gradient  
 
 
 
 
 
 
 
 
 
Compound 167 (R
1
 = R
4
 = H, R
2 
= R
3
 = caffeoyl): 44.3 mg 
Compound 72 (R
1
 = R
3
 = caffeoyl, R
2 
= R
4
 = H): 38.2 mg 
Compound 73 (R
1
 = R
2
 = caffeoyl, R
3 
= R
4
 = H): 26.3 mg 
Compound 168 (R
1
 = H, R
2
 = R
3 
= caffeoyl, R
4
 = Me): 13.6 mg 
Compound 169 (R
1
 = R
3
 = caffeoyl, R
2 
= H, R
4
 = Me): 9.4 mg 
Compound 170 (R
1
 = R
2
 = caffeoyl, R
3 
= H, R
4
 = Me): 10.5 mg 
 
Scheme 3.7 describes the complete isolation of compounds 72-73 and 167-170 from the 
aerial parts of G. divaricata. 
 
Scheme 3.7 The complete isolation of compounds 72-73 and 167-170 from G. divaricata 
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Compound 174 was isolated as a white powder. Its negative ESI mass spectrum displayed 
a pseudomolecular ion peak at 543 [M-H]-, suggesting a molecular formula C27H28O12. All 
of the NMR spectral data indicated that compound 174 was a 4,5-dicaffeoylquinic acid 
ethyl ester. The presence of an EtO group was supported by the appearance of q-like 
signal at δ ca. 4.16 integrating for two protons and a triplet signal at δ 1.26 integrating 
for three protons. By comparison of the chemical shifts of the EtO group with literature 
data reported, it was concluded that it was part of the carboxylic unit. Thus, compound 
174 was identified as ethyl 4,5-dicaffeoylquinate. The NMR spectral data of the isolated 
compound in the present study match well with those reported earlier.191 
 
The comparison of characteristic NMR data of compound 174 with literature data is 
listed in the Table 3.49.191 
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Table 3.49 Comparison of characteristic 1H NMR (300 MHz, CD3OD) and 
13C NMR (75 MHz, CD3OD) 
data of ethyl 4,5-dicaffeoylquinate 174 with literature data (200/50 MHz, acetone-d6)
191 
Position 
This work Literature data 
1H 13C 1H 13C 
1  75.6  75.86 
2 2.03-2.36 (2H, m) 38.3 2.06 (2H, m) 38.18 
3 4.34-4.36 (1H, m) 68.5 4.40 (1H, d, J = 3.0 Hz) 68.23 
4 5.09-5.13 (1H, m) 69.1 5.11 (1H, dd, J = 9.3, 3.0 Hz) 68.86 
5 5.50-5.57 (1H, m) 74.8 5.66 (1H, ddd, J = 9.3, 9.3, 3.9 Hz) 75.29 
6 2.03-2.36 (2H, m) 38.4 2.06(2H, m) 39.28 
COOCH2 4.13-4.21 (2H, m) 62.7 4.17 (2H, q, J = 7.0 Hz) 61.88 
CH2CH3 1.26 (3H, t, J = 7.2 Hz) 14.3 1.26 (3H, t, J = 7.0 Hz) 14.32 
COO  174.7  173.66 
1’/1”  127.6/127.5  127.46 
2’/2” 7.04/7.01 (2H, d, J = 1.7 Hz) 116.5 7.14/7.13 (2H, d, J = 1.9 Hz) 115.34/115.14 
3’/3”  146.8  145.30 
4’/4”  149.8/149.7  148.84 
5’/5” 6.76 (2H, d, J = 8.3 Hz) 115.1 6.88/6.84 (2H, d, J = 7.9 Hz) 116.32 
6’/6” 6.90-6.95 (2H, m) 123.1 7.02/7.00 (2H, d, J = 1.9, 7.9 Hz) 122.64 
7’/7” 7.61/7.51 (2H, d, J = 16.0 Hz) 147.7/147.6 7.58/7.54 (2H, d, J = 15.8 Hz) 146.28 
8’/8” 6.30/6.18 (2H, d, J = 16.0 Hz) 114.6/114.5 6.27/6.24 (2H, d, J = 15.7 Hz) 114.00/113.40 
9’/9”  168. 5/167.9  166.96/166.63 
 
Scheme 3.8 describes the complete isolation of compound 174 from the aerial parts of G. 
divaricata. 
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 Extraction with 
                                       80% aqueous ethanol 
 
 
 
 
                                       Liquid-liquid partitioned with 
n-hexane, EtOAc and n-BuOH, respectively 
                                         
 
    n-Hexane extract   EtOAc extract (47.5 g)  n-BuOH extract           residue 
                                   CC-Si:                                                                                                                    
n-hexane/EtOAc/acetone, gradient 
                           
 
Fr. D1  Fr. D2  Fr. D3  Fr. D4  Fr. D5  Fr. D6  Fr. D7 
(0.8 g)  (2.1 g)   (7.0 g)   (7.6 g)  (11.3 g)  (8.1 g) 
                CC-MCI CHP20P: 
MeOH/H2O, gradient 
 
 
Fr. D5-1    Fr. D5-2   Fr. D5-3    Fr. D5-4 
(2.4 g)       (1.3 g)      (6.2 g)      (0.8 g) 
                       Auto. flash-C18: 
                                    H2O/methanol, gradient 
 
 
Fr. D5-3-1    Fr. D5-3-2    Fr. D5-3-3    Fr. D5-3-4   Fr. D5-3-5 
           (1200 mg)    (1530 mg)    (610 mg)    (380 mg)    (750 mg) 
                            CC-Sephadex LH-20: 
H2O/MeOH, gradient 
                                     
            
Fr. D5-3-2-1   Fr. D5-3-2-2  Fr. D5-3-2-3 
(450 mg)      (680 mg)    (320 mg) 
                     CC-Si: 
          CHCl3/MeOH, gradient 
 
 
Fr. D5-3-2-3-1  Fr. D5-3-2-3-2  Fr. D5-3-2-3-3  Fr. D5-3-2-3-4 
(25 mg)        (26 mg)      (33 mg)       (46 mg) 
Prep-LC-C18                         
                             H2O-0.1% formic acid/MeCN 
                             65:35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
174 (1.0 mg) 
 
Scheme 3.8 The complete isolation of compound 174 from G. divaricata 
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4.1 Introduction 
The genus Gynura belongs to the family Asteraceae, comprising approximately 40 
species mainly distributed in Asia, Africa and Australia, of which 10 species were 
recorded in the south of China.196 Besides those species, Gynura medica is a newly found 
plant named by Yang and Wu.197 Many Gynura species are edible plants native to Asia, 
aerial parts are consumed in traditional dishes.153,198 Besides, some of them have been 
used heavily as traditional Chinese medicines in the treatment of hemostasis,199.200 
hypertension,201 and diabetes mellitus.174 In our investigation of natural medicines used 
in the traditional Chinese medical system for treatment of diabetes,52,151 a tea made 
from the fresh leaves of G. bicolor and/or G. divaricata was found to have excellent 
anti-hyperglycemia effects. G. bicolor also produces a pleasant flavor, associated with 
slightly green and earthy aromas.154 
 
To our knowledge, three studies investigated the volatile constituents from Gynura 
species, i.e. G. cusimbua202 and G. bicolor.153,154 Shimizu analyzed and compared the 
volatiles from extracts of leaves of field-grown plants and shoot cultures of G. bicolor 
using solvent-assisted flavour evaporation (SAFE) coupled with gas 
chromatography-mass spectrometry (GC-MS) identification.154 
 
Essential oils are volatile secondary metabolites produced by aromatic plants and play an 
important role in the protection and life cycle of plants.203 Due to their interesting 
biological effects, they play an important role in traditional pharmacopoeia. The 
chemical composition of essential oils is determined by local environmental factors 
influencing plant growth.203 The extraction techniques of essential oils are variable and 
under continuous development and can have an influence on the chemical composition 
which is typically determined by GC-MS analyses. As a solvent-free sampling technique 
for the determination of volatiles in plant essential oils, solid phase microextraction 
(SPME) has several advantages, compared with other extraction techniques such as 
traditional steam distillation-solvent extraction, such as high sensitivity and a small 
sample volume for rapid analysis of volatiles.204,205,206 When volatile profiles resulting 
from SPME techniques are compared with profiles obtained in essential oil research 
through conventional distillation techniques, it has to be taken into account that the 
profile acquired using an SPME fiber is influenced by several extraction parameters such 
as the type of fiber (different partition coefficients), time and temperature.206 
Nevertheless, the advantage of the need of a relative small sample volume makes SPME 
more useful facing plants with limited availability, specifically the wild types. Therefore, 
for the first time, the volatiles from fresh leaves of Gynura divaricata and G. bicolor were 
studied using a SPME method coupled with GC-MS. The present work reports the volatile 
compounds of G. divaricata, G. bicolor collected from two different origins, Nanjing and 
Nanping in the east of China. An analysis of the volatiles from leaves of Gynura medica 
was also performed. These three plants have all been reported as having hypoglycemic 
potential for the treatment of diabetes in a bioassay test.151,207,208 
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4.2 Experimental 
4.2.1 Plant material 
Gynura species from Nanping area were collected in September 2011 from the 
countryside of Jianou county, in the southeast of the Wuyi Mountain, Nanping, China. 
Species from Nanjing area were collected in October 2011 in Nanjing Botanical Garden 
Mem. Sun Yat-sen, in the south of the Zijin Mountain, Nanjing, China. The plants were 
identified by Professor Guo Rong-lin at the Institute of Botany, Jiangsu Province and 
Chinese Academy of Sciences. The voucher specimens of three Gynura species (No. 
510826-1~5) were deposited in the herbarium, Institute of Botany, Jiangsu Province and 
Chinese Academy of Sciences. 
 
Fresh leaves of Gynura species were air dried and then ground to a powder, weighted 
and subjected to headspace sampling. 
 
4.2.2 Headspace sampling 
The volatile metabolites from 2.0 g of dry leaf powder of the plant were extracted by 
headspace SPME during 30 min at 40 C with a 50/30 µm DVB/Car/PDMS fiber (Supelco, 
Bornem, Belgium) and desorbed for 2 min at 250 C. SPME extraction and desorption 
were performed automatically by means of a Multipurpose Sampler (MPS-2, Gerstel).205 
The sample extractions were conducted in triplicate. 
 
4.2.3 Analysis of the headspace extracts by GC-MS 
GC-MS analyses of the SPME extracts were performed with an Agilent 6890 GC Plus 
coupled to a quadrupole mass spectrometer 5973 MSD (Agilent Technologies, Diegem, 
Belgium), and equipped with a DB-5 capillary column (30 m length × 0.25 mm id; 0.25 
µm film thickness). Working conditions were: injector temperature 250 C, transfer line 
to MSD 260 C, carrier gas (He) 1 mL min-1; SPME desorption in a CIS-4 PTV injector 
(Gerstel) in split mode (10 : 1); ionisation: EI 70 eV; acquisition parameters: scanned m/z: 
40-200 (2-15 min), 40-300 (15-20 min), 40-350 (> 20 min); oven temperature starts at 60 
C, programmed from 60 C to 160 C at 3 C min-1, from 160 C to 250 C at 10 C min-1, 
hold 2 min. Retention indices were calculated using co-chromatographed standard 
hydrocarbons. The individual compounds were identified by comparing their retention 
indices, relative to C6-C18 n-alkanes, with literature values and by comparing their mass 
spectra and retention times with those of authentic samples or with data already 
available in the NIST 05 library and the literature. 
 
4.3 Results and Discussion 
Via headspace SPME/GC-MS analysis, a total of 55 different components were identified 
from fresh leaves of different Gynura species which were air dried. The constituents 
were identified by comparison of the mass spectrum with those of the computer mass 
library NIST 05 and/or calculated retention indexes (RI) with those reported in the 
literature (listed in Table 4.1). For G. bicolor, 47 and 33 compounds were identified from 
the species originating from Nanping and Nanjing, respectively. The main volatile 
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constituents of G. bicolor from Nanping were β-caryophyllene (203×106 peak area), 
α-caryophyllene (42×106), α-copaene (34×106), carvone (31×106) and limonene (31×106) 
as monoterpenes or sesquiterpenes. β-Caryophyllene (175×106), α-pinene (72×106), 
α-copaene (52×106), α-caryophyllene (50×106) and β-pinene (10×106) were the main 
monoterpenes or sesquiterpenes present in G. bicolor from Nanjing. 
 
The detected major volatiles in G. divaricata from Nanjing were qualitatively the same as 
for G. bicolor from Nanjing, but in smaller amounts. The volatile profiles of G. divaricata 
and G. bicolor from Nanping were more diverse. Instead of carvone and α-caryophyllene 
for G. bicolor, o-cymene was detected in G. divaricata, besides β-caryophyllene, 
limonene and α-copaene. 
 
In addition, for the first time, the volatiles of the fresh, air dried, leaves of G. medica 
collected from Nanjing were also identified via SPME/GC-MS, with γ-cadinene (81×106), 
β-caryophyllene (39×106), elixene (21×106) and monoterpene limonene (20×106) as the 
major components. The volatile profile of this third Gynura species is clearly different 
from that of G. bicolor and G. divaricata from the same origin. Overall, these results 
indicate that the volatile profile of Gynura species is not only species related, but is also 
influenced by the local environmental growth conditions. Since many studies proved the 
hypoglycemic effects of volatiles from plants,211,212 the further biotesting of total volatile 
extracts from Gynura species for antidiabetic activity will be of significant interest. 
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Table 4.1 Composition of the volatile compounds (GC-MS peak area ×106) from fresh (air dried) leaves of Gynura species identified by SPME/GC-MS. 
Compounda RIexp
b RIlit
c IDd 
G. bicolor 
 (Nanjing) 
G. bicolor 
(Nanping) 
G. divaricata 
 (Nanjing) 
G. divaricata 
(Nanping) 
G. medica 
(Nanjing) 
Toluenee 766  MS   4.3   5.3 3.1 
Hexanal 801 801 MS, RI 1.7 3.0 0.8 2.0 1.6 
(E)-2-Hexenal 847 846 MS, RI 0.3 0.6 0.3 0.7 4.9 
(E)-2-Hexenol 857 854 MS, RI   0.1   0.2 2.5 
1-Hexanol 861 863 MS, RI 0.2 0.4 0.2 0.8 2.1 
2,6-Dimethylpyridinee 877  MS   0.4   0.8   
2-Butylfurane 889  MS 0.3 0.1 0.2 0.3 0.3 
Styrenee 893  MS   0.2   0.3 0.2 
3-Nonenee 896  MS   5.7   8.7 6.9 
Heptanal 901 901 MS, RI 0.2 0.2 0.2 0.3 0.1 
(E,E)-2,4-Hexadienal 909 907 MS, RI 0.2 0.3 0.3 0.6 0.8 
α-Thujene 924 924 MS, RI 0.3 0.3 0.3 0.6 0.5 
α-Pinene 932 932 MS, RI 72.4 1.8 49.7 1.6 7.7 
(Z)-2-Heptenale 952  MS   0.8   0.6   
Benzaldehyde 959 952 MS, RI 1.1 0.5 0.7 0.5 0.6 
Sabinene 970 969 MS, RI 0.6 0.5 0.3 0.7 0.7 
β-Pinene 977 974 MS, RI 9.8 0.6 13.8 1.0 1.9 
Sulcatone 980 985 MS, RI 2.5 0.4 2.8 0.6 0.6 
Myrcene 987 988 MS, RI 3.9 4.0 1.8 4.2 4.9 
Ethyl caproate 996 996 MS, RI   0.6   1.0 1.2 
4-Carene209 999 1001 MS   0.5   0.8 0.8 
Octanal 1002 1001 MS, RI   0.2   0.3 0.3 
α-Phellandrene 1006 1002 MS, RI   2.8   3.9 4.4 
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δ-3-Carene 1008 1008 MS, RI 0.2   1.7     
α-Terpinene 1016 1014 MS, RI   3.5   4.8 6.1 
ortho-Cymene 1023 1022 MS, RI 0.5 9.0 1.0 10.9 12.9 
Limonene 1027 1024 MS, RI 0.5 30.8 0.4 21.0 20.1 
β-Phellandrene 1029 1025 MS, RI   2.6   5.1 4.0 
γ-Terpinene 1055 1054 MS, RI   3.1   3.8 4.8 
1-Undecene210 1089 1092 MS 5.2 0.5 0.2 0.5 1.0 
Linalool 1097 1095 MS, RI         0.3 
Nonanal 1102 1100 MS, RI   1.3   0.8 0.6 
Citronellal 1148 1148 MS, RI         0.6 
Menthone 1153 1148 MS, RI   3.1   1.4 0.8 
Menthol 1174 1167 MS, RI   1.3   1.6 1.0 
Methyl salicylate 1187 1190 MS, RI         0.5 
Carvone 1239 1239 MS, RI   30.9   4.5 1.3 
3-Cyclohexen-1-one, 2-isopropyl-5-methyl-e 1249  MS 1.6   1.8   0.3 
α-Cubebene 1341 1345 MS, RI 0.9   0.4   2.5 
Cyclosativene 1363 1369 MS, RI 4.4 2.0 1.8 1.4 1.5 
α-Copaene 1370 1374 MS, RI 51.6 33.5 23.3 17.6 12.9 
β-Elemene 1383 1389 MS, RI 1.5 1.9 0.3 0.2 4.0 
α-Gurjunene 1400 1409 MS, RI     2.0 2.2   
β-Caryophyllene 1413 1417 MS, RI 174.9 203.4 43.7 48.2 38.7 
α-Caryophyllene 1449 1454 MS, RI 49.5 41.7 9.0 5.0 17.2 
Unknown 1468   4.6 4.5 1.7 1.4 0.7 
γ-Muurolene 1474 1478 MS, RI 2.1 3.9 0.6 0.6 6.6 
Germacrene D 1476 1484 MS, RI   0.4   0.6 11.4 
β-Selinene 1482 1489 MS, RI 1.6 0.6 1.2 1.1 0.9 
Investigation of the volatile constituents of different Gynura species 
152 
Elixenee 1488  MS 9.6 6.7 2.7 0.8 21.1 
α-Muurolene 1492 1500 MS, RI 1.3 1.1 1.3 1.4 0.4 
α-Farnesene 1499 1505 MS, RI   0.1     0.5 
γ-Cadinene 1512 1513 MS, RI 9.1 9.6 5.6 4.3 80.8 
Dihydroactinidiolidee 1518  MS 0.5 0.6 0.3 0.5   
Spathulenol 1569 1577 MS, RI 6.4 7.7 1.7 1.2 6.4 
Caryophyllene oxide 1574 1582 MS, RI 8.7 16.3 2.2 4.6 0.3 
Unknown 1626           16.1 
aCompounds are listed in order of their retention time on a DB-5 column. 
bRIexp = retention indices are determined using n-alkanes (C6-C18) as reference materials. 
cRIlit = relative retention indices taken from Adams and/or Nist 05 for DB-5 capillary column. 
dIdentification methods: MS, by comparison of the mass spectrum with those of the computer mass libraries Adams and NIST 05; 
RI, by comparison of calculated RI with those reported in the literature. 
e Tentative identification 
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5.1 Introduction 
One of the therapeutic approaches to correct the increased blood glucose level in type 2 
diabetes mellitus is the management of postprandial hyperglycemia by reducing the 
production and absorption of glucose by inhibition of carbohydrate-digestion enzymes, 
such as -glucosidase, maltase and sucrase.213 The close link between -glucosidase and 
diabetes has led to a large number of studies dedicated to search for these enzymic 
inhibitors. Several natural -glucosidase inhibitors including acarbose, voglibose and 
miglitol are clinically used.214 
 
Protein tyrosine phosphatase-1B (PTP1B) is a widely distributed, nontransmembrane 
protein tyrosine phosphatase, originally identified in human placenta.215 It was proven to 
be negative regulator of insulin receptor signaling, which has emerged as a potential 
therapeutic target for treatment of type 2 diabetes and obesity.216 Therefore, the 
development of such phosphatase inhibitors will be beneficial for drug discovery for the 
treatment of type 2 diabetes. 
 
As a folk medicine, Gynura bicolor and Gynura divaricata have been used to prevent and 
treat diabetes for decades in China. One research was investigated to evaluate different 
extracts of Gynura divaricata on inhibition of α-amylase and α-glycosidase involved in 
the pathogenesis of hyperglycemia. The results suggest that G. divaricata may have 
potential hypoglycemic applications.207 However, the studies on antidiabetic effects of 
Gynura species were mainly focused on the activity of the extract and the active 
components of the extract were not ascertained.217,218,219 In addition, cinnamic acid and 
caffeic acid 76, the precursors of all caffeoyl derivatives,220 together with 5-caffeoylquinic 
acid (chlorogenic acid, 74)221 which were found to be present in the studied Gynura 
divaricata, have been well studied for PTP1B inhibitory activities. With the combined use 
of structure and medicinal chemistry, it was decided to study all the natural products 
isolated from Gynura bicolor and Gynura divaricata by enzyme assay-biotesting, to 
obtain small-molecule -glucosidase and PTP1B inhibitors with the requisite potency and 
selectivity. 
 
5.2 Screening of the natural products as α-glucosidase inhibitors 
The inhibitory activity against α-glucosidase (Type I, Sigma-Aldrich) was measured with a 
slight modification of the reported method.222 To each well of a 96-well microtiter plate 
was added 10 l of -glucosidase [1 U/ml in phosphate buffer (PBS), pH 6.8], 28 l of 
PBS, 2 l of the sample solution in 4% MeOH. The mixture was incubated at 37 C for 10 
min, then 4-nitrophenyl -D-glucopyranoside (10 l, 10 mM in PBS) was added, and the 
mixture was incubated for additional 35 min. The absorbance (A) of each well was 
measured at 405 nm with a microplate spectrophotometer (Infinite F50, Tecan). The 
inhibition activity was calculated using the following formula: Inhibition (%) = 
[1-(Asample/Acontrol)]  100%. The positive control was acarbose (Bayer) which was found to 
have an IC50 value of 1.38 mM against the same enzyme. 
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5.3 Screening of the natural products as Protein Tyrosine Phosphatase 1B inhibitors 
All compounds were dissolved in MeOH at a concentration of 10 mg/mL and 2 l was 
added to each well. The final concentration of solvent did not influence the activity of 
PTP1B. The assay was performed in a 96-well clear polystyrene microplate (Corning) 
according to a published procedure with slight modifications.223 Each well contained 0.05 
μg PTP1B (Enzo Life Sciences, Inc.), 1.5 mM Insulin Receptor ß residues (IR5, Enzo Life 
Sciences, Inc.) and 100 mM MES buffer [pH 6.0, 300 mM NaCl, 2 mM 
N,N,N’,N’-ethylenediaminetetraacetate (EDTA), 2 mM dithiothretiol (DTT), 0.1% NP-40). 
The final volume of the mixture was 100 μL. The reaction was initiated by addition of IR5, 
incubated at 37 °C for 30 min, and terminated with the addition of concentrated 
phosphate detection reagent (BIOMOL RED, Enzo Life Sciences, Inc.). The absorbance (A) 
of each well was measured at 620 nm with a microplate spectrophotometer (Infinite F50, 
Tecan). The inhibition activity was calculated using the following formula: Inhibition (%) = 
[1-(Asample/Acontrol)]  100%. The assays were performed in triplicate for all samples. A 
PTP1B inhibitor, SURAMIN (Enzo Life Sciences, Inc.) was used as the positive control.  
 
5.4 Results and discussion 
5.4.1 Inhibitory activities of isolated compounds against -glucosidase 
Among the isolated compounds, 3,4-dicaffeoylquinic acid 167, 4,5-dicaffeoylquinic acid 
73, methyl 3,4-dicaffeoylquinate 168 and methyl 4,5-dicaffeoylquinate 170 exhibited 
significant inhibitory activities against -glucosidase (Table 5.1). Their IC50 values were 
much lower than that of acarbose, in particular, while methyl 3,4-dicaffeoylquinate 168 
and methyl 4,5-dicaffeoylquinate 170 showed IC50 values of 12.23  0.64 M and 13.08  
0.86 M, respectively. It should be noted that methyl 3,4-dicaffeoylquinate 168 and 
methyl 4,5-dicaffeoylquinate 170 are derivatives of 3,4-dicaffeoylquinic acid 167 and 
4,5-dicaffeoylquinic acid 73, respectively. From this result, it was clear that their activities 
concerning inhibition of -glucosidase increased almost ten times after esterification. 
Besides, the flavonol quercetin 35 also showed significant activity against -glucosidase. 
 
Table 5.1 Inhibitory activities of isolated compounds against -glucosidase 
Compounds IC50 values 
3,4-Dicaffeoylquinic acid 167 187.2  12.9 M 
4,5-Dicaffeoylquinic acid 73 130.8  10.3 M 
Methyl 3,4-dicaffeoylquinate 168 12.23  0.64 M 
Methyl 4,5-dicaffeoylquinate 170 13.08  0.86 M 
Quercetin 35 36.09  2.81 M 
Acarbose 1.38 mM 
Notes: Data of other isolated compounds showing no activity on inhibition of -glucosidase were 
not listed in this table. IC50 is the concentration required to produce 50% inhibition of the 
enzyme activity. Values represent the means  standard deviation (SD) of n = 3 duplicate assays. 
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5.4.2 Inhibitory activities of isolated compounds against PTP1B 
As shown in Table 5.2, seven of forty-one isolated compounds from G. bicolor and G. 
divaricata exhibited an inhibition effect on PTP1B. 3,5-Dicaffeoylquinic acid 72 and 
4,5-dicaffeoylquinic acid 73 showed a considerable inhibitory effect on PTP1B, compared 
with the positive control of SURAMIN against the same enzyme in a parallel assay. On 
the contrary, 3,4-dicaffeoylquinic acid 167, the isomer of the above dicaffeoylquinic acids, 
displayed no inhibition activity against PTP1B. In addition, only methyl 
3,4-dicaffeoylquinate 168 showed very limited inhibition activity on PTP1B, suggesting 
that esterification will decrease their abilities on inhibition of PTP1B. p-Coumaric acid 
165, and its derivative 5-O-p-coumaroylquinic acid 171 showed comparable activities on 
the inhibition of PTP1B, which suggested that the quinic acid part did not influence the 
effect. Total DCQ, the total dicaffeoylquinic acid derivatives extract (Fr. D5-3-2-2) from G. 
divaricata, also showed comparable inhibition effect, while 3,5-dicaffeoylquinic acid 72 
and 4,5-dicaffeoylquinic acid 73 in this extract were deduced to be responsible for the 
inhibition efficacy. Among the other active compounds, megastigmane-type 
norisoprenoid compound vomifoliol 153 and the flavonoid compound quercetin 
3-O-β-D-glucoside 36 exhibited the highest inhibition against PTP1B, suggesting the 
particular molecular interaction between the compounds and the enzyme.  
 
Table 5.2 Inhibitory activities of isolated compounds against PTP1B 
Compounds PTP1B inhibition rate 
Vomifoliol 153 68.90 % 
5-O-p-Coumaroylquinic acid 171 27.30 % 
3,5-Dicaffeoylquinic acid 72 41.60 % 
4,5-Dicaffeoylquinic acid 73 58.20 % 
Methyl 3,4-dicaffeoylquinate 168 3.70 % 
p-Coumaric acid 165 28.80 % 
Quercetin 3-O-β-D-glucoside 36 68.10 % 
Total DCQ 57.30 % 
SURAMIN 44.60 % 
Notes: Sample “Total DCQ” is the total dicaffeoylquinic acid derivatives extract (Fr. D5-3-2-2) 
from G. divaricata. Data of other isolated compounds showing no activity on inhibition of PTP1B 
were not listed in this table. 
 
Based on the above, the hydroxycinnamic acid conjugates isolated from the aerial part of 
G. divaricata seem more active for the inhibition of the studied enzymes. The influence 
of the methyl ester, the linkage position between the quinic acid and the cinnamoyl 
group, and the number of caffeic acid moieties in the structure, was evaluated. By 
comparison of the reported activities of quinic acid, caffeic acid and coumaric acid 
derivatives,224,225 it was suggested that the number of caffeoyl groups attached to a 
quinic acid core were important for the -glucosidase inhibitory potency. Besides, the 
methyl esters of the isolates always produce more significant effect on the inhibition of 
-glucosidase. Regarding to the natural phenolics on the inhibition of PTP1B, flavonoids 
and caffeic acid were proven to show strong inhibitory activity.226 The result from the 
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present study would be a complementary evidence for the use of G. species for 
antidiabetes. 
 
Because of the small amounts of megastigmane-type norisoprenoids isolated from G. 
bicolor, the research work on their biological activity could not be studied further. 
However, it is interesting to note that (6S,9R)-roseoside, which is an isomer of 
(6S,9S)-roseoside (155) currently isolated, had previously been shown to increase insulin 
secretion from INS-1 β-cells.227 
 
The biological screening suggested that the hydroxycinnamic acid conjugates in G. 
divaricata were the major constituents responsible for its hypoglycemic activity. 
Meanwhile, with regard to our previous pharmacological investigation of Gynura species 
on alloxan-diabetic mice,151 it was deduced that its action was possibly related to the 
protection of pancreatic -cells or stimulation of undamaged cells to secrete more 
insulin. Recent studies have indicated that many plant secondary metabolites, such as 
hydroxycinnamic acid conjugates, have radical-scavenging activity, which is beneficial for 
alleviation of the high oxidative stress in cytotoxic-induced diabetic animal models.184,186 
To further investigate the potential antioxidant capacity of chemical constituents from G. 
bicolor and G. divaricata, the biotesting of isolated natural products on reactive oxygen 
species such as the hydroxyl radical (·OH), the superoxide anion radical (O2· )¯ and 
hydrogen peroxide (H2O2) in vitro is still going on. The results of the biological activity 
testing will be communicated later. 
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Historically, natural products provide considerable value to the primary health care of a 
large part of the world’s population. Chemical research directed towards the isolation of 
active constituents from plants used in traditional medicine continues to be a very 
important source of potentially useful therapeutic agents. 
 
The rapidly increasing incidence of diabetes mellitus is becoming a serious threat to 
human health in all parts of the world. There has been a growing interest in 
hypoglycemic agents from natural products, and their activities on diabetic related 
complications and their mechanism of action attract more attention as well. To gain 
insight in the antidiabetes activities of natural products and their multiple mechanisms 
of action, an overview of selected natural flavonoids with validated hypoglycemic 
properties and their use in the treatment of diabetic complications was presented in 
Chapter 1. The knowledge offered should help to provide leads to the ultimate goal of 
developing new, more efficient therapeutic drugs for the treatment of diabetes mellitus 
and its complications. 
 
Several plant species from the genus Gynura are used as folk medicines in China. Among 
them, Gynura bicolor and Gynura divaricata both displayed an excellent antidiabetic 
effect. As local secret recipes, G. bicolor and G. divaricata have been used to treat 
diabetes in Jiangsu, Zhejiang and Sichuan province in south China for decades. Our 
research group in China performed pharmacological tests to prove the antihyperglycemic 
effect of these two plants. These tests revealed that both ethyl acetate and butanol 
extracts of G. bicolor showed a significant effect on lowering the blood glucose level in 
normal and alloxan-diabetic mice, while the ethyl acetate and butanol extracts of the 
aerial part of G. divaricata were effective on lowering the blood glucose level in 
alloxan-diabetic mice in a low dosage. However, the phytochemical study of these 
species is scarcely reported in literature. Therefore, this PhD-thesis was designed to 
perform further research on the isolation of the active chemical constituents of these 
two species. 
 
This work describes the isolation and structure elucidation of natural products from G. 
bicolor (Chapter 2) and G. divaricata (Chapter 3). Due to the fact that G. bicolor also 
produces a pleasant flavor, three different Gynura species from two Chinese origins were 
collected and their volatile constituents were investigated using a SPME method coupled 
with GC-MS (Chapter 4). In addition, all the isolated natural products were subjected to a 
bioactivity screening for antidiabetes activity (-glucosidase and PTP1B inhibition), 
which was analyzed in Chapter 5. 
 
The extraction, fractionation, isolation and final purification of the natural products were 
achieved by means of liquid-liquid partitioning, column chromatography with different 
packing materials (silica gel, MCI CHP20P gel, Sephadex gel, C18), automatic flash and 
preparative high pressure liquid chromatography (prep-HPLC). 1H NMR, 13C NMR 
spectrometry (including 1H-1H COSY, HSQC, HMBC, DEPT, etc) and mass spectrometry 
were used to elucidate the structure of the isolated natural products. 
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Chapter 2 describes the phytochemical investigation of G. bicolor. The fractionation and 
isolation of the CH2Cl2 and EtOAc extracts of the aerial parts of G. bicolor resulted in 
sixteen pure compounds. Their structures were determined spectroscopically as 
5-(hydroxymethyl)furfural i, benzoic acid ii, 4-hydroxybenzaldehyde iii, vanillic acid iv, 
ficusic acid v, dehydrovomifoliol vi, loliolide vii, vomifoliol viii, boscialin ix, 
4-hydroxybenzoic acid x, roseoside xi, benzyl β-D-glucopyranoside xii, protocatechuic 
acid xiii, kaempferol xiv, 2-phenylethyl -D-glucopyranoside xv and 
3,3'-di-O-methylellagic acid 4-O-β-D-xylopyranoside xvi. It should be noted that all these 
compounds, except 4-hydroxybenzoic acid x and kaempferol xiv were isolated for the 
first time from this plant, and no evidence could be found of the previous reported 
presence of megastigmane-type norisoprenoids in the genus Gynura. 
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The phytochemical investigation of natural products of G. divaricata (Chapter 3) led to 
the isolation of twenty-five compounds. They were characterized by spectrometric 
methods as one organic acid (succinic acid xvii) and three of its derivatives (ethyl methyl 
succinate xix, methyl succinate xx and ethyl succinate xxi), four phenolic acids (salicylic 
acid xviii, isovanillic acid xxii, 4-hydroxybenzoic acid x and p-coumaric acid xxiii), one 
coumarin (esculetin xxiv), five flavonoids (quercetin xxviii, kaempferol xiv, rutin xxv, 
quercetin 3-O-β-D-glucoside xxvi and kaempferol 3-O-β-D-glucoside xxvii) and eleven 
quinic acid derivatives (5-O-caffeoylquinic acid xxxviii, methyl 5-O-caffeoylquinate xxxvi, 
5-O-feruloylquinic acid xxxvii and 5-O-p-coumaroylquinic acid xxxv, 3,4-dicaffeoylquinic 
acid xxix, 3,5-dicaffeoylquinic acid xxx, 4,5-dicaffeoylquinic acid xxxi, methyl 
3,4-dicaffeoylquinate xxxii, methyl 3,5-dicaffeoylquinate xxxiii, methyl 
4,5-dicaffeoylquinate xxxiv and ethyl 4,5-dicaffeoylquinate xxxix). It should be noted 
that compounds x, xvii-xxiv, xxvi, xxix and xxxi-xxxix were isolated for the first time 
from this plant. 
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In order to study the active natural products in these two Gynura species responsible for 
their antidiabetes properties, the individual compounds were tested for the inhibition of 
-glucosidase and Protein Tyrosine Phosphatase 1B (PTP1B). Among the isolated 
compounds, 3,4-dicaffeoylquinic acid xxix, 4,5-dicaffeoylquinic acid xxxi, methyl 
3,4-dicaffeoylquinate xxxii and methyl 4,5-dicaffeoylquinate xxxiv exhibited significant 
inhibitory activities against -glucosidase, with IC50 values of 187.2  12.9 M, 130.8  
10.3 M, 12.23  0.64 M and 13.08  0.86 M, respectively. Besides, the flavonol 
quercetin xxviii also showed significant activity against -glucosidase. Regarding the 
inhibition activity of isolated compounds against PTP1B, 3,5-dicaffeoylquinic acid xxx and 
4,5-dicaffeoylquinic acid xxxi showed considerable inhibitory effect on PTP1B. 
p-Coumaric acid xxiii and 5-O-p-coumaroylquinic acid xxxv also showed inhibition effects 
against PTP1B. Based on these findings, the hydroxycinnamic acid conjugates were 
deduced to be potentially responsible for their antidiabetes activity of Gynura divaricata. 
However, megastigmane-type norisoprenoid compounds from G. bicolor showed a slight 
activity against the above two enzymes, except for vomifoliol viii which exhibited a high 
inhibition of PTP1B, suggesting a particular molecular interaction between the 
compounds and the enzyme. 
 
Another part of the research work was focused on the volatile compounds of G. 
divaricata and G. bicolor collected from two different origins, Nanjing and Nanping in the 
east of China. Analysis of the volatiles from leaves of Gynura medica was also performed. 
Via headspace SPME/GC-MS analysis, a total of 55 different components were identified 
from fresh leaves of different Gynura species. By qualitative and quantitative analysis, it 
was indicated that the volatile profile of Gynura species is not only species related, but is 
also influenced by the local environmental growth conditions. 
 
The future perspectives of further research should be focused on the completion of the 
phytochemical work on the Gynura species. Preliminary in depth LC-MS profiling 
indicates that several minor isomers (both structural and stereo chemicals) are available 
of the hydroxycinnamic acid conjugates. Each isomer of the hydroxycinnamic acid 
conjugates needs to be structurally confirmed, which contributes to complete and 
comprehensive elucidation of the secondary metabolites from the Gynura plants and 
their potential for antidiabetic effect, due to their high concentrations. Furthermore, the 
bioactivity of the hydroxycinnamic acid conjugates needs to be further investigated for 
evaluation of the full ethnomedicinal potential of Gynura species.  
 
In recent years, a serious concern regarding Gynura plants (Asteraceae), especially G. 
japonica, exists due to the presence of hepatotoxic pyrrolizidine alkaloids (HPAs), which 
can bind to DNA or proteins after being activated in the liver.228 In 1989, the World 
Health Organization issued a Health and Safety Guide on utilization of HPAs-containing 
herbs to prevent the risk of human exposure to these alkaloids, and these herbs are 
strictly limited in western developed countries.229 Previous phytochemical investigation 
of G. divaricata showed the presence of integerrimine and usaramine classified as 
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retronecine type HPAs,22 indicating the toxic risk for using this medicinal plant. Therefore, 
a full investigation focusing on profiling of the HPAs in Gynura species and the safety 
assessment of the Gynura plants is necessary in future work. 
 
Natural products will continue to play a significant role as lead compounds for drug 
discovery, combined with new technologies such as combinatorial (bio)synthesis and 
gene mining. A bright future for natural products in drug development for treatment of 
all human being’s diseases, including diabetes, is foreseen. 
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Gynura bicolor en G. divaricata zijn, als lokale geheime recepten, in het zuiden van China 
gedurende decennia gebruikt om diabetes te behandelen. Om de actieve 
natuurproducten verantwoordelijk voor de antidiabetes eigenschappen te achterhalen, 
werd dit doctoraatsonderzoek uitgevoerd betreffende de isolatie van de actieve 
chemische bestanddelen van deze twee soorten Gynura. Een ander deel van het 
onderzoek was gericht op de vluchtige verbindingen van G. bicolor en G. divaricata 
verzameld uit twee verschillende oorsprongen, Nanjing en Nanping in het oosten van 
China.  
 
De fractionering en isolatie van de CH2Cl2 en EtOAc extracten van de bovengrondse 
delen van G. bicolor resulteerde in zestien zuivere verbindingen. Hun structuren werden 
spectroscopisch bepaald als: 5-(hydroxymethyl)furfural i, benzoëzuur ii, 
4-hydroxybenzaldehyde iii, vanillinezuur iv, ficusic zuur v, dehydrovomifoliol vi, loliolide 
vii, vomifoliol viii, boscialin ix, 4-hydroxybenzoëzuur x, roseoside xi, benzyl 
β-D-glucopyranoside xii, protocatechuic zuur xiii, kaemferol xiv, 2-fenylethyl 
-D-glucopyranoside xv en 3,3'-di-O-methylellaginezuur 4-O-β-D- xylopyranoside xvi. Het 
moet worden opgemerkt dat al deze verbindingen, behalve 4-hydroxybenzoëzuur x en 
kaemferol xiv, voor het eerst werden geïsoleerd uit deze plant, en er geen bewijzen zijn 
van eerdere gerapporteerde aanwezigheid van megastigmane-type norisoprenoiden in 
het genus Gynura. 
 
Het fytochemische onderzoek van de natuurproducten in G. divaricata leidde tot de 
isolatie van vijfentwintig bestanddelen. Hun structuren werden spectroscopisch bepaald 
als een organisch zuur (barnsteenzuur xvii) en drie van zijn derivaten 
(ethyl-methyl-succinaat xix, methylsuccinaat xx en ethylsuccinaat xxi), vier fenolzuren 
(salicylzuur xviii, isovanillinezuur xxii, 4-hydroxybenzoëzuur x en p-coumarinezuur xxiii), 
een coumarine (esculetin xxiv), vijf flavonoïden (quercetin xxviii, kaemferol xiv, rutin xxv, 
quercetin 3-O-β-D-glucoside xxvi en kaemferol 3-O-β-D-glucoside xxvii) en elf 
kininezuurderivaten (5-O-caffeoylkininezuur xxxviii, methyl-5-O-caffeoylquinaat xxxvi, 
5-O-feruloylkininezuur xxxvii en 5-O-p-coumaroylkininezuur xxxv, 3,4-dicaffeoyl- 
kininezuur xxix, 3,5-dicaffeoylkininezuur xxx, 4,5-dicaffeoylkininezuur xxxi, 
methyl-3,4-dicaffeoylquinaat xxxii, methyl-3,5-dicaffeoylquinaat xxxiii, methyl-4,5- 
dicaffeoylquinaat xxxiv en ethyl-4,5-dicaffeoylquinaat xxxix). Betreffende deze 
componenten, werden verbindingen x, xvii-xxiv, xxvi, xxix en xxxi-xxxix voor het eerst 
uit deze plant geïsoleerd. 
 
Alle individuele verbindingen werden getest op de inhibitie van -glucosidase en 
Proteïne Tyrosine Fosfatase 1B (PTP1B) betrokken bij de pathogenese van hyperglycemie. 
Van de geïsoleerde verbindingen, vertoonden 3,4-dicaffeoylkininezuur xxix, 
4,5-dicaffeoylkininezuur xxxi, methyl-3,4-dicaffeoylquinaat xxxii en methyl-4,5- 
dicaffeoylquinaat xxxiv significant inhiberende activiteiten tegen -glucosidase. 
Bovendien, 3,5-dicaffeoylkininezuur xxx, 4,5-dicaffeoylkininezuur xxxi, p-coumarinezuur 
xxiii en 5-O-p-coumaroylkininezuur xxxv vertoonden significant inhiberende activiteiten 
tegen PTP1B. Op basis hiervan werden de hydroxykaneelzuurconjugaten verondersteld 
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potentieel verantwoordelijk te zijn voor de antidiabetes werkzaamheid van G. divaricata. 
Megastigmane-type norisoprenoïde verbindingen uit G. bicolor vertoonden een 
beperkte activiteit ten opzichte van de twee bovengenoemde enzymen, behalve 
vomifoliol viii dat een sterke inhibitie van PTP1B vertoonde. De biotesting van alle 
isolaten op meer anti-diabetisch gerelateerde modellen in vitro is interessant voor 
verder onderzoek. 
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